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GLUT Glucose transporter
IDDM Insulin-dependent diabetes mellitus
ICU Intensive care unit
IQR Inter-quartile range
MPC Model predictive control
NEC Necrotising enterocolitis
NICU Neonatal intensive care unit
NIRTURE Neonatal insulin replacement therapy in Europe
NRLS Non-linear recursive least square
NZ New Zealand
PACF Partial auto-correlation function
PET Positron emission tomography
PID proportional-integral-derivative
SD standard deviation
SEM Standard error for mean
SPRINT Specialized Relative Insulin and Nutrition Tables
VBLW Very low birth weight
NOMENCLATURE xxiii
Mathematical variables
αG Michaelis-Menten constant for insulin-stimulated
glucose removal saturation [L/mU]
αI Michaelis-Menten constant for plasma insulin
disappearance saturation [L/mU]
c Variance estimator modification constant
CNS Central nervous system glucose uptake
[mmol/min]
EGPmax Endogenous glucose production at zero insulin
[mmol/min]
G Blood glucose concentration [mmol/L]
I Blood plasma insulin concentration [mU/L]
IB Endogenous insulin production [mU/L/min]
k Rate of insulin transport and utilisation in the
interstitium [1/min]
kpr Rise rate of exogenous plasma glucose appearance
[1/min]
kpd Decay rate of exogenous plasma glucose
appearance [1/min]
mbody Body mass [kg]
n Plasma insulin decay rate [1/min]
PTPN External nutrition infusion rate via parenteral
route [mmol/min]
PEN External nutrition infusion rate via enteral route
[mmol/min]
φ(x;xi, sigma
2
xi
) Normal probability distribution
pG Rate of endogenous glucose removal [1/min]
p(x, y) Joint probability density function
p(x|y) Conditional probability density function
Q Interstitium insulin concentration
SI Insulin sensitivity index
uex exogenous insulin input
uex Exogenous insulin infusion [mU/min]
VG,frac Glucose distribution volume as a fraction of body
weight [L/kg]
VI,frac Insulin distribution volume as a fraction of body
weight [L/kg]

Abstract
Hyperglycaemia is a common condition in the very low birth weight infant and is
linked to mortality and increased risks of morbidities such as sepsis and retinopa-
thy of prematurity. The preterm neonate is in a state of transition from complete
dependence on the mother to physiological independence. Many metabolic regu-
lation systems are under-developed, attenuating the natural metabolic hormonal
control response. Tight regulation of glucose levels can significantly reduce the
negative outcomes associated with hyperglycaemia, but achieving it remains clin-
ically elusive for the neonate.
Glucose control in adult critical care is a highly researched topic, and sev-
eral studies have demonstrated significantly improved outcomes with protocols
that modulate the insulin and/or nutrition inputs into the patient. Despite the
potential, no standard protocol exists for neonates. Glucose restriction is often
used as a treatment for neonatal hyperglycaemia, however this deprives the in-
fant of much needed energy for growth. Limited trials of insulin infusions have
been reported, based on fixed protocols or ad-hoc clinical decisions that do not
objectively account for an individual patient’s metabolic state.
Model-based methods can deliver control that is patient-specific and adaptive
to handle highly dynamic patients. A physiological model of the glucose-insulin
regulatory system is presented in this thesis, adapted from adult critical care.
This model has three compartments for glucose utilisation, effective interstitial
insulin and its transport, and insulin kinetics in blood plasma, with emphasis on
clinical applicability. The predictive control for the model is driven by the patient-
specific and time-varying insulin sensitivity parameter. A novel integral-based
parameter identification enables fast and accurate real-time model adaptation to
individual patients and patient condition.
xxvi ABSTRACT
Validation on retrospective clinical data demonstrated the model’s ability
to capture the major dynamics of the glucose-insulin system in the critically ill
neonate. Model fit and prediction performance analysis resulted in a similar level
of performance as adult intensive care models and thus suitable for model-based
targeted control. Comparison of insulin sensitivity profiles with adult critical care
patients highlighted the glycaemic control problem as one of managing inter- and
intra-patient variability.
Stochastic models and time-series methods for forecasting future insulin sensi-
tivity are presented in this thesis. These methods can deliver probability intervals
to support clinical control interventions. The risk of adverse glycaemic outcomes
given observed variability from cohort-specific and patient-specific forecasting
methods can be quantified to inform clinical staff. Hypoglycaemia can thus be
further avoided with the probability interval guided intervention assessments.
Simulation studies of clinical control trials on ‘virtual patients’ derived from
retrospective clinical data provided a framework to optimise control protocol
design in-silico. Comparisons with retrospective control showed substantial im-
provements in glycaemia within the target 4 - 7 mmol/L range by optimising the
infusions of insulin. The simulation environment allowed experimentation with
controller parameters to arrive at a protocol that operates within the constraints
imposed by the clinically fragile state of the preterm infant.
The resulting control system was piloted in seven 12-24 hour clinical trials
at the Christchurch Women’s Neonatal Department. Glucose levels were tightly
controlled in all cases over a trial cohort that represented a wide range of patient
conditions and severity of illness. Model predictive performance agreed with
simulation results and the stochastic model forecast bounds maintained patient
safety.
Overall, the research presented takes model-based neonatal glycaemic control
from concept to proof-of-concept clinical pilot trials. The thesis develops the full
range of models, tools and methods to optimise the protocol design and problem
solution. This research thus provides a template for model-based glycaemic con-
trol development in general that could be extended to other glycaemic control
and similar problems.
Chapter 1
Introduction
The survival of infants born before the full course of natural gestation is one of
the primary concerns of the neonatal intensive care unit (NICU). Preterm infants
represent a large, and growing, proportion of the neonatal critical care popula-
tion. Hyperglycaemia, an excess of glucose in the bloodstream, is a common
complication of prematurity, and may be caused by a number of factors related
to immaturity of the glucose regulatory system and stress of critical care.
The etiology of hyperglycaemia shares some commonality with the well-
researched adult critical care case. However, preterm neonates present a unique
state of human development and exhibit significant differing physiologies. Thus,
there is no simple translation of many treatments from the adult to the neonatal
case, even if the therapeutics, insulin and all forms of nutrition, are similar.
Insulin is a potent metabolic hormone that regulates many aspects of en-
dogenous glucose production and disposal. Tight blood glucose control meth-
ods employing infusions of insulin are gaining popularity amongst neonatal clin-
icians. However, great inter-patient heterogeneity is the hallmark of neonatal
metabolism, making designing insulin protocols difficult. Model-based methods
can capture the metabolic state of the infant in real-time and adapt control for
optimal insulin dosing. These methods have the potential to make tight blood
glucose control a clinical reality for improved outcomes amongst preterm infants
in critical care.
This chapter will introduce the problem of blood glucose control in the con-
text of neonatal intensive care. The control of hyperglycaemia is a well-researched
area of adult critical care, where tight control has resulted in improved outcomes.
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A growing body of evidence suggests control of blood glucose may improve neona-
tal outcomes as a parallel to the adult case. Adaptive, model-based control is
introduced as a solution to account for the differing physiologies of the neonate
versus the adult. Therefore, the primary goal of this research is to introduce
model-based control methods to neonatal intensive care to elicit the improved
outcomes that might be obtained by the provision of patient-specific tight con-
trol of blood glucose levels.
1.1 Preterm neonates
Preterm neonates are commonly classified by two criteria: gestational age at
birth, and birth weight. Some correlation exists between the categories of birth
weight and gestational age. Typical categories for birth weight are:
• Low birth weight (LBW): < 2,500 g
• Very low birth weight (VLBW): < 1,500 g
• Extremely low birth weight (ELBW): < 1,000 g
Typical definitions of prematurity at birth are:
• Preterm: < 36 completed weeks gestation
• Very preterm: < 31 completed weeks gestation
• Extremely preterm: < 27 completed weeks gestation
Due to increasing survival and prolonged hospital stay, extremely low birth weight
(ELBW) infants now represent most of the patient days in the neonatal intensive
care nursery [Farrag and Cowett, 2000].
Over the past 20-30 years the incidence of preterm birth in most developed
countries has been about 5-10% of live births [Tucker and McGuire, 2004; Lumley,
2003]. The incidence in the United States is higher, at about 12% [Tucker and
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McGuire, 2004]. Some evidence shows that this incidence has increased slightly
in the past few years, but the rate of birth before 32 weeks’ gestation is almost
unchanged, at 1-2% [Tucker and McGuire, 2004; Darlow et al., 2003; Graafmans
et al., 2001].
Most preterm births follow spontaneous, unexplained preterm labour, or
spontaneous preterm pre-labour rupture of the amniotic membranes. The most
important predictors of spontaneous preterm delivery are a history of preterm
birth and poor socioeconomic background of the mother [Lumley, 2003; Tucker
and McGuire, 2004]. About one quarter of preterm births occur in multiple
pregnancies. Half of all twins and most triplets are born preterm [Tucker and
McGuire, 2004; Kiely, 1998]. The incidence of multiple pregnancies in developed
countries has increased over the past 20-30 years [Tucker and McGuire, 2004].
This rise is mainly because of the increased use of assisted reproduction tech-
niques, such as drugs that induce ovulation and in vitro fertilisation [Lumley,
2003].
The rate of preterm birth varies between ethnic groups. In the United King-
dom, and even more markedly in the United States, the incidence of preterm
birth in women of African descent is higher than that in Caucasian women of
similar age [Demissie et al., 2001; Kiely, 1998]. The reason for this variation is
unclear because differences remain after taking into account socioeconomic risk
factors [Tucker and McGuire, 2004]. In New Zealand, Maori are over-represented
in preterm births compared to NZ Europeans [Mantell et al., 2004].
Broadly, outcomes improve with increasing gestational age, although for any
given length of gestation survival varies with birth weight. The outcomes for
preterm infants born at or after 32 weeks of gestation are similar to those for
term infants. Additionally, advancements in the care of very-low-birth-weight (<
1,500g) infants have resulted in increased survival [Richardson et al., 1998; Darlow
et al., 2003]. However, mortality rates are as high as 20% in those born less than
1kg [Beardsall et al., 2007b]. Most serious problems associated with preterm
birth occur in the 1% to 2% of infants who are born before 32 completed weeks
gestation, and particularly the 0.4% of infants born before 28 weeks gestation
[Tucker and McGuire, 2004].
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1.2 Significance of hyperglycaemia in preterm neonates
Clinically, in adults, hyperglycaemia can be a marker of severity of illness and is
directly associated with mortality. In addition, it is also associated with increases
in other negative clinical outcomes, including severe infection [Bistrian, 2001],
sepsis and septic shock [Das, 2003; Branco et al., 2005; Oddo et al., 2004; Marik
and Raghavan, 2004], myocardial infarction [Capes et al., 2000], and polyneu-
ropathy and multiple-organ failure [Van den Berghe et al., 2001; Langouche et al.,
2005]. In each of these cases or patient subgroups, lower blood glucose levels were
associated with reduced mortality and/or complications. Similar studies have
associated early hyperglycaemia (in a patient stay) with mortality in trauma pa-
tients [Laird et al., 2004; Jeremitsky et al., 2005; Holm et al., 2004]. Finally,
there is also evidence of significant reductions in the need for dialysis, bacteremia
testing and the number of blood transfusions with aggressive blood glucose con-
trol using intensive insulin therapy [Van den Berghe et al., 2001, 2003; Krinsley,
2003b]. All of these results point towards the conclusion that the control of blood
glucose levels in adult critical care has a significant clinical impact.
Currently, the exact reasons for the reductions in mortality and other clinical
outcomes in these adult cases are not fully known, but have been extensively
analysed in these original and other works [Bellomo and Egi, 2005; Diringer,
2005; Finney et al., 2003; Krinsley, 2003a; Langouche et al., 2005; Mesotten
et al., 2004; Van den Berghe, 2004b,a; Van den Berghe et al., 2005]. However,
recent studies by Weekers et al. [2003] on a rabbit model do indicate some major
causes. Specifically, tight glycaemic control reduces glucotoxicity due to high
blood glucose, which in turn:
1. Reduces oxidative stress and superoxides.
2. Reduces stress hormone responses.
3. Reduces damage to the endothelium and vascular walls [Langouche et al.,
2005].
4. Increases immune response and bacteriocidal activity.
These results have been supported by a variety of recent, closely related studies
[Soop et al., 2002; Hansen et al., 2003; Jeschke et al., 2004; Butler et al., 2005;
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Table 1.1: Associations between hyperglycaemia and worsened outcomes in neonates.
Investigators Outcomes
[Heimann et al.,
2007]
Mortality increased in subjects with median BG
≥ 8.3 mmol/L and gestational age < 27 weeks.
[Alaedeen et al.,
2006]
Hyperglycaemia correlated with prolonged
ventilator dependence and increased hospital
stay in preterm septic infants. Average
maximum serum glucose level significantly
higher in non-surviving infants (13.4 mmol/L
vs 7.8 mmol/L). Increased odds of death and
sepsis in infants with early severe (OR: 5.07,
95% CI: 1.06 - 24.3) and persistent severe
hyperglycaemia (OR: 6.26, 95% CI: 0.73 -
54.0) over 201 patients.
[Hall et al., 2004] Higher mortality for infants with maximum BG >
11.9 mmol/L compared with maximum BG <
11.9 mmol/L, and late mortality (> 10 days
from admission) significantly higher (29% vs
2%) Maximum BG significantly related to
length of stay.
[Hays et al.,
2006]
BG significantly associated with early death and
severe intra-ventricular haemorrhage. Longer
periods of hyperglycaemia during first week of
life associated with longer hospital stay.
[Ertl et al., 2006] Hyperglycaemia was an independent risk factor in
development of retinopathy of prematurity.
[Garg et al.,
2003]
Increased risk of retinopathy of prematurity for
each 0.56 mmol/L increase in mean glucose
level (OR: 2.7, 95% CI: 1.003-7.27)
Dandona et al., 2006; Gubern et al., 2006]. All of these studies examine aspects
of systemic inflammation that is common in critical illness, immune response,
and the resulting impact or damage at a cellular level.
An increasing body of recent literature links hyperglycaemia in preterm neo-
nates to worsened outcomes, including an increased risk of further complications,
such as sepsis, increased ventilator dependence, retinopathy of prematurity, hos-
pital length of stay and mortality [Ertl et al., 2006; Garg et al., 2003; Hays et al.,
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2006; Kao et al., 2006; Hall et al., 2004; Alaedeen et al., 2006; Heimann et al.,
2007]. Hyperglycaemia may also cause an osmotic diuresis and intra-ventricular
hemorrhaging [Hemachandra and Cowett, 1999; Ditzenberger et al., 1999]. High
rates of proteolysis are also common in low birth weight infants, reducing mus-
cle mass and inhibiting growth [Agus et al., 2006, 2004]. Specific studies are
summarised in Table 1.1.
The incidence of hyperglycaemia is 45% to 80% in infants < 1,500 grams, with
increased incidence associated with lower birth weight [Dweck and Cassady, 1974;
Heimann et al., 2007]. Persistent hyperglycaemia has been observed in 20% to
50% of extremely low birth weight infants, even in patients with no family history
of diabetes [Hays et al., 2006]. Hyperglycaemia commonly occurs in infants if the
glucose load exceeds 12 grams/kg/day [Pildes and Pyati, 1986].
Despite the stature of hyperglycaemia as a widely recognised perturbation
of metabolic homeostasis, a universally accepted operational definition of hyper-
glycaemia in very preterm infants is lacking [Hey, 2005]. Glucose control targets
exhibit significant variation between clinics, as shown in Figure 1.1 [Alsweiler
et al., 2007], and between reports of glucose control, which hampers comparisons
between studies. A blood glucose concentration < 2.6 mmol/L can increase the
risk of long term neurological deficiencies [Lucas et al., 1988], and is often cited
as a limit for hypoglycaemia [Cornblath et al., 2000]. However, the precise up-
per limit for clinically desirable blood glucose concentration is still under debate
[Cowett and Farrag, 2004; Alsweiler et al., 2007]. For this study the range of 4 -
7 mmol/L, as used in several adult studies, was considered the target range for
normal glucose levels.
Thus, hyperglycaemia is a common problem in both adult and neonatal in-
tensive care. The control of blood glucose has resulted in improved outcomes
for adult patients. Neonatal hyperglycaemia is prevalent amongst the youngest
patients and has been linked to deleterious effects in a similar pattern to adults,
indicating tight blood glucose control may be beneficial for this vulnerable cohort.
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Figure 1.1: Definition of hyperglycaemia, criteria for starting insulin and blood glu-
cose level target range for neonatal units in Australasia. Circles indicate definition of
hyperglycaemia. Squares indicate threshold for commencing insulin infusions (filled
squares include glycosuria in the criteria for starting insulin). Arrows represent target
BG range. Blood glucose level expressed in mmol/L. Adapted from [Alsweiler et al.,
2007].
1.3 Pathogenesis of hyperglycaemia
Hyperglycaemia in very sick patients is most likely an effect of stress and thus
increased levels of catecholamines, which are known to stimulate glucose metabo-
lism [Guyton and Hall, 2000; Vander et al., 2001]. In this regard, very premature
infants are not different from older, critically ill patients. However, the glucose
intolerance observed in otherwise healthy, premature infants receiving glucose
infusions at rates exceeding their normal glucose turnover rate is specifically
related to their immaturity. Conditions associated with hyperglycaemia in the
neonate are summarised in Table 1.2.
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Table 1.2: Conditions associated with hyperglycaemia in the neonate. Adapted from
[Farrag and Cowett, 2000].
Origin Condition or disease
Immature hepatic and pancreatic
response to change in glucose
concentrations
Very low birth weight and extreme
prematurity
Elevated circulating levels of
cortisol, glucagon and
catecholamines
Stress, surgery, severe systemic illness
(eg: respiratory distress, cardiac
failure, sepsis, necrotising
enterocolitis)
Drug related Dexamethasone, methylxanthines (eg:
theophylline), dopamine and
administration of glucose at
excessive rates
Reduction of glucose use Administration of intravenous fat
emulsion with/without amino acids
In the preterm infant, continuous glucose infusion is always required to main-
tain homeostasis and prevent hypoglycaemia. The conundrum is that many
neonates develop hyperglycaemia during glucose infusion [Dweck and Cassady,
1974; Pildes and Pyati, 1986]. Hyperglycaemia is associated with many treat-
ments that are presently considered standard care for the so-called micropremie,
including administration of total parenteral nutrition and the use of dexam-
ethasone for the treatment of bronchopulmonary dysplasia. Nutritional support
regimes with high carbohydrate content are also provided to increase neonate
weight, but often compound the counter-regulatory response [Alaedeen et al.,
2006]. Additionally, lipids and lipid components in nutritional inputs, particularly
free fatty acids, can also promote hyperglycaemia [Hemachandra and Cowett,
1999].
It has been shown that preterm infants can mount a hormonal response to
stress similar to older critically ill patients [Barker and Rutter, 1996]. Sources
of stress for these infants include respiratory distress, surgery and recurrent in-
vasive procedures. Increased secretion of counter-regulatory hormones leads to a
prominent rise in endogenously produced glucose and the rate of hepatic gluco-
neogenesis, as well as a reduction in insulin sensitivity [McCowen et al., 2001].
Inhibiting the physiological response to increased glycaemic levels are factors
such as increased insulin resistance, absolute or relative insulin deficiency, and
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drug therapy [Thabet et al., 2003; Hemachandra and Cowett, 1999; Goldman and
Hirata, 1980; Farrag and Cowett, 2000].
The pathogenesis of stress-induced hyperglycaemia between critically ill adults
and VLBW infants may differ. In particular, the development of hyperglycaemia
in the neonate is unique in that several pathophysiologies are directly related to
the immaturity of the glucose regulatory system:
Hepatic unresponsiveness to glucose infusions: The hepatic glucose pro-
duction response to parenteral glucose infusion or increased glucose con-
centration is attenuated [Cowett et al., 1983].
Insulin resistance: Preterm infants require higher insulin levels than term in-
fants to maintain euglycaemia [Mitanchez-Mokhtari et al., 2004], and pe-
ripheral glucose uptake is only increased with the exogenous delivery of
insulin to 6-10x basal concentrations [Farrag and Cowett, 2000].
Impaired pancreatic β-cell secretion: The β-cells of hyperglycaemic preterm
infants secrete increased amounts of pro-insulin, which is up to 10 - 16 times
less active than regular insulin [Mitanchez-Mokhtari et al., 2004].
Immaturity of glucose transport system: The expression of glucose trans-
porters (GLUT), which facilitate the movement of glucose across mem-
branes of specific tissues, is dependent on maturation. The limited expres-
sion of GLUT-2 in the hepatocyte may explain the inability of the preterm
neonate to suppress hepatic glucose production, and may explain the de-
creased sensitivity of the preterm pancreas to increased glucose concentra-
tions [Raney et al., 2008]. The expression of insulin-sensitive GLUT-4 is
limited in fetal tissues, increasing after birth to reach adult levels later on
in life [Farrag and Cowett, 2000].
Limited number of insulin-dependent tissues: Very low birth weights in-
fants have little skeletal muscle and adipose tissue and therefore have de-
creased peripheral glucose uptake [Raney et al., 2008].
Thus, hyperglycaemia as a response to the stress of critical illness is an origin
of altered metabolic state common to both adults and neonates. Glucose intoler-
ance in the neonate may also be due, at least in part, to immaturity, which adds
a new dimension to this control problem.
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Table 1.3: Principal actions of insulin [Ditzenberger et al., 1999].
Time category Actions
Immediate:
seconds
Increased transport of glucose, amino acids
and potassium into insulin sensitive cells
Intermediate:
minutes
Stimulates protein synthesis, inhibits protein
degradation and activates enzymes
necessary for glucose synthesis
Delayed:
hours
Increases mRNA for lipogenic activities
1.3.1 The glucose-insulin regulatory system
After food is consumed, the body reduces the complex carbohydrate and sugar
molecules to the simple six-carbon sugar known as glucose. Glucose is the body’s
fuel, and upon the reduction by the body, it is either utilised or stored. Sensing
glucose in the bloodstream leads the β-cells in the pancreas to produce insulin.
The concentration of insulin acts as the body’s signal as to how to manage its
storage and transportation needs, and thus determines the utilisation rate of the
glucose.
Insulin is a small protein, which consists of 51 amino acids in two closely
connected chains. Insulin molecules and their connecting fragments are then
packed together in small granules in the β-cells, which are secreted through the
islets of Langerhans in the pancreas. Along with β-cells, the 1 to 2 million islets
of Langerhans contain α and δ cells which secrete glucagons and somatostatin
respectively, which act as additional blood glucose regulatory hormones. The α,
β and δ cells are approximately 25%, 60% and 10% of the total islets and are all
very closely related [Guyton and Hall, 2000; Joslin, 1985].
The level of insulin in the bloodstream is the signal that facilitates the
metabolic response to produce the desired effects, which are summarised in Ta-
ble 1.3. A high insulin level promotes storage of glucose, and a low insulin level
signals the need for the release of glucose fuels, currently in storage, back into the
blood stream. A meal results in an increase of insulin concentration in the blood,
due to the increased secretion of insulin by the β-cells, and signals the liver and
muscles to consume the extra fuel (glucose) available. The liver stores glucose
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as glycogen or fat, and the muscles utilise glucose primarily to repair damaged
muscle cells, for energy storage as glycogen and lastly storage in the fat cells.
Counter regulatory hormones, such as glucagon and adrenaline, signal the
liver to release glucose. Too much glucose removal from the blood-stream can
result in dangerously low blood glucose levels. When the glucose available is
not sufficient to supply the brain’s requirements, hypoglycaemic symptoms in-
clude hunger, anxiousness, restlessness, agitation, perspiration, tachycardia (rac-
ing pulse) and palpitation (irregular and/or forced heart-beats). These symptoms
are partly a result of the release of adrenaline by the body as a counter regulatory
measure to restore normal blood glucose levels, as shown by Figure 1.2. When
there is a deficit in the amount of insulin released, the signal is not available to
the body to indicate it should remove glucose from the blood stream. The blood
glucose level therefore rises and remains higher than the body’s natural basal
glucose level for an extended period, resulting in hyperglycaemia.
In the body’s fasting state the organs must be supplied fuel (glucose) from
the reserves in storage in the liver to retain function. The need for glucose
reserves is indicated by a low insulin concentration in the blood. The brain is the
body’s priority for supply and continuously requires glucose. If the glucose is not
available to supply all major organs, the energy requirement of the brain is still
met by the liver’s stored glycogen reserves. Neonates typically possess limited
endogenous glycogen reserves, and it has been demonstrated that ketones provide
a substantial proportion of the brain’s energy requirements [Avery et al., 1994].
These dynamics are shown in Figure 1.3.
Insulin is an anabolic hormone and promotes growth, while lowering glucose
levels [Vander et al., 2001]. However, endogenous deficiency or lack of effect due
to high insulin resistance will have a negative impact on glycaemic levels [Thabet
et al., 2003]. Additionally, studies have shown reduced proteolysis, and thus
preservation of muscle mass associated with insulin therapy in neonates [Agus
et al., 2006, 2004], independent of glucose infusion [Hertz et al., 1993]. Insulin
also increases the activity of other enzymes, primarily those involved in glycogen,
lipid and protein synthesis, and inhibits the activity of those that catalyse glucose
degradation.
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Figure 1.2: Effect of high and low blood glucose levels on the body. Adapted from
endocrineweb.com.
1.4 Glucose control
Clinical interventions to control blood glucose levels typically focus on modulating
two common exogenous inputs into this metabolic system: glucose and insulin.
Hardware for implementing glucose control via modulating insulin and nutrition
inputs is well developed and part of standard critical care equipment. Blood
glucose sensors are widely available in a range of configurations from discrete
and continuous point-of-care devices to laboratory-grade measurement systems
[Chase et al., 2006a]. Thus, the success of a glucose control system depends upon
disseminating the available clinical information into effective recommendations
to direct glucose and insulin infusions.
Two landmark studies controlling blood glucose by modulating only the in-
sulin input have shown the impact of tight control on mortality and other clinical
outcomes in adults. First, van den Berghe and colleagues [2001; 2003] showed
that tight blood glucose control to less than 6.1 mmol/L reduced cardiac surgical
ICU patient mortality by up to 45% in a randomised controlled trial. Krins-
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ley and colleagues [2003b; 2004] reported a 17-29% total reduction in mortality
over a wider, more critically ill, ICU population with a higher glucose limit of
7.75 mmol/L. However, this study was a comparison to a matched cohort of
retrospective data with enough patients to show statistical significance for the
intervention.
The SPRINT protocol [Chase et al., 2008b; Lonergan et al., 2006b,a] modu-
lated both the insulin and nutrition inputs using a paper protocol that emulated
model-based control. A 26%-35% reduction in hospital mortality for adult ICU
patients compared to matched retrospective data was observed following the in-
troduction of the protocol as a clinical practice change. Insulin effect saturation in
adults often limits the gains that can be achieved through insulin-only protocols.
Hence, the addition of nutrition modulation provides a non-saturable pathway to
gain and maintain tight glucose control.
There is currently no best-practice method available for neonates. Hypergly-
caemic infants are often treated by glucose restriction [Hemachandra and Cowett,
1999; Thabet et al., 2003; Farrag and Cowett, 2000]. However, prolonged severe
glucose restriction may adversely affect the infant’s nutritional status and may
also be a reason for poor growth observed in these infants [Thabet et al., 2003].
The rate of fetal growth varies throughout gestation, increasing from 5 grams/day
at the end of the first trimester to 30-35 grams/day at 32-34 weeks gestation [Zyl-
berberg and Pepper, 2001].
Limited trials of glucose control using only insulin to control glucose in
neonates have been reported [Meetze et al., 1998; Collins et al., 1991; Binder
et al., 1989; Ostertag et al., 1986; Vaucher et al., 1982; Beardsall et al., 2007a,
2008; Vlasselaers et al., 2009; Kanarek et al., 1991; Thabet et al., 2003; Ng et al.,
2005]. Positive outcomes of improved glycaemic control, glucose tolerance and
growth have been reported [Binder et al., 1989; Collins et al., 1991; Kanarek et al.,
1991; Thabet et al., 2003; Ostertag et al., 1986; Meetze et al., 1998; Vaucher et al.,
1982]. Reduced proteolysis in response to insulin infusions has also been demon-
strated in neonates [Poindexter et al., 1998; Agus et al., 2006, 2004]. However,
most studies are limited by small study cohorts.
In particular, [Vlasselaers et al., 2009] used a relatively low target band of
2.6 - 4.4 mmol/L for preterm infants in their study that included older children,
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and reported overall positive outcomes. However, these low glucose target levels
were subject to debate [Fendler and Mlynarski, 2009; Van den Berghe et al., 2009].
The NIRTURE study [Beardsall et al., 2008] was a large, multi-centre randomised
controlled trial that recruited 389 patients from 8 neonatal units. The goal of
the study was to provide insulin replacement therapy to prevent catabolism, as
opposed to directly combat hyperglycaemia. Thus, insulin, together with sup-
plementary glucose, was infused into patients with and without hyperglycaemia,
using a fixed weight-based protocol [Beardsall et al., 2007b]. The study was
discontinued early due to concerns over excessive hypoglycaemia, which over-
shadowed the improved glucose tolerance and weight profile results. This latter
result for the NIRTURE trial also highlights the requirement for glucose con-
trol protocols to account for the significant variations in patient condition, drug
therapies and tolerance to glucose and insulin.
Fixed protocols do not account for inter-patient variation, and ad-hoc proto-
cols that rely on clinician judgement increase clinician workload and the potential
for variation due to subjective reasoning [Chase et al., 2006a, 2008a]. Model based
methods allow information about the metabolic state of the patient, and infant
in this case, to be inferred from serial blood glucose measurements and records
of nutrition and insulin administration [Chase et al., 2007, 2006a; Hann et al.,
2005]. Therefore, a model capturing the fundamental dynamics of the neonatal
glucose regulatory system could be used to develop methods to better control
blood glucose levels in this cohort, while also enhancing nutritional support and
improving outcomes.
Thus, the current state of glucose control therapies in current clinical practice
is that tight blood glucose control has been employed in adult intensive care via
insulin and/or nutrition modulation with positive outcomes. Glucose restriction
is a common treatment for hyperglycaemia in the neonate, but can result in neg-
ative growth outcomes [Mena et al., 2001]. All reported insulin infusion trials in
neonates have used either fixed protocols or clinician judgment to determine in-
sulin infusion rates. Hence, there is currently no standard protocol that accounts
for specific patient sensitivity to glucose and insulin, and thus no protocol that
is adaptive to patient-specific variability.
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1.5 Model-based glycaemic control
Currently, most typical practice in intensive care glycaemic management using in-
sulin for both adults and neonates is comprised of ad-hoc protocols based primar-
ily on experience, where intravenous insulin is titrated against glucose measure-
ments variably taken every 1–4 hours. When combined with the unpredictable
and sudden metabolic changes that characterise this aspect of critical illness
and/or clinical changes in nutritional support, this approach results in highly
variable blood glucose levels. The overall result is sustained periods of hyper- or
hypo- glycaemia, characterised by oscillations between these states. The situa-
tion is exacerbated by exogenous nutritional support regimes with high dextrose
content. Hence, there is an emerging, strong need for the more rigorous analysis
and methods that model-based control methods bring to this type of problem.
A physiological model that captures the glucose-insulin system dynamics is
thus the basis for more optimally addressing the glycaemic control problem.
Metabolic modelling of the glucose-insulin system has a very deep history in
the published literature. The vast majority of these models have their roots in
basic compartment modelling with differential equations [Carson and Cobelli,
2001]. To date, the primary use of metabolic models has been the development
of model-based measures to assess metabolic parameters, with a particular focus
on measuring insulin sensitivity [e.g. Bergman et al., 1979, 1981, 1985; Pacini and
Bergman, 1986; Yang et al., 1987; Mari, 1998; Mari et al., 2001, 2003; Lotz et al.,
2006, 2008; Toffolo et al., 1999, 2006].
However, a model for glycaemic control in intensive care needs to be applica-
ble for real-time clinical control, addressing the needs and limitations typical of
most ICUs. Metabolic models that are complex in physiological details, although
accurate given rigorous laboratory data, are not often practical for real-time gly-
caemic control utilising less frequent and noisier blood glucose measurements.
These issues will be explored with examples in Chapter 2. Therefore, a model
suitable for glycaemic control in any type of intensive care setting needs to satisfy
the following basic criteria:
• Accurately capture insulin and glucose pharmacokinetics and pharmacody-
namics typical of critically ill patients.
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• Feature a simple structure preferably requiring only blood glucose levels as
physiological feedback.
• Address inter- and intra-patient variability over time.
• Have rapidly identifiable patient specific model parameters.
Given an accurate model satisfying these criteria, model-based glycaemic
control can offer individualised control adaptable to the critically ill patient’s
highly dynamic physiological condition. Furthermore, such a physiological model
may also be used as a patient simulator for protocol development given realistic
patient specific parameters [Hann et al., 2005; Wong et al., 2006a; Lonergan et al.,
2006b,a; Chase et al., 2007]. Additional knowledge of the critically ill population’s
variable dynamics can further enhance model-based control with more accurate
predictive performance.
1.6 Control performance measures
Understanding the difficulties and defining desired controller performance is the
first step to controller design. A variety of performance metrics have been used in
different critical care glycaemic studies, with their differences often confounding
direct comparisons between studies. These metrics can be summarised as four
basic goals:
Mean blood glucose level: calculated over all measurements [Krinsley, 2004]
or over limited measurements, such as first morning measurement [Van den
Berghe et al., 2001, 2003]. The average is the simplest performance measure
and the one used in both landmark clinical studies. However, it provides
no further information on glucose excursions or tightness of control. An
important consideration is the use of a trapezoidal mean to obtain the
proper mean value if the sampling period is particularly irregular [Doran,
2004; Shaw et al., 2005]. In addition, an average value should utilise all
blood glucose measurements and not just a morning average, as in Van den
Berghe et al. [2001, 2006], which can hide variability and poor control.
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Figure 1.4: Comparison of normal and lognormal distributions fitted to a sample of
1,091 BG measurements from neonatal intensive care. The fitted lognormal distribution
more accurately represents the underlying BG measurement distribution, compared to
the symmetrical normal distribution.
Distribution of blood glucose level: Most studies report an average glycae-
mic level and standard deviation, assuming blood glucose measurements are
normally distributed. As a negative blood glucose concentration is physi-
cally impossible, a log-normal distribution provides a more accurate repre-
sentation of the underlying spread of measurements. Figure 1.4 provides an
example of a typical distribution of BG measurements, and a comparison
of fitted normal and lognormal probability density functions. Finally, em-
pirical cumulative distribution functions provide a framework to display all
measurements and allow interpretation of results for any desired glycaemic
band.
Time in a glycaemic band: calculated as the time or percentage of measure-
ments in a specific band, such as 4–6.1 mmol/L [Lonergan et al., 2006b;
Wong et al., 2006a,b] or 4.5–6.1 mmol/L [Plank et al., 2006]. Maximising
this metric is essentially equivalent to minimising the Hyperglycaemic In-
dex (HGI) or area under the blood glucose level curve [Van den Berghe,
2004b; Vogelzang et al., 2004]. This metric provides a surrogate measure of
the average value, as well as an indication of the tightness of the glycaemic
control result. Using multiple overlapping or contiguous bands provides a
good definition of the total glucose distribution under control.
Glucose variability: measured as the standard deviation or 90% interval over
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the data. This metric has only been employed recently [Chase et al., 2005a;
McDonnell et al., 2005] and measures the tightness of blood glucose control
around the average or target value. It is also increasingly important in man-
aging Type 1 diabetes [Kovatchev et al., 2004, 2005; Hirsch and Brownlee,
2005]. However, it provides no indication of the absolute glycaemic levels
obtained and some methods assume normal or other statistical distribu-
tions that may not match the data. Hence, confidence intervals determined
from the data may prove more useful. Note that recent studies indicate
the variability in control may be a critical determinant of outcome [Chase
et al., 2006b].
Hypoglycaemic episodes: measured as the number or percentage of measure-
ments that are below a defined hypoglycaemic threshold. The typical defini-
tion is 2.2 mmol/L, although some studies use higher thresholds [Lonergan
et al., 2006b; Plank et al., 2006]. Variability also captures some of this
information when associated with the average or median glucose values.
More importantly, this measure is a critical indicator of the safety of the
control methods used.
Finally, clinical end-points such as mortality are a patient-specific outcome
and tied to the control of glucose on a per-patient basis. Whole cohort results
allow analysis of the full glycaemic control data set to assess outcomes such
as hypoglycaemia, which has a typically low incidence rate but great clinical
implications. Thus, each categorisation method provides a different insight into
the data, and both are required to clearly describe the performance of a particular
protocol [Goldberg et al., 2006].
1.7 Specific considerations for neonatal control
Blood glucose control for the neonate poses several challenges that differ from the
adult critical care case. Absolute blood volumes in preterm infants are relatively
small [Cassady, 1966; Leipala et al., 2003; Avery et al., 1994]. Thus, the number
of blood glucose measurement must be optimised to a minimum useful number
to conserve volume.
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Endogenous energy supply stores are limited in preterm infants at birth as fat
accretion does not occur until the 3rd trimester [Hume et al., 2005; Avery et al.,
1994; Mena et al., 2001]. Thus, preterm infants must be constantly fed to provide
enough energy for basal requirements in addition to growth [Hay et al., 1999]. In
contrast, the adult can tolerate periods of reduced caloric intake. Tight glucose
control may allow clinicians to more actively manage nutrition. The primary
goal of premature infant nutrition is to achieve weight gain comparable to fetal
growth without additional stress to immature metabolic and excretory functions
[Ditzenberger et al., 1999]. Thus, it is desirable to administer adequate calories
to facilitate growth, whilst maintaining glucose homeostasis. Overfeeding can
lead to excessive oxidation demands for respiration, taxing the premature lung
[Poindexter et al., 1998], and over-aggressive nutrition regimes may lead to obesity
and insulin resistance in later life [Hay, 2006].
Many pharmacokinetic studies routinely performed in adults are technically
and ethically difficult in the preterm neonate [Farrag and Cowett, 2000]. Thus,
adapting known physiology from the adult case with available data for the neonate
is important to develop a clinically sound model of the glucose-insulin regulatory
system for the preterm neonate.
1.8 Preface
Preterm infants represent a significant proportion of the neonatal population. Hy-
perglycaemia is an altered state of metabolic homeostasis that commonly afflicts
the youngest and sickest infants. A growing body of evidence links the degree of
hyperglycaemia to increased morbidity and mortality, and reflects similar findings
in the adult critical care case. Tight glucose regulation through insulin and/or
nutrition modulation has shown positive outcomes in adults. However, such a
level of tight control has not yet been achieved for the preterm neonate.
The pathophysiology of hyperglycaemia exhibits some marked differences in
the neonate compared to the adult case, and the goals for tight control in neonates
emphasise nutrition and growth outcomes in addition to the protective effects of
insulin and normoglycaemia. Significant physiological differences means there is
no simple translation of adult therapies to the unique neonatal case.
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Model-based methods can identify patient-specific parameters in real-time
and adapt control, and provide a pathway for clinically realistic glycaemic con-
trol systems that handle the great heterogeneity that is the hallmark of neonatal
glucose metabolism. This thesis presents the adaptation of a validated glucose-
insulin regulatory system model to the unique case of the neonate. Stochastic
modelling of the insulin sensitivity parameter is used to forecast likely changes
in condition to enhance safety against hypoglycaemia and manage intra-patient
variability. Simulations performed on virtual patients are used to optimise proto-
col performance in-silico, and the system is piloted in a series of 24-hour clinical
trials.
Chapter 2 reviews models of glucose and insulin pharmacokinetics that have
been applied to control of glycaemia in critical care. A model that accounts
for the unique physiology of the neonate is developed.
Chapter 3 presents the integral-based parameter identification method, and
adapts model parameters based on available neonatal data.
Chapter 4 presents the validation of the neonatal glucose-insulin model on ret-
rospective data, including assessments of model fit and prediction perfor-
mance, and suitability for use in real-time clinical control.
Chapter 5 develops methods for insulin sensitivity variation forecasting. Stochas-
tic and time-series analysis techniques are used to generate likelihood bands
for future blood glucose concentration to improve control performance and
add safety.
Chapter 6 presents simulated control trials on ‘virtual patients’ as a tool to
optimise controller robustness and performance prior to any clinical imple-
mentation.
Chapter 7 presents the pilot trials of the model-based glucose control system
in the Christchurch Women’s Hospital Neonatal Department.
Chapters 8 and 9 summarise the key aspects of the thesis and present possible
future improvements and applications for this research.

Chapter 2
Model development
2.1 Introduction
The dynamics of the human glucose-insulin system have been extensively studied.
A number of researchers have created models with different levels of detail and
complexity to suit different clinical or research applications. In particular, many
models have been designed to provide model-based measures to assess metabolic
parameters, with a particular focus on measuring insulin sensitivity [e.g. Bergman
et al., 1979, 1981, 1985; Pacini and Bergman, 1986; Yang et al., 1987; Toffolo
et al., 1999, 2006; Mari, 1998; Mari et al., 2001, 2003]. Several researchers have
constructed control system models to dose insulin infusions for the control of
blood sugar levels [Chase et al., 2006a; Deutsch et al., 2004]. Biomedical control
system models can capture, as well as predict, patient behaviour. Such a model
offers a safe and fast means for protocol development without the limitation
of clinical data scarcity [Chase et al., 2007]. However, control system models
must often work with clinically available data in real-time, which limits feasible
model complexity and detail compared to models designed to illuminate human
physiology in research settings [Chase et al., 2006a].
To date, no model has specifically accounted for the glucose-insulin dynamics
of the preterm neonate. Whilst it has been shown that major metabolic markers
and control systems are present from a very early age, significant physiological and
hormonal differences imply existing control system models will require adaptation
to provide a clinically acceptable level of performance. The clinically fragile
nature of preterm neonates means that pharmacokinetic data from invasive tests
is limited due to technical, clinical and ethical constraints. Thus, knowledge
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gained from control system modelling in adults can guide model development in
neonates.
This chapter examines several forms of existing metabolic control-relevant
models that have been used in adult intensive care. A neonatal control system
model is developed from this foundation that utilises available physiological data.
To make this transition, several model parameters are adapted from the adult to
the neonatal case based on clinical data.
2.2 Models in critical care
Intensive care represents a highly controlled environment where most glucose-
insulin system inputs and outputs can be accounted for and thus modelled.
However, the stress of critical illness can significantly disturb the glucose-insulin
regulatory system from a healthy baseline [McCowen et al., 2001; Capes et al.,
2000; Van den Berghe et al., 2001; Mizock, 2001; Thorell et al., 2004; Bloomgar-
den, 2003; Christensen, 2001; Coursin and Murray, 2003; Esposito et al., 2003;
Finney et al., 2003; Umpierrez et al., 2002]. This situation is exacerbated by the
myriad of medications administered to the critically ill, many of which exhibit
highly patient-specific effects on glucose metabolism. Such detailed pharmacody-
namic information may not be measurable in a typical clinical setting. Thus, any
control system model must make a compromise between physiological validity,
clinical applicability and mathematical identifiability, as shown schematically in
Figure 2.1.
Mathematical 
identifiability
Physiological
completeness
Clinical
applicability
Figure 2.1: Competing requirements of modelling in a critical care environment
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There have been several metabolic models used in clinical examination of
critical care patients and glycaemic control [Wong et al., 2006a,b; Hovorka et al.,
2004; Chee et al., 2003a,b; Plank et al., 2006], as reviewed in [Chase et al., 2006a].
Each model is substantially different, based in part on the modelling direction
taken or clinical focus. A common theme, and benefit, is the ability to tailor
insulin dosage to the current, inferred, patient condition. The first model is that
of Chee and colleagues [2003a; 2003b] who used an optimised PID form of control.
Insulin increment =

4 U/hr, if ‖W zone‖ > 4.5
2 U/hr, if 3.6 ≤ ‖W zone‖ ≤ 4.5
1 U/hr, if 2.7 ≤ ‖W zone‖ ≤ 3.6
0 U/hr, if ‖W zone‖ < 2.7
(2.1)
where:
∥∥W zone∥∥ = 1∑24
i=1 i
(
24∑
n=1
n.Wzone[n]
)
(2.2)
Bolus =

6 U/hr, if ∆yproj ≥ 2 mmol/L
4 U/hr, if 1 ≤ ∆yproj < 2 mmol/L
0 U/hr, if ∆yproj < 1 mmol/L
(2.3)
∆yproj =
(∑6
i=1XiYi∑6
i=1X
2
i
)
.∆x (2.4)
Xi = xi − x˜ and Yi = yi − y˜ (2.5)
x˜ =
xmax + xmin
2
and y˜ =
ymax + ymin
2
(2.6)
where:
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Table 2.1: Sliding table with BG zone assignment. Adapted from [Chee et al., 2003b].
BG range Insulin dose Assigned
(mmol/L) (U/hr) zone
> 20.0 4 6
15.1 - 20.0 3 5
12.1 - 15.0 2 4
10.1 - 12.0 2 3
8.1 - 10.0 1 2
6.1 - 8.0 1 1
0.0 - 6.0 0 0
xmax = maximum time value in the 30-min window
xmin = minimum time value in the 30-min window
ymax = maximum BG value in the 30-min window
ymin = minimum BG value in the 30-min window
The integral control (Equation 2.1) is implemented when sliding tables do
not provide adequate glycaemic reduction and the amount of additional insulin
is calculated using Equation 2.2, a normalized weighted average of the BG zones
shown in Table 2.1 using a 2-hour triangular window. Derivative control is im-
plemented using Equations 2.3-2.6. Expert control is implemented by keeping an
active sliding table and ‘offsetting’ the recommended sliding table input accord-
ing to several conditions, based on Equations 2.3-2.6, in order to determine the
control input.
The ideal weighting values used in this form of control may be difficult to
ascertain from physiological data, and thus would require re-tuning for each
unique clinical population or individual patient. In particular, given the sig-
nificant metabolic differences in the neonate compared to the adult critical care
patient, any tuning would be based on current clinical judgement and/or require
extensive testing. Additionally, as this model is designed from a control view-
point, with little specific physiological dynamics, inferences of patient condition
are not easily linked to known physiology in the same way a physiologically-based
control model can.
The second model is that of Hovorka et al, which has been used in clini-
cal practice to provide blood glucose control for patients with Type 1 diabetes
[Hovorka et al., 2004] and, in similar form, for 48 hour trials on cardiac surgery
2.2 MODELS IN CRITICAL CARE 27
 
FC01Q1 
VGG 
-FR 
Q1 Q2 k12 
x1 
x2 
x3 
Gut 
absorption 
UG 
G=Q1/VG 
EGP0 
I
 
ka1 
ka2 
ka3 
kb1 
kb2 
kb3 
Insulin 
absorption 
UI/VI 
ke 
Figure 2.2: Compartmental model of glucose-insulin system (Adapted from [Hovorka
et al., 2004])
patients with stress-induced hyperglycaemia [Hovorka et al., 2007; Plank et al.,
2006]. The overall structure of the model is shown in Figure 2.2.
Q˙1(t) = −
[
F c01
VGG(t)
+ x1(t)
]
Q1(t) + k12Q2(t)
−FR + UG(t) + EGP0[1− x3(t)] (2.7)
Q˙2(t) = x1(t)Q1(t)− [k12 + x2(t)]Q2(t) (2.8)
y(t) = G(t) = Q1(t)/VG (2.9)
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F c01 =
{
F01 if G ≥ 4.5 mmol/L
F01G/4.5 otherwise
(2.10)
FR =
{
0.003(G− 9)VG if G ≥ 9 mmol/L
0 otherwise
(2.11)
UG(t) =
DGAGt exp (−t/tmax,G)
t2max,G
(2.12)
S˙1(t) = u(t)− S1(t)
tmax,I
(2.13)
S˙2(t) =
S1(t)
tmax,I
+
S2(t)
tmax,I
(2.14)
I˙(t) =
UI(t)
VI
− keI(t) (2.15)
where:
UI(t) = S2(t)/tmax,I (2.16)
x˙1(t) = −ka1x1(t) + kb1I(t) (2.17)
x˙2(t) = −ka2x2(t) + kb2I(t) (2.18)
x˙3(t) = −ka3x3(t) + kb3I(t) (2.19)
where Q1 and Q2 represent masses of glucose in the accessible and inaccessible
compartments, k12 the transfer rate between the inaccessible and accessible com-
partments, VG the distribution volume of the accessible compartment, y and G
the measurable glucose concentration, and EGP0 the endogenous glucose pro-
duction extrapolated to zero insulin concentration. F c01 is the total non-insulin-
dependent glucose flux corrected for the ambient glucose concentration and FR is
the renal glucose clearance above the glucose threshold of 9 mmol/L. UG(t) is the
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gut absorption rate, dependent upon the carbohydrates digested, DG, carbohy-
drate bio-availability, AG, and the time-of-maximum appearance rate of glucose
in the accessible compartment, tmax,G. The insulin subsystem is described by
Equations 2.13-2.15. S1 and S2 are a two-compartment chain for absorption
of subcutaneously administered rapid-acting insulin, u(t) the insulin input (bo-
lus/infusion), and tmax,I the time-to-maximum insulin absorption. I(t) is the
plasma insulin concentration, ke is the fractional elimination rate and VI the dis-
tribution volume. The insulin action subsystem consists of three components,
endogenous glucose production, transport/distribution and disposal (x1, x2 and
x3). Finally, kai and kbi (i = 1, . . . , 3) represent the activation and deactivation
rate constants of insulin action respectively.
Overall, the model uses 9 population values or generic constants, and requires
a further 6 patient specific parameters to be identified. Nonlinearity comes from
insulin action on parameters of glucose production, glucose distribution/transport
and glucose disposal, and difference in the activation/deactivation profile of the
three insulin actions. As a result it requires a significant number of measurements
to be identifiable for controlling a specific patient.
This model represents an approach aimed for the physiologically descriptive
sector of the modelling space described in Figure 2.1. In particular, this model
defines insulin sensitivity as a ratio of ‘activation’ and ‘deactivation’ rates for
insulin in a remote, unmeasurable compartment: kbi and kai (i = 1, . . . , 3) re-
spectively. This relatively detailed physiological modelling allows the separation
of insulin action into specific effects on disposal, transportation and suppression
of endogenous glucose production. The separation of these effects allows measure-
ment of their temporal variation to a challenge in insulin and/or glucose through
double-labelled tracer studies, showing its original focus and use for physiological
research [Hovorka et al., 2002].
The compartmental form of Equations 2.17-2.19 can capture ‘delay’ and
‘memory’ effects of insulin action on the relevant glucose uptake and metabolism
pathways. The double-labelled tracer study is a relatively intensive study in
terms of blood requirements. Thus, gathering such dense data may be techni-
cally difficult in the preterm neonate, which is the focus of this thesis.
Reported data has been collected from healthy, adult patients, and showed
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substantial inter-subject variation [Hovorka et al., 2002]. It is expected in critical
care that the relationship of insulin effects on metabolism may be different. In
particular, varying levels of circulating counter-regulatory hormones typical of
stress-induced hyperglycaemia may change rapidly with patient condition and
enhance such inter-patient and intra-patient variability.
Finally, Chase and colleagues used a model loosely based on Bergman’s mini-
mal model [Bergman et al., 1987] with additional non-linear terms and a grouped
term for insulin sensitivity [Chase et al., 2007; Wong et al., 2006b,a]. This model
has been employed in several critical care glycaemic control trials using different
control approaches, as well as in retrospective analyses [Lonergan et al., 2006b;
Chase et al., 2007, 2008c, 2005c,b; Wong et al., 2005, 2006b,a].
G˙ = −pGG− SI(G+GE) Q
1 + αGQ
+ P (t) (2.20)
Q˙ = −kQ+ kI (2.21)
I˙ = − nI
1 + αII
+
uex(t)
V
(2.22)
P (ti < t < ti+1) = P¯i+1 + (P (ti)− P¯i+1)e−kpd(t−ti)where P¯i+1 < P (ti) (2.23)
P (ti < t < ti+1) = P¯i+1 + (P (ti)− P¯i+1)e−kpr(t−ti)where P¯i+1 > P (ti) (2.24)
where G(t) is the plasma glucose above an equilibrium level, GE, and I(t) is
the plasma insulin resulting from exogenous insulin input, uex(t). The effect of
previously infused insulin being utilised over time is represented by Q(t), with
k accounting for the effective life of insulin in the system. Patient endogenous
glucose clearance and insulin sensitivity are pG and SI , respectively. V is the
insulin distribution volume and n is the constant first order decay rate for insulin
from plasma. Total plasma glucose input is denoted P (t). Michaelis-Menten
functions are used to model saturation, with αI used for the saturation of plasma
insulin disappearance, and αG for the saturation of insulin-dependent glucose
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clearance [Hann et al., 2005; Chase et al., 2005c]. The parameters kpr and kpd
relate to the effective half lives of glucose transport from gut to plasma for both
increasing (kpr) and decreasing (kpd) feed rates respectively, and P¯i+1 are the
steps in enteral glucose feed rates.
The final two equations account for glucose appearance from enteral nutri-
tion via feeding tube as the glycaemic control studies using this model [Chase
et al., 2005a; Wong et al., 2006a] modulate both insulin and nutrition inputs to
reduce plasma glucose levels. This approach thus looks at both sides of the glu-
cose balance, exogenous insulin removal of glucose and glucose appearance from
exogenous nutrition, to reduce glycaemic levels in the face of insulin resistance
and insulin saturation.
Modulating nutritional dextrose inputs also provides a physiologically non-
saturable path to reduce plasma glucose, at least to the point of eliminating
nutritional input entirely. It is important to note that this approach is focused
on controlling the dextrose carbohydrate content exacerbating hyperglycaemia,
rather than the overall nutritional profile. This last issue could be practically
addressed, for example, by separating the dextrose and protein-fat nutritional
inputs infused.
The model of Equations 2.20 - 2.24 has been extensively validated in long-
term data fitting [Hann et al., 2005]. As noted, its clinical validity is well estab-
lished in glycaemic control in ICU. In all these cases, the insulin sensitivity term
SI was found to be the dominant term driving control system dynamics, and thus
has been used as the major parameter that is time-varying, patient-specific and
fitted to measured data as required. The physiological and clinical relevance of
this SI value has also been seen in the very high correlations to the euglycaemic
clamp [Lotz et al., 2006, 2008].
2.3 Neonatal BG system model
The model of Chase et al shown in Equations 2.20 - 2.24 is used as a starting point
from which a neonatal glucose-insulin system control model will be developed,
based on success in real-time glycaemic control, long-term patient parameter
identification, and virtual-patient simulation for in-silico protocol development
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[Chase et al., 2007; Lonergan et al., 2006b].
The model will be adapted with reference to specific relevant elements of
neonatal physiology that are particularly different to adults, and to account for
relevant neonatal physiological data present in literature. Population parameter
values used in the model will thus be derived from available literature sources.
The final model is presented in summary form in Section 2.4, but Figure 2.3
presents an overall schematic of the model structure.
 
Figure 2.3: Basic outline of the fundamental physiology of glucose sources, insulin
sources and their utilisation to remove glucose.
The concept of a time-varying, patient-specific insulin sensitivity is preserved
in this model. Several clinical studies [Vaucher et al., 1982; Ostertag et al.,
1986; Beardsall et al., 2007a] have reported the neonatal response to exogenous
insulin and nutrition inputs is highly patient-specific. Thus, a similar approach
is taken in this model adaptation to use population constant parameters for the
glucose-insulin kinetics and fit insulin sensitivity as a lumped parameter. Thus
SI effectively captures the overall patient response to exogenous nutrition and
insulin inputs. This approach, just as in the adult applications of this model,
thus minimises the unknown to critical parameters and, as a result, maximises
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identifiability. Hence, with its physiologically relevant structure, it sits in the
intersection of Figure 2.1.
2.3.1 Glucose kinetic modelling
The model of Equations 2.20 - 2.24 uses a mono-compartmental description of
glucose kinetics. Three-compartment models of glucose kinetics have been identi-
fied by various dose-response and glycaemic clamp tests with the help of glucose
tracers [Insel et al., 1974; Cobelli et al., 1984]. However, the costly nature of
multi-tracer experiments limit their use to very specialised research studies and
render them impractical for control or clinical use.
As the fastest equilibrating compartment in the 3-compartment model was
found to be too fast to identify accurately (time constant 0.6 min, [Cobelli et al.,
1984]), it was proposed to combine the ‘fast’ and ‘medium’ compartments. Some
researchers assume a fixed relationship between glucose compartments [Hovorka
et al., 2002]. The neonatal system model will be used to identify patient pa-
rameters from measurements spaced 1-4 hours apart, and rapid changes in blood
glucose concentration are not a goal of control in this setting. Thus, the main ad-
vantage of the glucose compartment structure used here is its identifiability using
limited plasma samples, while still accounting for the dominant physiologically
relevant dynamics.
The term GE in Equation 2.20 originated in the minimal model and is defined
as the basal glucose level. This term is available in studies such as intravenous
and oral glucose tolerance tests, as typically these investigations begin with the
patient in a fasted state and thus permit measurements of baseline variables.
However, in critical care such baseline measurements are not feasible and, due
to the critical illness of the patient, the baseline glucose level may be altered or
time-varying due to circulating counter-regulatory hormones. This approach is
also not feasible in the preterm neonate with limited endogenous energy stores,
who must be fed continuously.
Thus, the term G(t) in Equation 2.20 can be redefined as the total blood
glucose concentration. This change creates a constant term (pG.GE), which rep-
resents the endogenous balance between glucose output (eg: from the liver) and
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non-insulin mediated glucose uptake (eg: central nervous system). Equation 2.25
shows the glucose compartment model adapted from Equation 2.20. The endoge-
nous glucose production and central nervous system uptake terms are explicitly
defined, and nutritional inputs are separated in enteral (PEN) and parenteral
(PTPN) pathways to reflect typical NICU nutrition practices:
G˙ = −pGG− SIG
(
Q
1 + αGQ
)
+
PTPN(t) + PEN(t)
VG,frac ×mbody
+
((EGPmax − CNS.mbrain,frac)×mbody)
VG,frac ×mbody (2.25)
where G(t) [mmol/L] is the total plasma glucose. Patient endogenous glucose
clearance and insulin sensitivity are pG [min
-1] and SI [L/(mU.min)], respec-
tively. Endogenous glucose production is denoted by EGPmax [mmol/kg/min]
and VG,frac [L/kg] represents the glucose distribution volume per kilogram of body
weight. CNS [mmol/kg/min] represents non-insulin mediated glucose uptake by
the central nervous system, and mbrain,frac represents brain weight as a propor-
tion of body weight. Body weight is denoted by mbody [kg]. Michaelis-Menten
functions are used to model saturation with αG [L/mU] used for the saturation
of insulin-dependent glucose clearance. PTPN(t) [mmol/min] represents dextrose
from parenteral sources and PEN(t) [mmol/min] represents dextrose absorption
from enteral sources via the gut.
The parameter CNS represents non-insulin mediated glucose uptake by the
central nervous system. In contrast to the adult case, the brain represents a ma-
jor source of glucose uptake in infants, due to their larger brain-to-body weight
ratio [Hertz et al., 1993; Farrag et al., 1997]. Glucose metabolism by the brain is
relatively constant [Gruetter et al., 1998] and independent of insulin concentra-
tion [Cowett and Farrag, 2004]. Positron Emission Tomography (PET) is used to
quantify cerebral glucose uptake, however this technique requires the use of ra-
dioactive compounds, and thus is technically and ethically difficult to perform in
preterm neonates. The value used for CNS in this study was 8.8µmol/min/100g
brain weight (0.088 mmol/min/kg brain weight) based on [Powers et al., 1998].
This study used PET to quantify cerebral glucose uptake in neonates with sus-
pected hypoxic-ischaemic encephalopathy to justify subjecting the patients to
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radioactive compounds. The value used for CNS in this study is taken from
patients in [Powers et al., 1998] that did not display any long-term neurological
deficits, and thus represents an estimate of cerebral glucose uptake in a neonatal
brain without any major defects. The average brain weight of the preterm infant
at the age used in this cohort was estimated at 14% of body weight [Ho et al.,
1981].
The parameter EGPmax represents endogenous glucose production, which
can be measured in tracer studies [Hertz et al., 1993; Poindexter et al., 1998;
Cowett et al., 1983; Sunehag et al., 1999; Tyrala et al., 1994; Van Kempen et al.,
2003; Kalhan et al., 1986]. Endogenous glucose production is decreased in the
presence of increased blood glucose concentration and increased plasma insulin
concentration [Kalhan et al., 1986; Bergman et al., 1985]. Because of the fragile
nature of this population, the true fasting rate of glucose production cannot
be explicitly determined. In addition, almost all such studies are performed
concurrently with parenteral nutrition to avoid underfeeding the low birth weight
neonate.
However, Figure 2.4 plots the average endogenous glucose production against
blood glucose concentration for the available literature reporting tracer studies
in preterm neonates, the details of which are shown in Table 2.2. At G = 0, the
pG and SI terms in Equation 2.25 become zero. Thus, the range of values for
EGPmax = [0.0172 to 0.0312 mmol/kg/min] suitable for this model formulation
were obtained from Figure 2.4 at G = 0 (the intercept with the y-axis). This
extrapolation of endogenous glucose production to zero glucose is similar to the
procedure employed by [Hovorka et al., 2002], and also used by Bergman to
evaluate renal uptake [Bergman et al., 1985]. Bootstrapping with replacement
(N=1000) was used to determine the mean intercept and the upper and lower 5%
of possible intercepts that define this range for the data shown.
The estimates of basal endogenous glucose production used in this study are
higher than the values seen in adults [Hertz et al., 1993; Thorell et al., 2004].
The explanation for this difference is that the extra glucose is required in infants
for growth and to supply the glucose requirements of the relatively large brain
in the infant compared to total body weight [Kalhan, 2003]. In particular, it has
been shown that endogenous glucose production (via glycogenolysis and gluco-
neogenesis, primarily from the liver) may not be suppressed in the preterm infant
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Figure 2.4: Endogenous glucose production (EGP) against steady-state blood glucose
concentration. Dashed lines represent the 5%-95% confidence interval range of possible
endogenous glucose production (0.0172-0.0312 mmol/kg/min).
by exogenous glucose infusions [Farrag et al., 1997; Cowett et al., 1983]. Specif-
ically, [Farrag et al., 1997] found a maximal suppression of endogenous glucose
production of 58% of basal rates. This result is in marked contrast to the healthy
adult who can effectively completely suppresses endogenous glucose production.
However, it is similar to the critically ill adult [Chase et al., 2006a; McCowen
et al., 2001]. In this research, some of this effect is captured by the parameters
pG and SI , which incorporate contributions of increased insulin concentration
[Hertz et al., 1993] and plasma glucose concentration [Farrag and Cowett, 2000]
to decreasing net hepatic glucose output.
Several studies have reported that many neonates produce an inadequate
glucose raising response to decreases in glucose infusion [Van Kempen et al.,
2003] and to a bolus of glucagon [Jackson et al., 2003]. Additionally, it has
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Table 2.2: Endogenous glucose production (EGP) measured in preterm neonates.
Gest. age
(weeks)
Weight
(kg)
EGP
(mg/kg/min)
Blood glucose
(mmol/L)
Source
34.5 2.1 3 3.6
[Cowett et al., 1983]
34.2 2.0 1.4 5.39
28.2 1.0 10.9 3.0 [Sunehag et al., 1999]
26.2 0.9 1.0 6.9 [Hertz et al., 1993]
26.3 0.9 1.2 5.7 [Poindexter et al., 1998]
23-28 0.9 12.3 5.4 [Tyrala et al., 1994]
31.0 1.1 6.0 4.3
[Van Kempen et al., 2003]
31.0 1.1 8.8 3.4
34.5 1.7 7.8 3.7
34.5 1.7 11.6 3.4
39.1 3.0 1.1 5.0
[Kalhan et al., 1986]
38.0 2.1 1.8 3.6
35.5 2.2 1.9 4.5
38.0 2.1 4.3 2.8
39.1 3.0 3.5 3.4
35.5 2.2 3.5 2.4
been shown that many preterm infants have concentrations of hepatic glucose-
6-phosphatase, the rate limiting enzyme in gluconeogenesis, below the limit of
normal term infants [Hume et al., 2005]. Glycogen stores in premature infants
to produce further glucose for use are also relatively sparse [Mena et al., 2001;
Hume et al., 2005]. Therefore, low birth weight infants must be fed adequately
to prevent long-term deficiencies in growth and development [Hay et al., 1999].
The majority of exogenous dextrose supply for preterm infants is in the form
of parenteral nutrition, typically through pre-made parenteral nutrition formulas
or occasionally mixed with other medications such as morphine, insulin and dobu-
tamine. Enteral feedings are often initiated during the first week of life through
administration of expressed breast milk (EBM). The PEN term in Equation 2.25
represents the absorption of enteral nutrition through the gut. The uptake of dex-
trose from enteral sources for neonates uses the same model as Equations 2.23
and 2.24. The parameters kpr and kpd represent the rate of change of dextrose
absorption into the bloodstream following a change in the enteral nutrition rate,
based on [Wong et al., 2006b], and are set to half-lives of 20 minutes and 100
minutes respectively, similar to the adult case.
Enteral feedings represent a minor source of glucose in this cohort and its
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administration is highly dependent upon clinical condition. Many preterm infants
with insulin infusions receive less than 5-10% of total daily glucose via the enteral
route based on retrospective data, and in many cases infants receive no enteral
nutrition. Thus, the values used for kpr and kpd are assumed to have a small effect
on model dynamics. EBM is modelled with an effective glucose concentration of
approximately 7% [Anderson et al., 1983].
In normal, healthy subjects most glucose filtered through the kidney is re-
absorbed and very little is lost through urine. In diabetic subjects, high blood
glucose concentrations exceed the renal threshold for glucose reabsorption and
renal losses account for a measurable amount of glucose disposal. Coulthard and
Hey [1999] showed that in ventilated preterm neonates renal glucose excretion
showed a less well-defined threshold value than in adults, and that the amount
of renal excretion was related to the amount of filtered glucose and hence blood
glucose concentration. Thus, in the model presented here, this effect is assumed
to be largely captured in the pG term of Equation 2.25.
With respect to saturation effects [Farrag et al., 1997] found no plateau in
the rate of glucose uptake at several increasing levels of insulin infusion during
clamp tests, and that the neonatal glucose response to insulin far exceeded the
maximal response reported in the adult [Rizza et al., 1981]. This result suggests
that insulin mediated glucose uptake does not saturate at the insulin delivery
rates typically encountered in neonatal intensive care. Therefore, the parameter
representing saturation of insulin mediated glucose uptake, αG, was set to zero
in this study. This lack of saturation effect is significantly different to the adult
case, where the significant glucose uptake saturation can occur [Wong et al.,
2006a; Prigeon et al., 1996; Chase et al., 2004; Natali et al., 2000].
The distribution of fluids in the neonatal body is markedly different from chil-
dren and adults. In particular, the extra-cellular fluid compartment is a much
higher percentage of total body weight [Lorenz et al., 1995; Hartnoll et al., 2000;
Simpson and Stephenson, 1993]. It can also change over time as very preterm
neonates can pass through a diuretic stage in the first few days of life [Lorenz
et al., 1995; Bidiwala et al., 1988], and the body fluid compartments redistribute
over the first few weeks of life to approach adult proportions, as shown in Ta-
ble 2.3. Hence, a population-based, time-varying volume of glucose distribution
as a proportion of body weight was created for the parameter VG,frac based on
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Figure 2.5: Proportion of body weight used to estimate VG. Adapted from [Avery
et al., 1994].
Table 2.3: Body water distribution in preterm infants and adults. All values are
expressed as percentage of body weight. Adapted from [Avery et al., 1994].
Gestation(weeks)
Adult
24 28 32 36 40
Total body water 86% 84% 82% 80% 78% 60%
Intra-cellular fluid 27% 28% 30% 32% 34% 40%
Extra-cellular fluid 59% 56% 52% 48% 44% 20%
the clinical data shown in Figure 2.5 [Avery et al., 1994; Cassady, 1966].
2.3.2 Insulin kinetic modelling
The two-compartment insulin model of Equations 2.21 and 2.22 upon which this
model is based allows ‘delay’ in insulin action and ‘memory’ effects of previously
infused insulin to be captured, similar to the Hovorka model of Equations 2.13-
2.15 [Hovorka et al., 2002]. These effects are accounted for via physical insulin
transport in the I and Q compartments, as opposed to remote insulin-action com-
partments, which allows model calibration using plasma insulin measurements.
The insulin compartments used in this model are thus defined:
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Q˙ = −kQ+ kI (2.26)
I˙ =
−nI
1 + αII
+
uex(t)
VI,frac ∗mbody + IBe
−
(
kI
uex(t)
VI,frac∗mbody
)
(2.27)
where I(t) [mU/L] is the plasma insulin, exogenous insulin input is represented
by uex(t) [mU/min] and basal endogenous insulin secretion IB [mU/L/min], with
kI [min
-1] representing the suppression of basal insulin secretion in the presence
of exogenous insulin. The effect of previously infused insulin being utilized over
time is represented by Q(t) [mU/L], with k [L/(mU.min)] accounting for the
effective life of insulin in the system. The parameter VI,frac [L/kg] is the insulin
distribution volume per kilogram body weight and n [1/min] is the constant first
order decay rate for insulin from plasma. Michaelis-Menten functions are used
to model saturation, with αI [L/mU] used for the saturation of plasma insulin
disappearance.
2.3.2.1 Plasma insulin compartment (I)
The distribution volume for insulin, VI,frac, was set to a neonatal plasma volume
of approximately 4.5% of the body weight expressed in kilograms [Leipala et al.,
2003; Cassady, 1966]. The parameter IB represents basal insulin secretion in the
presence of no exogenous insulin input. This parameter provides an estimate of
basal insulin secretion to better model the actual physiological situation. It also
makes the model robust in the sometimes frequent periods where no exogenous
insulin is administered. It is assumed that exogenous insulin administration sup-
presses endogenous insulin secretion and the parameter kI broadly captures this
suppression effect.
The parameter IB was set to a population constant of 10 mU/L/min to
achieve steady state basal insulin concentrations of approximately 12 mU/L (ie:
the concentration I for which I˙ in Equation 2.27 is equal to zero). This value is
very similar to the reported clinical results shown in Table 2.4.
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Table 2.4: Basal plasma insulin concentration in preterm neonates. N indicates num-
ber of patients in each study.
Basal plasma
Source
insulin
7 mU/L (N=11)
[Pildes et al., 1969]
14 mU/L (N=8)
15 mU/L (N=11)
[Andronikou and Hanning, 1987]
18 mU/L (N=12)
6 mU/L (N=11)
16 mU/L (N=12)
13.9 mU/L (N=14)
[Poindexter et al., 1998]
11.9 mU/L (N=12)
4 - 9 mU/L (N=30) [Farrag et al., 1997]
The parameter kI was set to 0.1 to produce a suppression of endogenous
insulin that matched data reported in [Farrag et al., 1997], who found plasma
insulin concentration was relatively insensitive to rate of insulin infusion for low
insulin infusion rates, and a proportional increase in plasma insulin concentration
for higher rates of insulin infusion. Figure 2.6 shows the modelled appearance rate
of insulin into the plasma compartment against rate of exogenous insulin infusion.
The appearance of insulin is dominated by the endogenous insulin production
estimate at low exogenous insulin infusion rates, and matches exogenous insulin
infusion at higher rates.
The parameter n represents the disappearance of insulin from plasma. Fac-
tors influencing this parameter include transport into the interstitial space and
removal by the liver and kidneys. Data shown in Table 2.5 are adapted from
studies that achieved a steady state of insulin infusion. The values of n in Ta-
ble 2.5 were obtained by numerically solving Equation 2.27 using the constant
insulin infusion rate documented for each study until steady-state was reached.
The resulting concentrations were compared to the reported literature study, and
the parameter n was adjusted until the simulated and reported plasma insulin
concentrations matched. In this study, a value of n = 0.9min−1 was used, com-
pared to 0.16 min−1 in adults [Hann et al., 2005]. The values and range from
these studies are presented in Table 2.5. This result matches observations that
the rate of insulin clearance was much higher in neonates compared to healthy
adults [Farrag et al., 1997].
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Figure 2.6: Endogenous and exogenous components of the rate of appearance of
insulin into the plasma compartment against rate of exogenous insulin infusion. uen
represents the endogenous insulin production term and uex represents exogenous insulin
infusion.
Figure 2.7 shows the plasma insulin model and population constants are valid
for a wide range of reported insulin concentrations from steady exogenous insulin
infusions. Typical insulin infusion rates expected in neonatal control scenarios
would occupy the left half of the range shown in Figure 2.7, below 0.3 U/kg/hr.
Agus et al [2006; 2004] used supra-physiological concentrations of insulin to de-
termine the effects of insulin on protein breakdown. Thus, they provide further
data points but at clinically irrelevant values.
Typical steady state insulin concentrations for the adult insulin model of
Equation 2.22 for similar weight-based rates of insulin infusion are shown in Fig-
ure 2.7. Neonatal plasma insulin concentrations are significantly lower than adults
for similar weight-adjusted rates of exogenous insulin infusion [Farrag et al., 1997].
This result may represent a much higher metabolic clearance rate of insulin in
the neonate. To date, the specific mechanisms that create a higher metabolic
clearance rate in neonates remain as open questions. The goal of this study was
to generate a model designed for control purposes that matches observable insulin
kinetics in the neonate and further investigation of physiological mechanisms of
insulin transport is outside the scope of this research.
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Figure 2.7: Modelled and measured steady-state plasma insulin concentration against
insulin infusion rate. The neonatal model used for this study neglecting insulin disposal
saturation and the model used for adults are shown for comparison. The discrete points
represent individual studies as presented in Table 2.5
Published data was not available to directly estimate the insulin removal
saturation parameter αI , so this parameter was held at the same value as the
adult case. Figure 2.7 shows that the effect of αI is only relevant at very high
insulin infusion rates, and that the value employed provides a good fit to the
supra-physiological results of [Agus et al., 2004, 2006]. The insulin model in
adults exhibits instability for insulin infusion rates greater than approximately
18 U/hr for a typical 70kg adult due to the insulin removal saturation term αI .
The adult model was designed for use for insulin in the range of 0 - 8 U/hr (0 -
0.11 U/kg/hr). The dynamics of the neonatal model allow stability for a insulin
infusion rates up to 1.4 U/hr for a typical 1kg infant, and represents an infusion
rate approximately 3x - 9x higher than would be used for control.
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2.3.2.2 Insulin delay compartment (Q)
The Q compartment reflects accumulation dynamics of insulin [Doran, 2004].
This compartment can be pictured in terms of a delay in the action of insulin
due to transport of insulin through the interstitium to the site of action. Given
the 1-3 hour window between BG measurements and insulin interventions, and
that the sole method of insulin delivery to be used in neonates is via infusion
(as opposed to bolus), the effects of any extra non-linear dynamics that could be
introduced using a bolus-based regime are minimized. Thus, the I compartment
to Q compartment transport is likely to play less importance in neonatal control
compared to adults. The ratio of extra-cellular fluid (ECF) to plasma is higher in
neonates compared to adults, as shown in Table 2.3. Thus, it is possible that the
model may over-estimate the accumulated insulin ‘on-board’ as a conservative
assumption to minimise a model-based controller over-infusing insulin.
The effective life of insulin, k was assumed not to differ significantly from
adults [Hann et al., 2005], and that passive diffusion can explain the major trans-
port phenomenon between plasma and the interstitium [Castillo et al., 1994;
Rasio et al., 1967; Sjostrand et al., 1999; Yang et al., 1989; Steil et al., 1996]. It
should also be noted that a constant excretion would be expected in the presence
of relatively constant nutritional infusions.
Finally, Figure 2.8 shows a typical response of the I and Q compartments
developed in this section to a typical insulin infusion regime from clinical data.
The plasma insulin concentration (I) closely follows the insulin infusion rate due
to the relatively short effective half-life of insulin in this compartment. The
response of the Q compartment demonstrates the overall smoothing effect to
create a physiologically likely insulin effect response.
2.3.2.3 Comparison with adult model
The response of the individual compartments of the insulin kinetics model to
typical insulin infusions in neonates and adults are compared in Figure 2.9. The
data points in Figure 2.9 are generated by comparing the hourly average concen-
tration in the specific compartment, I or Q, with the average rate of exogenous
insulin administration over the hour. Polynomial curves are fitted to the data to
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Figure 2.8: Plasma insulin (I) and insulin accumulation (Q) compartment response
to a typical insulin infusion profile from retrospective neonatal data.
generate curves that represent the 95% prediction bounds for comparison. The
data for the NICU analysis was obtained from the retrospective cohort described
more fully in Section 3.2. The data for the adult ICU analysis was obtained
from the SPRINT study [Chase et al., 2008b]. SPRINT primarily uses boluses as
the insulin delivery route, discretised to 1U increments, which creates the vertical
banding effect in Figures 2.9b and 2.9d. Also note the scales are different between
cohorts.
The response of the plasma insulin compartment is much tighter in neonates
compared to adults, as evidenced by the tighter 95% prediction bounds in Fig-
ure 2.9a versus Figure 2.9b. This result is a consequence of the significantly higher
insulin clearance rate in neonates. The modelled plasma insulin concentrations
are generally lower than adults, as a result.
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(a) NICU Iavg vs. uex,avg (b) Adult Iavg vs. uex,avg
(c) NICU Qavg vs. uex,avg (d) Adult Qavg vs. uex,avg
(e) NICU Qavg vs. Iavg (f) Adult Qavg vs. Iavg
Figure 2.9: Comparison of average values of I and Q compartment with exogenous
insulin infusion rate. Dashed lines represent 95% prediction bands.
The insulin delay compartment, Q, shows a similar difference between adults
and neonates. The averaged modelled concentrations in the I and Q compart-
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ments shows a near 1:1 ratio in neonates (Figure 2.9e), reflecting the use of
infusions and the typical longer time period between infusion rate changes that
allows both compartments to equilibrate. The ratio of concentrations is lower
than 1:1 in adults suggesting that transport between the insulin compartments
plays a more significant role.
A primary reason for the shallower slope in Figure 2.9f is the bolus method
of delivery for the adult data. A bolus of insulin is effectively a very high insulin
infusion rate over a relatively very short amount of time. The effectively high
infusion rate leads to a high plasma insulin concentration that saturates the mod-
elled insulin clearance mechanisms, determined by the value of αI , and creates
non-linear effects. Thus, clinical considerations, such as the method of insulin
delivery, play a role in determining the relative importance of model parameters.
Any and all of the insulin clearance pathways could be feasibly altered in
the neonate. More detailed insulin kinetics models exist for the adult case that
incorporate separate liver and kidney insulin clearances with separate saturation
mechanics, tissue insulin breakdown and back-flow transport of insulin from the
interstitial compartment to the plasma compartment [Lotz et al., 2006; Sherwin
et al., 1974]. The model presented here uses lumped parameters to broadly
capture these effects to create a system that may be useful for control and reflects
the compromise required to make use of limited clinical data.
The cohort for control and the method of insulin delivery can influence the
model BG response. As a simulated example, Figure 2.10 shows two virtual trials
of an adult patient for a sliding-scale protocol using the same absolute amount
of insulin per hour, delivered as a bolus on the hour for the ‘Bolus’ method, and
a constant infusion for the ‘Infusion’ method. Virtual trial methodology will be
covered in detail in Chapter 6. The bolus method resulted in a lower simulated
BG response. This result is due to the non-linear clearance of insulin. Thus, more
insulin is available to bind with tissue receptors and stimulate glucose uptake in
the bolus case, causing an overall lower BG response. Therefore, the saturation
of plasma insulin clearance would be an important parameter for control of gly-
caemia in a bolus-based scheme. However, neonatal glucose control is entirely
infusion based. Thus, the plasma insulin clearance saturation mechanisms carry
a lower weighting in creating a model designed for glycaemic control in neonates.
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Figure 2.10: Virtual trial BG response for bolus and infusion insulin delivery methods.
The top panel shows simulated blood glucose concentration. The middle panels show
the concentrations in the I and Q compartments for infusion and bolus insulin delivery
methods. Model-fitted insulin sensitivity is displayed in the bottom panel. The bolus
method of insulin delivery resulted in a generally lower blood glucose profile.
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2.4 Model summary
In summary, the overall model used in this work is defined:
G˙ = −pGG− SIG
(
Q
1 + αGQ
)
+
PTPN(t) + PEN(t)
VG,frac ∗mbody
+
((EGPmax − CNS.mbrain,frac) ∗mbody)
VG,frac ∗mbody (2.28)
Q˙ = −kQ+ kI (2.29)
I˙ =
−nI
1 + αII
+
uex(t)
VI,frac ∗mbody + IBe
−
(
kI
uex(t)
VI,frac∗mbody
)
(2.30)
PEN(t) = P¯EN,i+1 + (PEN(ti)− P¯EN,i+1)e−kp(t−ti) for ti < t < ti+1 (2.31)
where:
kp =
{
kpr where P¯EN,i+1 > PEN(ti)
kpd where P¯EN,i+1 < PEN(ti)
where G(t) [mmol/L] is the total plasma glucose and I(t) [mU/L] is the plasma
insulin, exogenous insulin input is represented by uex(t) [mU/min] and basal en-
dogenous insulin secretion IB [mU/L/min], with kI [L/(mU.min)] representing
the suppression of basal insulin secretion in the presence of exogenous insulin.
The effect of previously infused insulin being utilized over time is represented
by Q(t) [mU/L], with k [min-1] accounting for the effective life of insulin in the
system. Body weight and fractional brain weight are denoted by mbody [kg] and
mbrain,frac respectively. Patient endogenous glucose clearance and insulin sensitiv-
ity are pG [min
-1] and SI [L/(mU.min)], respectively. The parameter VI,frac [L/kg]
is the insulin distribution volume per kilogram body weight and n [min-1] is the
constant first order decay rate for insulin from plasma. Endogenous glucose pro-
duction is denoted by EGPmax [mmol/kg/min] and VG,frac [L/kg] represents the
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Table 2.6: Constant model parameter values
Parameter Value
k 0.0086 min-1
n 0.90 min-1
αI 1.70 x 10
−3 L/mU
αG 0 L/mU
CNS 0.088 mmol/min/kg brain weight
mbrain 0.14 * mbody kg
IB 10 mU/L/min
VI,frac 0.045 L/kg
VG,frac ECF proportion
a L/kg
EGPmax 0.02838 mmol/kg/min
pG 0.003 min
-1
a ECF proportion derived from Figure 2.5
glucose distribution volume per kilogram of body weight. CNS [mmol/kg/min]
represents non-insulin mediated glucose uptake by the central nervous system.
Michaelis-Menten functions are used to model saturation, with αI [L/mU] used
for the saturation of plasma insulin disappearance, and αG [L/mU] for the sat-
uration of insulin-dependent glucose clearance. PTPN(t) [mmol/min] represents
dextrose from parenteral sources and PEN(t) [mmol/min] represents dextrose ab-
sorption from enteral sources via the gut due to set exogenous dextrose rates
P¯EN . The parameters kpr [min
-1] and kpd [min
-1] are the effective half lives of
glucose transport from gut to plasma for both increasing (kpr) and decreasing
(kpd) feed rates respectively.
Table 2.6 summarises the parameters used in this model. For this study, k,
n, αI , αG, CNS, IB and VI,frac are set to generic population values based on
reported data, as described in this chapter. Prior clinical and model sensitivity
studies with the similar adult model [Hann et al., 2005; Wong et al., 2006a]
have shown this choice to be robust with respect to prediction of response to
clinical interventions. The specific values for EGPmax and pG are determined
from parameter sensitivity studies presented in Section 3.3.
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2.5 Summary
Glucose-insulin system dynamics are described by models designed for applica-
tions from interpreting detailed tracer studies and quantifying human physiology,
to control system models that capture patient dynamics and variability based on
the limited data available in critical care. The model presented in this section
is developed for ready clinical control applicability. The focus of development
in this case is more a robust, adaptable model, rather than being metabolically
correct in every detail.
While glucose-insulin dynamics in neonates has not to date been extensively
modelled, the rich history of model-based methods in adults helps guide the
adaptation of the model to the neonatal case. Differences in both neonatal phys-
iology and aspects of routine neonatal care can be quantified and explored in a
model-based environment.
Finally, the model developed in this section provides an overall measure of a
critically ill patient’s sensitivity to exogenous insulin and nutrition inputs. The
following chapter uses retrospective hospital data to validate the model against
a cross-section of typical preterm neonatal patients to explore model robustness
and performance metrics.
Chapter 3
Parameter identification and sensitivity analysis
This chapter presents the parameter identification methods used to identify crit-
ical model parameters. It thus also presents a sensitivity analysis on several
model parameters to ensure the choices of population constant parameter values
and identified parameters are robust. Thus, it implicitly presents a limited model
validation analysis in its evaluation of model parameters and model performance
versus retrospective clinical data. A full, complete validation of the model, while
partly overlapping some results, is left for Chapter 4.
3.1 Fitting methods
The insulin sensitivity parameter SI is the critical time-varying, patient-specific
parameter to be identified from either retrospective data in simulation-based vir-
tual patient studies, or in clinical real-time. The fitting procedure must be able
to account for significant patient variation over time. It must also be compu-
tationally simple enough to be performed in clinical real-time of 1-5 minutes,
or preferably faster. Finally, fitting the patient specific parameters in any of
the models presented typically presents a non-convex optimisation problem, due
primarily to the series of non-linear differential equations involved [Carson and
Cobelli, 2001].
The most commonly used method for fitting parameters in these types of
compartment models is non-linear recursive least squares (NRLS) [Carson and
Cobelli, 2001; Marquardt, 1979]. Given the non-convex nature of the problem this
method will produce results that are starting point dependent, and thus require a
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range of initial values to generate optimal results. NRLS is also computationally
intense [Carson and Cobelli, 2001], particularly where longer periods of data are
being fit than those encountered in short 30-300 minute physiological research
studies.
Iterative, Bayesian and gradient descent based methods have also been used
in a variety of forms [Vicini and Cobelli, 2001; Hovorka et al., 2002; Erichsen
et al., 2004; Zheng and Zhao, 2005]. Given the non-convex and non-linear models
involved, these methods are all specific to the exact model and methods employed.
In addition, they still rely on a core optimisation problem that is non-convex,
computationally intensive and not necessarily robust to noise in the data. Thus,
they are essentially problem specific and not necessarily generalisable to broader
situations.
Overall, a variety of fitting methods are available. Traditional methods, such
as NRLS, offer results with some potential limitations depending on the specific
problems. However, these methods also require repeated re-simulation to generate
gradients for each variable to be fit, resulting in significantly added computation.
An emerging method that simplifies many of these problems is the integral
method of [Hann et al., 2005]. Integrating the differential model equations con-
verts the problem to one of matching areas under curves. Parameterising un-
known, time-varying patient specific parameters as piecewise constant, or higher
order, functions recreates the problem in terms of unknown constants that are
more readily identified. Using measured data and numerical integration, the prob-
lem can thus be converted into a convex linear least squares problem to obtain
these constants. The numerical integration further low-pass filters the data mak-
ing it robust to noise. Finally, it does not require gradients or, thus, re-simulation
of the model saving significant computational effort. The integral method has
been used in a variety of clinical glycaemic control studies [Wong et al., 2006a,b;
Hann et al., 2005; Chase et al., 2005b] and in other similar biomedical models
[Hann et al., 2006; Lotz et al., 2006], providing significant in-silico and clinical
validation.
The integral-based method is used to identify SI in the neonatal model. For
this study, the form of the insulin sensitivity function is chosen to be piecewise
constant, with a new value determined every hour, which has been shown to
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adequately capture the variation in SI [Lin et al., 2006, 2008]. Equation 2.28
defines the glucose kinetics for this model, and is repeated below:
G˙ = −pGG− SIG
(
Q
1 + αGQ
)
+
PTPN(t) + PEN(t)
VG,frac ∗mbody
+
(EGPmax − CNS ∗mbrain,frac) ∗mbody
VG,frac ∗mbody (3.1)
The integral-based method fits insulin sensitivity by first integrating both
sides of the glucose compartment equation between the limits ta and tb, defined
as the fitting start and end time respectively:
∫ tb
ta
G˙(t)dt =
∫ tb
ta
{
−pGG− SIG
(
Q
1 + αGQ
)
+
PTPN(t) + PEN(t)
VG,frac ∗mbody
+
(EGPmax − CNS ∗mbrain,frac) ∗mbody
VG,frac ∗mbody
}
dt (3.2)
All values except insulin sensitivity (SI) are known, measured or approxi-
mated population constants. A linear piece-wise polynomial fit to the BG mea-
surements is used to approximate G(t) between measured values. Insulin sensitiv-
ity is assumed constant over the fitting window ta to tb. This interval is typically
1 hour, but can be made any convenient length. Additionally, it may be allowed
to vary more or less frequently than the measurement rate [Hann et al., 2005].
Thus, Equation 3.2 can be rearranged:
G(tb)−G(ta) =
−SI
∫ tb
ta
{
G
(
Q
1 + αGQ
)}
dt (3.3)
+
∫ tb
ta
{
−pGG+ PTPN(t) + PEN(t) + (EGPmax − CNS ∗mbrain,frac) ∗mbody
VG,frac ∗mbody
}
dt
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Table 3.1: Time segments used to generate a system of equations for a fitting window
of [0 60] minutes
ta,i (mins) tb,i (mins)
0 15
15 30
30 45
45 60
0 30
15 45
30 60
0 45
15 60
0 60
Rearranging terms yields:
SI
∫ tb
ta
{
G
(
Q
1 + αGQ
)}
dt =
− (G(tb)−G(ta)) (3.4)
+
∫ tb
ta
{
−pGG+ PTPN(t) + PEN(t) + (EGPmax − CNS ∗mbrain,frac) ∗mbody
VG,frac ∗mbody
}
dt
Equation 3.4 can be used to generate a system of linear equations that can be
solved by linear least-squares methods. The system of equations is generated by
splitting the fitting window (ta, tb) into a set of time segments, which allows more
accurate area-fitting of the non-linear model in a least-squares sense. Table 3.1
shows an example of splitting the fitting period into 10 segments, although any
number might be used [Hann et al., 2005] to allow higher fitting higher order
functions for the insulin sensitivity parameter SI . Equations can be generated
by integrating between different pairs of time segments.
The use of several time segments creates an over-determined system that can
be solved using the method of least squares. The resulting set of equations can
be arranged into a standard linear-algebra form (for k time segments):
Ax = b (3.5)
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where
A =

∫ tb,1
ta,1
{
G
(
Q
1+αGQ
)}
dt
. . .
. . .∫ tb,k
ta,k
{
G
(
Q
1+αGQ
)}
dt
 (3.6)
x = SI (3.7)
b =

− (G(tb,1)−G(ta,1))
+
∫ tb,1
ta,1
{
−pG + PTPN (t)+PEN (t)+(EGPmax−CNS∗mbrain,frac)∗mbodyVG,frac∗mbody
}
dt
. . .
. . .
− (G(tb,k)−G(ta,k))
+
∫ tb,k
ta,k
{
−pG + PTPN (t)+PEN (t)+(EGPmax−CNS∗mbrain,frac)∗mbodyVG,frac∗mbody
}
dt

(3.8)
Finally, solving Equation 3.5 yields the value of SI over the time window [ta, tb].
Further details and analysis of the integral-based fitting method are available in
[Hann et al., 2005].
Overall, the integral-based method has several merits specific to the estima-
tion of insulin sensitivity in glycaemic control:
• Ability to fit entire patient record and multiple measurements all at once
to generate virtual patient insulin sensitivity profiles.
• Hour-to-hour measurements may be fitted in real-time for model-based con-
trol.
• Requires no re-simulation and is 10-100 times faster than NRLS [Hann
et al., 2005].
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A caveat of the integral-based method is that relatively ‘dense’ blood glucose
measurements are required for accurate identification. The method has been suc-
cessfully used to identify insulin sensitivity using retrospective BG measurement
data with measurement intervals of up to 3-4 hours [Hann et al., 2005; Doran,
2004].
3.2 Retrospective data
Retrospective data from 25 episodes of insulin therapy treatment in Christchurch
Women’s Neonatal Intensive Care Unit was used in the study for model validation.
Ethics approval for the collection and publication of data was obtained from the
Upper South A Ethics Committee. The 25 episodes of insulin usage comprised
21 individual patients representing 3,567 hours of patient data. Gestational age
at birth ranged from 23 to 28.9 weeks, and birth weight ranged from 600 to 1,280
grams. Inclusion criteria were birth weight less than 1,500 grams and a period of
treatment with insulin of at least 12 hours. The clinical details of the retrospective
cohort are presented in Table 3.2. Data was collected during episodes of insulin
infusions, and includes periods around the times of insulin usage where blood
glucose was actively monitored even though no insulin was infused.
The retrospective cohort contained 14 female and 7 male patients. Five pa-
tients were of Maori ethnicity, which tend to be over-represented in the population
of preterm neonates in New Zealand [Mantell et al., 2004]. Two patients died
in-hospital and represent the mortality of this cohort.
Table 3.3 summarises the major glycaemic control information for each ret-
rospective patient.
The distribution of blood glucose measurements, insulin infusion rates and
dextrose administration are shown in Figure 3.1. In particular, 31% of blood
glucose measurements were within the 4 - 7 mmol/L range, with median insulin
usage of 0.032 U/kg/hr. The majority of dextrose infusion rates spanned a 3-fold
range of approximately 5 - 15 mg/kg/min.
Patients 1, 12 and 23 had low minimum BG measurements (≤ 2.6 mmol/L).
Several of these cases were not associated with insulin infusions, and thus rep-
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resent other causes of neonatal hypoglycaemia. Such causes would include low
endogenous stores of nutritional substrates, and reduced expression of key ele-
ments involved in gluconeogensis, such as glucose-6-phosphatase [Van Kempen
et al., 2003; Diderholm et al., 2007]. These events were close to the initiation of
insulin therapy, and were thus included in the retrospective data.
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(a) Blood glucose measurements in retrospective patients, with µˆgeo = 7.9 mmol/L and σˆgeo
= 1.17.
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(b) Insulin infusions (hourly average) in retrospective patients. Median rate [IQR] = 0.037
[0.026 - 0.050] U/kg/hr.
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(c) Dextrose infusion rates (enteral and parenteral) in retrospective patients. Median rate
[IQR] = 9.6 [8.3 - 10.4] mg/kg/min.
Figure 3.1: Distribution of glycaemic variables in retrospective cohort.
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Also evident in Figure 3.1a is the right-skewed spread of blood glucose mea-
surements resembling a lognormal distribution. Thus, the summary metrics in
Table 3.3 are reported using lognormal statistics. For a given set of BG mea-
surements the lognormal distribution parameters for the sample, µˆ and σˆ, are
fitted using maximum likelihood parameter estimation. The geometric mean and
geometric standard deviation are given by µgeo = e
µˆ and σgeo = e
σˆ respectively,
and are quoted in Table 3.3. Upper and lower bounds for confidence intervals
for the data are given by multiplying and dividing the geometric mean by the
geometric standard deviation. For example, the 2σ confidence interval is given
by
[
µgeo/σ
2
geo, µgeo.σ
2
geo
]
.
3.3 Parameter identification and sensitivity analysis
3.3.1 Endogenous glucose production and glucose uptake
parameters
The parameters EGPmax, pG and SI are the remaining parameters to explicitly
determine from the data. As a result of using EGPmax at G = 0, the parameters
pG and SI incorporate the effects of insulin and blood glucose concentration to in-
hibit endogenous glucose production. Finally, the range of EGPmax in Figure 2.4
delimits the acceptable values for this parameter, but not a specific population
or patient-specific value.
A grid search was performed to determine the optimal population values of
EGPmax and pG for this cohort. In particular, pG was found to be relatively
constant in an adult intensive care population [Hann et al., 2005], and is initially
assumed so here. However, no such indication exists for EGPmax.
To this end, the time-varying parameter SI was fitted to the clinical data using
several values of EGPmax held constant within the range of [0.01442 - 0.03396]
mmol/kg/min, based on Figure 2.4. The range of EGPmax assessed in simulation
extends beyond the 5%-95% range shown in Figure 2.4 to more fully observe the
effect of this model parameter. The value of pG was also held constant within the
range [0.0005 - 0.02] min-1. This range of pG is based on a wide range of adult
results [Doran, 2004] with no further data or indication available for the neonate.
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The time-varying SI profile found for each (pG, EGPmax) pair for values is
smoothed using a 3-point moving average to reduce any effects of sensor noise.
The smoothed insulin sensitivity profile was then used to generate a model derived
BG curve to compare to the clinical data and thus assess the model. A total of
2,000 such assessments were made over the ranges of pG and EGPmax for the 25
patient cohort with SI identified for each (pG, EGPmax) set of values.
The median and IQR of absolute fitting error and prediction error were the
metrics used to compare the ability of the model to fit the data for any set of
parameters. Fitting error was assessed by analyzing the absolute percentage dif-
ference between measured blood glucose concentration and identified model gen-
erated blood glucose concentration. Prediction error is clinically more important
and was assessed over 1, 2, 3 and 4-hour intervals. Predictions were generated at
each blood glucose measurement by holding all parameter values constant over
the prediction interval. Prediction error was analyzed by comparing the error
between the predicted blood glucose concentration and its measured value, or
where a measurement was not available the prediction was compared to a lin-
early interpolated value between two appropriate blood glucose measurements.
The optimal or best (pG, EGPmax) values are thus those that provide the best
outcomes in these fitting and prediction metrics.
Hence, the goal of this model is to provide a vehicle for real-time blood
glucose control. It is therefore desirable to minimise the number of patient-specific
parameters to be identified to avoid identifiability issues with limited (glucose
only) measurements. This issue is particularly important in this neonatal case
where real-time tracer studies are not viable and control must be based upon a
very minimal number and volume of blood samples compared to the adult case.
This latter point is a salient difference from the critically ill adult case where
the blood sampling frequency used is primarily a question of clinical burden.
Therefore, the model must provide better longer term prediction performance at
2 or more hours forward, which is dependent on good identification.
Figure 3.2 shows that median fit and prediction errors, comparing model and
measured glucose values, plateau at minimum levels. These results suggest that
a range of values for pG and EGPmax will provide robust fitting and prediction
performance. In particular, Figure 3.2 also shows the 1, 2, 3 and 4-hour prediction
errors over these same ranges result in similar plateaus of minimal error for pG
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Figure 3.2: Median cohort percentage fit error and model prediction error for several
values of endogenous glucose production (EGPmax) and endogenous glucose clearance
(pG). Fit and prediction quality is very robust to the value of pG and EGPmax utilised.
< 0.01 min-1 and EGPmax > 0.02 mmol/kg/min.
Maximum per-patient fitting error acts as a more sensitive additional assess-
ment metric. This provides more weight to areas of poor fit and prediction instead
of overall fit quality. This aspect is important from a safety standpoint, as it is
more likely that isolated cases of poor model fit and/or prediction will compro-
mise safety and it is thus very important that these instances are highlighted.
The sum of the maximum five BG fitting errors per patient profile was used
to choose the optimum values of pG and EGPmax within the plateau region
of Figure 3.2. The combination of pG = 0.003 min
-1 and EGPmax = 0.02838
mmol/kg/min provided the smallest sum of maximum fitting errors across the
entire cohort.
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3.3.2 Parameter sensitivity
A parameter sensitivity analysis was performed on the model and retrospective
data to determine the effect of assumed population constants on the model fit
and prediction performance. Population parameters in this model are estimated
from literature data, or adapted from adult data where no information on the
parameter in neonates was available. The model parameters pG and EGPmax
are robust to reasonable estimation errors as shown in the Section 3.3.1. The
robustness of the model to the variations in the remaining population constant
parameters is assessed in this section.
This parameter analysis explores two effects stemming from using population
constants in the model:
Model sensitivity to errors in population constants: This sensitivity is as-
sessed by comparing the model fit and prediction performance for variations
in population constants over the whole cohort.
Appropriateness of using a particular population-based constant: This
aspect is assessed by comparing model fit and prediction errors on a per-
patient basis for variations in population constants to determine whether
significantly different or better performance is achieved.
The constants αI , CNS, k, kpr, kpd, n, VG and VI were varied by -50%, -10%,
+10% and +50%. The retrospective cohort data was re-fitted for each parameter
variation. BG fit and prediction analyses were performed to assess performance
to address the questions above.
A model sensitivity analysis was performed for the adult ICU case by [Hann
et al., 2005], and found relatively little difference in insulin sensitivity and model
performance for up to 20% variation in the parameters n, k, αG, and αI . Addi-
tionally, pG was shown to exhibit little variation, compared to insulin sensitivity.
However, differences between adult and neonatal physiology, as well as clinical
practices may weight the sensitivity of the model to variations in these parameters
differently. Such differences, if they exist, may also provide unique insight.
The results in Table 3.4 and Figure 3.3 show that the model performance is
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relatively insensitive to the variations in population constants introduced here.
The volume of glucose distribution, VG, created the greatest effect on model
performance at -50% of the population value used here, which is a very large
change for a typically well known or understood parameter. A reduction of VG of
50% brings this volume closer to the value used for adults in proportion to body
weight. Thus, recognising the increased proportion of body weight taken up as
extra-cellular fluid in neonates is seen to be relevant to accurate glucose control.
This last result provides a further model validation, in that good model perfor-
mance requires accurate neonatal physiology where such differences to adults are
known to exist.
The applicability of constant population parameter values for this model was
tested by assessing the per-patient fit and prediction errors for each population
constant parameter. The BG fit and 1-hour prediction errors are presented for
the parameter VG in Tables 3.5 and 3.6, which are also the worst-case scenario
based on the whole-cohort results of Table 3.4 and Figure 3.3. Variation in the
other population parameters produced similar inter-patient variations in model
performance, but decreased in absolute magnitude.
Thus, the model is overall robust to moderate errors in population param-
eters. Additionally, the choice of population parameters appears appropriate
for the cohort as a whole, as no particular patients exhibited significantly better
model fit or prediction performance when variations in population constants were
introduced. The maximum difference in fit and prediction performance results
are presented in Tables 3.5 and 3.6 for each patient to identify any individual
patient records that are particularly sensitive to the parameter changes.
The median per-patient model fit errors showed largely little inter-patient
variation. The maximum difference in fit performance was less than 2% for 24
of 25 patients. Similarly, the maximum difference in 1-hr prediction performance
was less than 4.2% for 24 of 25 patients. The greatest contributor to this metric
was the 50% reduction in glucose distribution volume, VG. If the results for
this parameter reduction are neglected, the maximum difference between results
per-patient drops to < 2.7% for all patients.
The largest error results belongs to Patient 13. This patient spent a large
amount of time off insulin, and thus provides a ‘stress-test’ for the model to
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Figure 3.3: Model fit and prediction sensitivity to population parameters.
handle the clinically likely periods off insulin. The relatively large maximum
errors in fit and prediction result from increased errors when simulating a 50%
reduction in the glucose volume of distribution. This outlying result further
supports the use of a volume of glucose distribution, VG, that is more compatible
with the body fluid compartment proportions reported in neonatal literature.
This result also highlights that periods without insulin infusions in particular are
more sensitive to variations in the assumed glucose volume of distribution, likely
due to the significant variability in observed endogenous insulin production (IB
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Table 3.5: Per-patient model fit performance sensitivity to variations in VG. Max.
diff. indicates the maximum difference in performance between results for any two
values of VG.
Patient -50% -10% +10% +50% Max. diff.
1 3.0% 2.5% 2.4% 2.3% 0.6%
2 2.9% 1.9% 1.8% 1.5% 1.4%
3 3.4% 2.3% 2.1% 1.8% 1.6%
4 2.1% 1.5% 1.3% 1.3% 0.8%
5 3.7% 2.8% 2.5% 2.0% 1.8%
6 3.7% 3.5% 3.4% 4.9% 1.5%
7 2.8% 1.5% 1.2% 1.3% 1.6%
8 2.4% 1.6% 1.2% 1.0% 1.4%
9 1.1% 1.1% 1.2% 1.2% 0.1%
10 3.7% 2.5% 2.3% 2.0% 1.7%
11 1.4% 1.2% 1.2% 1.3% 0.2%
12 0.6% 0.6% 0.7% 0.7% 0.2%
13 5.3% 2.1% 2.2% 2.6% 3.3%
14 1.9% 1.2% 1.0% 1.3% 0.9%
15 2.4% 2.1% 1.7% 1.6% 0.8%
16 2.6% 1.7% 1.7% 1.4% 1.2%
17 3.9% 3.4% 3.0% 2.1% 1.9%
18 1.8% 1.4% 1.3% 1.4% 0.5%
19 2.7% 2.1% 2.1% 2.3% 0.6%
20 3.1% 2.2% 2.0% 1.6% 1.5%
21 2.7% 2.2% 2.1% 2.0% 0.7%
22 2.6% 2.3% 2.3% 2.0% 0.6%
23 5.9% 5.9% 6.1% 5.8% 0.2%
24 3.4% 3.1% 3.0% 3.0% 0.5%
25 1.4% 0.6% 0.7% 1.0% 0.8%
in the model) and efficacy in neonatal cohorts [Mitanchez-Mokhtari et al., 2004;
Meetze et al., 1998; Farrag and Cowett, 2000].
Overall, the population parameter that appeared to have the most influence
on model fit and prediction errors was the glucose volume of distribution, VG.
Outside this parameter, the low sensitivity of model performance to the remaining
parameters is similar to the adult case [Hann et al., 2005]. This result may imply
that, with the right neonatal parameters, neonates and adults exhibit ‘similar’
metabolic dynamics, which may be unexpected given the differing external clinical
management of metabolism in these patient groups.
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Table 3.6: Per-patient model 1-hr prediction performance sensitivity to variations in
VG. Max. diff. indicates the maximum difference in performance between results for
any two values of VG.
Patient -50% -10% +10% +50% Max. diff.
1 8.4% 7.1% 6.0% 6.1% 2.3%
2 4.9% 3.8% 4.0% 3.3% 1.6%
3 6.5% 4.2% 3.2% 2.8% 3.6%
4 3.9% 3.7% 3.5% 3.5% 0.4%
5 4.9% 3.5% 3.5% 3.3% 1.6%
6 6.3% 5.9% 5.8% 5.4% 1.0%
7 4.8% 3.5% 3.0% 2.6% 2.3%
8 5.5% 3.2% 3.4% 2.6% 3.0%
9 5.3% 4.6% 4.3% 3.6% 1.7%
10 7.8% 6.3% 6.5% 7.8% 1.5%
11 4.9% 5.0% 4.8% 3.7% 1.2%
12 8.1% 5.4% 5.5% 5.5% 2.7%
13 12.9% 7.4% 6.9% 4.8% 8.2%
14 3.4% 5.0% 5.1% 4.8% 1.7%
15 4.4% 4.0% 4.5% 4.7% 0.7%
16 5.0% 3.1% 3.1% 3.5% 2.0%
17 6.0% 4.8% 6.9% 6.8% 2.1%
18 5.6% 5.0% 4.8% 4.9% 0.8%
19 7.7% 4.4% 4.0% 3.5% 4.2%
20 8.2% 5.8% 4.9% 4.3% 3.9%
21 5.6% 5.3% 4.9% 4.8% 0.8%
22 5.7% 4.7% 4.3% 4.4% 1.4%
23 11.4% 10.9% 11.0% 11.3% 0.5%
24 7.1% 6.1% 5.2% 5.4% 1.8%
25 5.5% 5.3% 5.5% 5.4% 0.2%
3.3.3 The impact of assuming constant values for EGPmax
and pG
Population values were chosen for the parameters pG and EGPmax based upon
model fitting and prediction performance in Section 3.3.1. In this section, the
parameter sensitivity analysis is extended to explore the effects of holding these
variables as population constants using a ‘fit-predict’ method. More specifically,
should they be constant or time-varying and what is therefore the impact of
holding them constant?
The parameters to be tested were held piecewise-constant over a period of
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time, and re-evaluated at the end of each period. In this case, periods of 1
and 6 hours were used. At the end of each period, the model is re-simulated
several times over the previous 1 or 6 hours of data using a different value of the
parameter each time to determine which value would have, in retrospect, given
the best 1-hour prediction performance. This best performing parameter value
is then used over the next 1-hour or 6-hour period.
In an additional analysis, both pG and SI were fitted simultaneously using the
integral-based fitting method. These simulations would thus generate parameters
that produce an optimal fit on a per-patient basis, and track any potential changes
in this parameter over time. CDF plots of pG, EGPmax and SI were used to
examine the behaviour and interaction of these parameters.
The fit and prediction results are shown in Table 3.7. Allowing variations in
the endogenous glucose production parameter, EGPmax, overall produced fit and
prediction results similar to holding the parameter constant, with slightly worse
prediction performance. The CDF of EGPmax values selected by the fit-predict
method showed values tended towards the upper limit of the allowable EGP
range. In contrast, the fit-predict method selected pG values at either the upper
or lower limit of the allowable range. These results created greater variability in
fitted insulin sensitivity, as shown by a flatter CDF. Thus, these effects combine
to create significantly worse fit and prediction results.
Finally, using the integral-based method to fit pG generated slightly better
BG fit results, however prediction performance was significantly weakened. Ad-
ditionally, the resulting shape of the insulin sensitivity distribution was different
to all other results. All these results highlight parameters trading-off with each
other when fitting multiple parameters to serial BG measurements.
3.3.4 Effect of enteral feed on model prediction
The enteral feed model used in this study was adapted from the similar model
used successfully in adult intensive care. This model accounts for delays in the
appearance of glucose in the bloodstream from changes in the enteral infusion
rate, and accounts for differing rates due to increases and decreases in feed rates.
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Figure 3.4: Model 1-hr prediction error against proportion of dextrose fed via enteral
route. Each individual point represents a single retrospective patient. The fitted line
shows the correlation neglecting the outlying Patient 23 (R2 = 2.2x10-4, p = 0.94).
EBM = Expressed Breast Milk.
Enteral feeding represents a minority route for dextrose into the body for
these patients. Over half of the retrospective cohort had at least 90% of dextrose
administered via the intravenous parenteral route or TPN. Figure 3.4 shows the
effect of the proportion of dextrose fed via EBM against the median 1-hour model
prediction error. The outlying point belongs to Patient 23, who, as will be de-
scribed in Section 4.2, experienced much more rapid swings in glucose control
compared to other patients despite relatively constant nutritional inputs. Ne-
glecting this outlying point there is no significant correlation between proportion
of dextrose via EBM and model prediction performance (p = 0.94).
3.3.5 Insulin pump and tubing adsorption errors in model
Daily fluid balances are a critical component of neonatal intensive care. The small
volume of the neonate necessitates very low pump flow rates for infusions. These
flow rates are often near the limit of accuracy for many pumps. Additionally,
adsorption of insulin to the walls of the plastic tubing from the pump to the
patient has been shown to alter the net amount of insulin delivered to the patient
in laboratory studies [Hewson et al., 2000; Fuloria et al., 1998; Zahid et al.,
2008]. Christchurch Women’s Neonatal Department flushes all insulin tubing
with insulin solution prior to use to saturate the tube binding sites and minimize
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this latter delivery variation.
To explore these effects on the model prediction performance, four case sce-
narios were simulated to assess the impact. These scenarios adjusted the insulin
input into the model (uex(t) in Equation 2.30) to simulate typically reported
effects:
• Baseline model. No change to retrospectively recorded insulin rates.
• Pump error model. When pump rate increases, 40% of the change occurs
immediately, and the remaining 60% occurs after 5 - 60 minutes, depending
on the new pump rate. Assumes decreases/stoppages are instant. Data
for this scenario model was adapted from the Alaris CC pump instruction
manual [Cardinal Health, 2008].
• Tubular adsorption model. When insulin is started from zero-rate, assume
60% is available instantly, up to 85% after 2 hours. Data adapted from
[Hewson et al., 2000].
• Smoothed insulin. Insulin rate is smoothed using 3-point moving average
if infusion rate of zero is not present.
An example of the pump error model, tubular adsorption model and smoothed
insulin is shown in Figure 3.5. The effect of the insulin delivery models on 1-hour
prediction performance are shown in Table 3.8.
Overall, the insulin delivery models present a relatively small impact to the
overall performance of the model both in a whole-cohort and per-patient sense.
The tubular adsorption and pump models have a relatively small impact on the
insulin delivery rate for typical-to-worst-case values reported in the literature and
technical documentation. In particular, no individual patient shows dramatic
changes in prediction performance accounting for the various errors.
More specifically, the insulin smoothing model accounts for errors during the
data recording and collection process. Infusions in the Christchurch Women’s
Hospital Neonatal Department are recorded as a cumulative amount for the day
to aid in assessing daily fluid balances. Thus, pump flow rates are obtained by
taking the first difference of the recorded data. This process is thus susceptible
3.4 SUMMARY 75
2500 3000 3500 4000 4500 5000
0
0.5
1
1.5
2
2.5
In
su
lin
 
ra
te
 
[m
U/
m
in
]
Pump model
 
 
2500 3000 3500 4000 4500 5000
0
0.5
1
1.5
2
2.5
Time [mins]
Tubing adsorption model
2500 3000 3500 4000 4500 5000
0
0.5
1
1.5
2
2.5
Smoothed insulin profile
 
 
Pump set rate
Pump model rate
Figure 3.5: Effect of tubular adsorption models and pump error models on net insulin
flow rate. The pump set rate represents the intended flow rate as set at the pump. The
pump model rate represents the net rate of insulin reaching the patient.
to noise from errors in the time the observation was recorded. Additionally,
pump displays typically report in units of 0.1 or 0.01 mL, and this rounding
may introduce a relatively large error given the very low flow rates. However,
the insensitivity of model prediction performance to smoothed and un-smoothed
insulin data suggests these errors are minor and relatively evenly dispersed, as well
as that they may provide both reductions and increases in errors that effectively
cancel in summary. This last result would imply that these effects are thus inside
the effective model resolution, which, given the generally low prediction errors
compared to measurement errors, means they have little impact.
3.4 Summary
A model of the glucose regulatory system has been adapted from adult critical
care to the neonatal case. Model fit and prediction performance was found to be
robust to a range of values for endogenous glucose production and non-insulin me-
diated glucose clearance parameter values. Further parameter sensitivity analysis
found model performance, when known neonatal physiology was accounted for,
was insensitive to relatively large deviations in population-constant parameters.
Finally, the integral-based fitting method was presented as an efficient parameter
estimation procedure for both in-silico and real-time clinical utility.
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Table 3.8: Tubular absorption and insulin pump model effects on 1-hour BG prediction
performance. Values are median 1-hr prediction error (%) and [Average of largest 5
errors (%)]
Patient Baseline model Pump-model Tubing model Smoothing insulin
1 6.6% [48.0%] 7.9% [43.6%] 8.0% [44.5%] 6.8% [44.0%]
2 4.2% [23.7%] 4.8% [23.2%] 4.5% [24.0%] 4.0% [24.6%]
3 4.2% [19.6%] 5.0% [25.0%] 5.3% [25.1%] 3.2% [23.2%]
4 3.7% [24.6%] 4.2% [22.5%] 4.4% [23.0%] 4.1% [23.0%]
5 3.9% [16.0%] 4.7% [17.9%] 4.2% [17.8%] 2.8% [16.6%]
6 6.3% [21.6%] 6.3% [23.2%] 6.3% [23.4%] 6.3% [23.9%]
7 3.9% [15.3%] 3.7% [16.7%] 3.7% [17.4%] 3.1% [14.8%]
8 4.5% [12.2%] 5.5% [11.8%] 5.0% [12.2%] 4.6% [12.3%]
9 4.3% [11.6%] 5.1% [11.2%] 5.2% [11.2%] 4.9% [10.4%]
10 6.4% [22.2%] 5.9% [25.4%] 5.5% [28.9%] 6.6% [21.8%]
11 4.9% [18.4%] 4.8% [19.6%] 5.2% [19.4%] 5.3% [19.3%]
12 5.6% [12.8%] 5.7% [11.1%] 5.7% [11.1%] 5.7% [10.4%]
13 8.3% [22.4%] 8.3% [18.6%] 7.4% [14.0%] 7.4% [18.6%]
14 5.0% [17.3%] 5.1% [19.6%] 5.3% [19.8%] 4.4% [18.4%]
15 4.1% [22.8%] 5.0% [23.2%] 4.5% [22.8%] 3.3% [22.4%]
16 2.6% [13.5%] 3.6% [12.9%] 3.5% [12.3%] 3.6% [13.6%]
17 7.1% [16.7%] 7.6% [16.7%] 8.7% [18.0%] 5.2% [15.3%]
18 4.7% [8.6%] 5.1% [9.0%] 5.1% [9.2%] 4.8% [9.0%]
19 5.1% [14.3%] 6.0% [10.8%] 4.3% [12.8%] 4.6% [12.7%]
20 6.6% [21.0%] 8.1% [22.0%] 8.1% [22.4%] 6.9% [20.0%]
21 5.9% [12.4%] 6.2% [17.2%] 6.7% [17.1%] 5.9% [17.1%]
22 4.4% [31.5%] 4.9% [31.8%] 4.7% [31.8%] 4.0% [32.7%]
23 11.1% [44.1%] 10.8% [44.5%] 10.8% [43.9%] 11.1% [46.4%]
24 5.7% [28.8%] 7.9% [32.4%] 8.8% [32.5%] 7.8% [33.1%]
25 5.5% [13.5%] 4.6% [11.3%] 4.6% [10.5%] 6.0% [12.5%]
Cohort 5.2% [25.8%] 5.8% [26.4%] 5.8% [26.5%] 5.2% [26.3%]
Chapter 4
Model validation on retrospective clinical data
This chapter presents the overall and complete validation of the model on ret-
rospective clinical data using the final parameter values selected in Chapter 3.
Model validation was assessed through ability to fit the data and capture patient
dynamics, as well as its ability to provide predictions for future blood glucose
concentration. Thus, there is some overlap between Chapters 3 and 4, which
is repeated here for completeness of this critical part of the study. Finally, the
variation in fitted insulin sensitivity in neonates is compared to adult critical care
patients and the influence of several clinical variables on insulin sensitivity is in-
vestigated, as well as a brief analysis of these distributions and their potential
impact on control.
4.1 Model fit to clinical data
The ability of the model to fit clinical data with a given identified set of phys-
iologically relevant parameters validates whether the mathematically modelled
dynamics are able to capture the clinical dynamics observed in the data.
Table 4.1 shows the median and IQR for absolute percentage model fit error
and absolute fit error in mmol/L for the 3,567 hours of patient data over 25 patient
episodes described previously in Table 3.2. The median absolute cohort model fit
error was 2.4% or 0.2 mmol/L. The median non-absolute model fitting error was
0.2% indicating no significant tendency for the model fits to over-shoot or under-
shoot BG concentration. The insulin sensitivity smoothing process results in a
more physiological profile at the expense of a potentially greater fit error. Two
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Table 4.1: Relative and absolute model fitting error for NICU cohort for pG = 0.003
min-1 and EGPmax = 0.02838 mmol/kg/min.
Patient
Length of Percentage fit error Absolute fit error [mmol/L]
fit [hours] Median IQR Median IQR
1 305 2.6% [1.3%-5.4%] 0.2 [0.1-0.4]
2 334 2.0% [1.0%-3.8%] 0.2 [0.1-0.3]
3 211 2.7% [0.6%-5.1%] 0.2 [0.1-0.3]
4 288 1.5% [0.5%-3.6%] 0.1 [0.0-0.3]
5 142 3.0% [1.2%-5.2%] 0.2 [0.1-0.3]
6 94 3.6% [1.8%-5.3%] 0.3 [0.1-0.4]
7 110 2.1% [0.6%-2.9%] 0.2 [0.0-0.2]
8 103 1.6% [0.9%-1.9%] 0.1 [0.1-0.2]
9 91 1.0% [0.3%-2.9%] 0.1 [0.0-0.2]
10 65 2.6% [1.2%-4.5%] 0.1 [0.1-0.3]
11 118 1.3% [0.8%-2.3%] 0.1 [0.1-0.2]
12 34 0.6% [0.1%-1.8%] 0.0 [0.0-0.1]
13 58 2.1% [1.0%-5.0%] 0.2 [0.0-0.4]
14 182 1.3% [0.6%-4.4%] 0.1 [0.1-0.3]
15 206 2.1% [0.8%-4.7%] 0.2 [0.1-0.3]
16 43 1.8% [0.9%-4.0%] 0.2 [0.1-0.3]
17 46 4.5% [1.4%-7.4%] 0.3 [0.1-0.4]
18 91 1.5% [0.5%-2.8%] 0.1 [0.0-0.2]
19 43 2.4% [1.0%-3.6%] 0.2 [0.1-0.2]
20 113 2.3% [1.2%-3.8%] 0.2 [0.1-0.4]
21 139 2.2% [1.2%-4.1%] 0.2 [0.1-0.4]
22 283 2.2% [0.8%-4.9%] 0.2 [0.1-0.4]
23 305 6.2% [2.9%-11.5%] 0.6 [0.2-1.1]
24 142 3.1% [1.3%-6.6%] 0.3 [0.1-0.6]
25 31 0.6% [0.4%-6.2%] 0.1 [0.0-0.5]
Cohort 2.4% [0.9% - 4.8%] 0.2 [0.1 - 0.4]
of the 25 resulting parameter identifications are presented in Figures 4.1 - 4.2,
including measurement error bars to provide context for the fit error.
Table 4.2 shows the median fitting error for all patients, as well as repeating
the retrospective lognormal geometric blood glucose mean, geometric standard
deviation, median insulin rate and median dextrose delivered. The results show
a relatively constant level of fitting error spanning a range of cases of relatively
unstable blood glucose, indicated by a higher standard deviation and/or higher
mean blood glucose. They also show varying levels of insulin and glucose admin-
istration over these same results. Thus, there is no apparent bias in fitting error
with respect to glucose level, glucose variability, or intervention.
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Figure 4.1: Patient 3 blood glucose data fit (top panel, solid line), measured BG
concentration (top panel, crosses), corresponding insulin sensitivity SI (middle panel),
and insulin (solid line) and dextrose (dashed line) inputs (bottom panel).
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Figure 4.2: Patient 4 blood glucose data fit (top panel, solid line), measured BG
concentration (top panel, crosses), corresponding insulin sensitivity SI (middle panel),
and insulin (solid line) and dextrose (dashed line) inputs (bottom panel).
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4.2 Model prediction validation
It is imperative that a model used for glycaemic control is able to accurately
predict the response to a given clinical intervention. This capability is not the
same as being able to fit the data, as in Section 4.1. Many glycaemic control
models in the literature do not use or present any form of prediction validation,
despite its importance.
Table 4.3 shows the median absolute percentage prediction error for 1, 2,
3 and 4-hour prediction intervals using the final parameter values selected in
Section 3.3.1, Chapter 3. The predictions are generated by holding insulin sensi-
tivity constant at the most recent fitted value, and simulating the blood glucose
response using this value of SI over the 1-4 hour prediction interval. Results
are compared to blood glucose measurements or linearly interpolated between
retrospective measurements where none are available for a given interval.
The cohort median absolute prediction error was 5.2% at 1 hour, 9.4% at 2
hours, 11.9% at 3 hours and 13.6% at 4 hours. This result also emphasizes the
importance of frequent blood glucose measurement to provide tighter continuous
control and is similar to adult analyses [Hann et al., 2005]. The non-absolute
prediction errors for the cohort were -0.2% at 1-hour, -0.3% at 2-hours and -0.8%
at 3 and 4 hours. The spread of prediction errors is thus relatively symmetrical
about 0%. Figure 4.3 shows the distribution of absolute blood glucose prediction
error, with increasing variance as the prediction interval increases. Figure 4.4
summarises these percentage blood glucose prediction results. In particular, 85%
of 1-hour predictions and 67% of 2-hour predictions were within ±15% of the
linearly interpolated target.
In all these prediction analyses BG is compared to a linearly interpolated
value as BG was not always measured at a constant interval or exact hour. Thus,
some error may be introduced due to this approximation. In addition, insulin sen-
sitivity was assumed constant over the entire prediction interval, and thus ignores
any hour-to-hour changes, which might be significant [Lin et al., 2008]. Thus,
this prediction analysis provides an indication of the model ability to broadly
capture patient dynamics for prediction in a clinical control scenario. A typi-
cal prediction profile is shown in Figure 4.5, where larger discrepancies between
model BG value and prediction are evident at longer prediction intervals, as ex-
82 CHAPTER 4 MODEL VALIDATION ON RETROSPECTIVE CLINICAL DATA
T
ab
le
4.
3:
M
ed
ia
n
pr
ed
ic
ti
on
er
ro
rs
co
m
pa
re
d
to
lin
ea
rl
y
in
te
rp
ol
at
ed
B
G
va
lu
e.
A
bs
.
A
vg
.
B
G
sl
op
e
is
th
e
av
er
ag
e
of
ab
so
lu
te
B
G
sl
op
e
ex
pr
es
se
d
in
[m
m
ol
/L
/h
r]
.
P
at
ie
n
t
1-
h
ou
r
2-
h
ou
rs
3-
h
ou
rs
4-
h
ou
rs
A
v
g
B
G
sl
op
e
M
ed
ia
n
IQ
R
M
ed
ia
n
IQ
R
M
ed
ia
n
IQ
R
M
ed
ia
n
IQ
R
1
6.
6%
[3
.3
%
-1
2.
7%
]
12
.5
%
[6
.2
%
-2
0.
9%
]
15
.6
%
[9
.2
%
-2
7.
6%
]
22
.8
%
[8
.0
%
-3
8.
0%
]
0.
59
2
4.
2%
[1
.5
%
-8
.8
%
]
7.
9%
[4
.0
%
-1
4.
0%
]
11
.1
%
[3
.5
%
-1
8.
6%
]
11
.5
%
[6
.3
%
-2
0.
1%
]
0.
33
3
4.
2%
[2
.2
%
-7
.1
%
]
6.
9%
[3
.3
%
-1
6.
4%
]
10
.0
%
[3
.1
%
-2
3.
7%
]
11
.9
%
[5
.9
%
-2
6.
1%
]
0.
5
4
3.
7%
[1
.5
%
-6
.7
%
]
5.
5%
[2
.3
%
-1
3.
1%
]
8.
5%
[3
.5
%
-1
5.
3%
]
8.
9%
[4
.3
%
-1
5.
9%
]
0.
35
5
3.
9%
[1
.1
%
-9
.3
%
]
7.
7%
[1
.9
%
-1
2.
8%
]
6.
6%
[3
.4
%
-1
1.
1%
]
7.
0%
[3
.4
%
-9
.9
%
]
0.
73
6
6.
3%
[2
.8
%
-1
0.
7%
]
12
.5
%
[8
.7
%
-2
0.
9%
]
19
.1
%
[9
.3
%
-2
7.
4%
]
21
.9
%
[1
2.
9%
-3
4.
5%
]
0.
72
7
3.
9%
[1
.4
%
-9
.2
%
]
6.
3%
[3
.4
%
-1
1.
1%
]
5.
1%
[2
.9
%
-1
0.
5%
]
6.
1%
[4
.9
%
-1
2.
9%
]
0.
26
8
4.
5%
[2
.3
%
-6
.8
%
]
10
.9
%
[5
.1
%
-1
8.
6%
]
13
.5
%
[7
.3
%
-2
0.
4%
]
12
.3
%
[6
.0
%
-1
8.
8%
]
0.
35
9
4.
3%
[2
.1
%
-7
.9
%
]
4.
2%
[1
.3
%
-9
.3
%
]
6.
4%
[1
.8
%
-1
2.
8%
]
5.
2%
[3
.1
%
-1
4.
0%
]
0.
49
10
6.
4%
[3
.2
%
-1
5.
7%
]
13
.7
%
[3
.7
%
-2
9.
1%
]
13
.3
%
[5
.7
%
-2
4.
5%
]
21
.4
%
[1
2.
3%
-3
0.
0%
]
0.
62
11
4.
9%
[2
.1
%
-7
.9
%
]
7.
5%
[2
.6
%
-1
6.
6%
]
13
.6
%
[6
.6
%
-3
0.
3%
]
19
.6
%
[8
.5
%
-3
5.
1%
]
0.
64
12
5.
6%
[3
.1
%
-9
.7
%
]
10
.0
%
[6
.3
%
-2
0.
7%
]
15
.3
%
[7
.9
%
-3
1.
5%
]
21
.0
%
[1
0.
3%
-3
8.
8%
]
0.
69
13
8.
3%
[4
.3
%
-1
4.
0%
]
12
.7
%
[6
.9
%
-2
9.
3%
]
16
.7
%
[1
0.
6%
-5
6.
7%
]
16
.6
%
[9
.8
%
-6
5.
6%
]
1.
96
14
5.
0%
[1
.6
%
-8
.6
%
]
8.
1%
[1
.9
%
-1
4.
9%
]
7.
8%
[3
.3
%
-1
8.
4%
]
12
.7
%
[5
.7
%
-1
9.
8%
]
0.
55
15
4.
1%
[2
.3
%
-9
.3
%
]
8.
5%
[3
.1
%
-1
5.
7%
]
12
.3
%
[5
.9
%
-2
1.
2%
]
13
.0
%
[6
.1
%
-2
2.
8%
]
0.
46
16
2.
6%
[1
.7
%
-8
.8
%
]
6.
8%
[2
.7
%
-9
.9
%
]
11
.2
%
[5
.2
%
-2
5.
8%
]
12
.4
%
[4
.4
%
-2
4.
2%
]
0.
57
17
7.
1%
[2
.2
%
-8
.3
%
]
8.
8%
[4
.0
%
-1
7.
2%
]
15
.9
%
[7
.9
%
-2
5.
2%
]
11
.3
%
[1
0.
4%
-2
3.
9%
]
0.
56
18
4.
7%
[4
.3
%
-6
.8
%
]
6.
2%
[4
.2
%
-9
.6
%
]
5.
9%
[2
.8
%
-9
.8
%
]
6.
7%
[5
.0
%
-1
1.
5%
]
0.
31
19
5.
1%
[2
.9
%
-1
0.
3%
]
11
.5
%
[6
.8
%
-1
5.
1%
]
14
.3
%
[4
.7
%
-2
9.
4%
]
18
.2
%
[1
0.
0%
-4
2.
2%
]
0.
39
20
6.
6%
[2
.6
%
-1
0.
1%
]
9.
7%
[3
.9
%
-1
8.
3%
]
14
.3
%
[5
.0
%
-2
6.
6%
]
15
.4
%
[6
.3
%
-2
9.
4%
]
0.
56
21
5.
9%
[4
.1
%
-8
.3
%
]
11
.6
%
[6
.4
%
-1
7.
7%
]
14
.3
%
[7
.5
%
-2
3.
8%
]
18
.5
%
[6
.5
%
-2
9.
7%
]
0.
66
22
4.
4%
[2
.2
%
-1
0.
0%
]
7.
2%
[3
.8
%
-1
6.
7%
]
8.
9%
[4
.1
%
-1
8.
5%
]
10
.8
%
[4
.5
%
-2
3.
0%
]
0.
58
23
11
.1
%
[4
.9
%
-1
9.
3%
]
17
.4
%
[7
.3
%
-3
4.
2%
]
17
.3
%
[7
.8
%
-3
5.
5%
]
18
.7
%
[1
0.
0%
-3
8.
3%
]
1.
41
24
5.
7%
[2
.5
%
-1
5.
0%
]
10
.4
%
[5
.2
%
-2
5.
7%
]
13
.7
%
[6
.7
%
-3
1.
3%
]
17
.7
%
[6
.4
%
-3
4.
6%
]
0.
94
25
5.
5%
[3
.2
%
-1
1.
7%
]
10
.9
%
[8
.5
%
-1
8.
7%
]
12
.8
%
[8
.0
%
-2
4.
2%
]
11
.8
%
[7
.1
%
-2
2.
5%
]
0.
89
C
oh
or
t
5.
2%
[2
.5
%
-1
0.
3%
]
9.
4%
[4
.5
%
-1
8.
4%
]
11
.9
%
[5
.1
%
-2
3.
7%
]
13
.6
%
[6
.3
%
-2
7.
6%
]
4.2 MODEL PREDICTION VALIDATION 83
0 10 20 30 40 50 60 70 80 90 100
0
50
100
150
1-hour
0 10 20 30 40 50 60 70 80 90 100
0
50
100
150
2-hour
Nu
m
be
r 
of
 
pr
ed
ic
tio
ns
0 10 20 30 40 50 60 70 80 90 100
0
50
100
150
3-hour
0 10 20 30 40 50 60 70 80 90 100
0
50
100
150
4-hour
BG prediction error (%)
 
Figure 4.3: Distribution of blood glucose prediction errors at 1, 2, 3 and 4-hour
prediction intervals. Summary statistics are presented in Table 4.3.
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Figure 4.4: Box and whisker plot showing percentage BG prediction error. The boxes
represent the inter-quartile range and are intersected by the median. The whiskers
represent 1.5* IQR limit, and crosses represent outlying measurements.
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pected. Insulin sensitivity forecasting models, covered in Chapter 5, can provide
more detailed estimates of prediction performance.
Figure 4.6 shows that there is no strong relationship between proportion of
time on exogenous insulin and the model fitting error. This result suggests that
the model can adequately handle the, generally brief, periods off insulin that are
interspersed within episodes of insulin usage. Whilst this result also suggests
that the population values used to estimate endogenous insulin secretion are
appropriate, it should be noted this model is primarily designed to handle the
case of exogenous insulin administration.
Figure 4.7 shows part of the record for Patient 13. This episode is dominated
by the BG measurement of 31.2 mmol/L at 7 hours, a change of 25.7 mmol/L
from the measurement 1.5 hours prior. The gradual decrease in BG over the next
11 hours suggests this measurement was not due to error in the measuring device.
This patient had severe metabolic imbalances, was relatively clinically unstable,
and did not survive intensive care. A glucose/insulin mixture was administered
for clinical reasons at 6 hours that contained 0.26U insulin in 8mL/kg of 50%
dextrose. The 0.26U is approximately 9.4x the 0.034 U/kg/hr average dose given
in Table 3.3 to the cohort for this 860g infant, and is thus very large. Interestingly,
the model was able to account for this relatively extreme intervention and the
resulting deviation in blood glucose concentration, and accurately captured the
impact of this sudden large amount of added dextrose on BG concentration, as
well as its long term clearance and impact.
It should be noted that the frequency of measurement of retrospective data
can influence the accuracy of blood glucose predictions, where some dynamics
may be missed by sparse data collection. This issue is especially evident in the
relatively poor prediction results for Patient 23. The average absolute BG slope
for these patients shown in Table 4.3 indicates that this patient experienced
much more rapid swings in blood glucose compared to the rest of the cohort by a
factor of approximately 2x. Figure 4.8 shows a part of the record for Patient 23,
highlighting a period of rapid change in blood glucose. This period of glycaemic
instability coincided with steroid and antibiotic administration, very unstable
respiratory periods requiring resuscitation, a number of new IV lines, and some
BG measurements taken using a GlucoCard glucometer, rather than the typical
blood gas analyser. In general, more frequent blood glucose measurements would
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Figure 4.6: Correlation of model fit error with proportion of patient time receiving
exogenous insulin.
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Figure 4.7: Model-generated fit for Patient 13, highlighting extreme rise in blood
glucose. The top panel shows the blood glucose data fit (solid line) and measured BG
concentration (crosses), the middle panel shows the corresponding insulin sensitivity
SI , and the bottom panel shows insulin (solid line) and dextrose (dashed line) infusions.
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Figure 4.8: Model generated fit for Patient 23, highlighting area of large swings in
blood glucose concentration.
enable the model to more accurately capture such periods of rapid change in
glucose concentration, as well as provide insight into the relative contributions
to the observed unstable glucose due to patient condition, intervention therapy,
and noise from measurement devices.
The predictive ability presented is similar to other studies that have success-
fully applied similar models to control glycaemia in adult intensive care patients
[Hann et al., 2005]. The model sufficiently captures the varied dynamics ob-
served in the neonatal cohort. This outcome suggests that adults and neonates
are not dissimilar in metabolic dynamics, even though fundamental parameter
values representing specific physiological differences may vary.
4.2.1 Clarke Error Grid Analysis
The Clarke Error Grid Analysis (EGA) is often considered a “gold-standard”, or
at least well-accepted, method to compare the accuracy of blood glucose sensors
to a reference method [Clarke, 2005]. EGA was performed on the 1-4 hour blood
glucose prediction intervals. This analysis allows a more detailed comparison of
the prediction ability of the model with reported data for typical blood glucose
sensors, as well as putting it into a clinical decision-making context.
88 CHAPTER 4 MODEL VALIDATION ON RETROSPECTIVE CLINICAL DATA
The EGA method categorises the differences between reference BG concen-
tration and a test method into five divisions labelled ‘A’ to ‘E’. ‘A’ represents
the highest correlation between the test and the reference method, and ‘E’ repre-
sents significant deviation likely to cause harm. The ranges reflect typical adult
values for a Type I diabetic. The main discriminator is whether the error from
the reference method would result in a difference clinical intervention (‘A’ = no),
and how harmful that different intervention might be (‘B’ to ‘E’). Whilst neonatal
BG targets are typically lower, the adult ranges provide a reasonable comparison.
Figure 4.9 presents the BG model prediction against the “reference” method of
linear-interpolated BG from the retrospective clinical data.
Overall, 93% of 1-hour predictions were in zone A and a further 6% of 1-hour
predictions were in zone B. The proportion of 2-hour predictions in zone A was
80%, with 18% in zone B. The performance of 1-hour predictions compares well
with [Hovorka et al., 2004], which achieved 95% of 1,674 predictions in zone A
and 5% in zone B for a prediction horizon of 15-60 min (0.25 - 1.0 hours) on 15
adult patients with Type I diabetes, shown in Figure 4.9e.
Greater variations are introduced with longer prediction intervals, as ex-
pected. This analysis provides further evidence of the model to predict BG over a
clinically useful 1-2 hour window, and further emphasises the importance of mea-
suring frequently to obtain good control. Additionally, it quantifies the increase
in risk of providing an inappropriate or harmful treatment when measurement
periods are extended from a more optimal 1-3 hours for glycaemic control to the
4-6 hour measurement period reported in some studies [Beardsall et al., 2008],
clearly illustrating a major factor in the success or failure of control.
More specifically, these predictions and EGA analysis indicate the tradeoff of
tight control and measurement frequency. Similar to adult studies [Hann et al.,
2005; Lonergan et al., 2006b; Chase et al., 2007, 2008b], a 1-2 hour interval
provides a relatively optimal result compared to clinical or in-silico results at
longer intervals. Thus, a first main result of this research would be that anything
longer than 3 hours (1-2 hours preferred) will not be able to provide tight glucose
control.
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(a) CEGA for 1-hr predictions.
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(b) CEGA for 2-hr predictions.
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(c) CEGA for 3-hr predictions.
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(e) Clarke Error Grid analysis for Hov-
orka model. Adapted from [Hovorka
et al., 2004].
Figure 4.9: Clarke Error Grid analysis of model BG prediction performance.
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Figure 4.10: Per patient empirical cumulative distribution of insulin sensitivity. The
overlaid dashed line shows the median and the shaded region represents the 5%-95%
range of per-patient insulin sensitivity. Each line represents a fitted insulin sensitivity
profile for one of the 25 retrospective patient data sets.
4.3 Insulin sensitivity variation
The model can be seen to account for a range of different patient responses,
which include a range of insulin sensitivity values. This variation indicates that
these patients can be highly dynamic metabolically. Figure 4.10 shows that each
patient’s insulin sensitivity distribution is unique, as well as showing there are
also no significantly outlying patient profiles.
Figure 4.11 compares histograms of the empirical probability distribution
functions of model-fitted insulin sensitivity for the neonatal cohort of this research
to 393 adult intensive care patients totalling 44,386 hours of fitted data from the
SPRINT study [Chase et al., 2008b]. The median insulin sensitivity for neonates
was 0.68x10-3 L/(mU.min), compared to 0.24x10-3 L/(mU.min) for adults, and
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Figure 4.11: Empirical probability distribution function of model-fitted insulin sensi-
tivity in adult critical care (light grey) and neonatal (dark grey) cohorts. The shaded
area of each plot is equal to 1.0. The 5%-95% rage of insulin sensitivity for adult and
neonatal cohorts are shown by the dashed and dash-dot lines respectively.
the 5%-95% data interval was [0.17 - 1.70]x10-3 L/(mU.min) for neonates and
[0.06 - 0.79]x10-3 L/(mU.min) for adults respectively. The range and variation of
model-fitted insulin sensitivity has been studied in adult critical care populations
using similar models [Lin et al., 2006, 2008]. However, this research is the first
time this form of modelling and analysis has been applied to a neonatal cohort.
Two reasons for the higher median insulin sensitivity are higher rates of glu-
cose turnover and higher metabolic clearance of insulin resulting in lower plasma
insulin concentrations. More specifically, [Farrag et al., 1997] found greater pe-
ripheral sensitivity to insulin compared to adult controls. In addition, [Hertz
et al., 1993] found their estimate of non-insulin mediated glucose uptake to be
similar to that of normal adults. Thus, the lower insulin concentrations normally
found in infants require a higher value of SI to account for the remaining glucose
uptake, and matches the relatively sparse clinical evidence available.
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The model-fitted insulin sensitivity and its hour-to-hour changes are also
quantified for neonates. These results can then be compared to model-fitted
insulin sensitivity for adults. Thus, a similar model is used for neonates as in
adult critical care, with the results shown in Figure 4.12.
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Figure 4.12: Temporal variation in insulin sensitivity for adult and neonatal cohorts.
‘SPRINT’ represents adult intensive care data from patients on the SPRINT protocol.
The distributions of insulin sensitivity variation between adults and neonates
in Figure 4.12 is significantly different for intervals of 1-3 hours (p < 0.05, Mann-
Whitney test). NICU patients show significantly less variation in insulin sensitiv-
ity over 1-hourly and 2-hourly periods compared to adult critical care patients.
Thus, noting the wider spread in Figure 4.11, NICU patients exhibit less intra-
patient variation and higher inter-patient variation compared to adults.
More specifically, Figure 4.10 shows that each patient has a uniquely identified
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insulin sensitivity profile. The intra-patient variability of response to exogenous
insulin is heightened in the neonate, increasing the importance of accurate iden-
tification for control. Thus, an adaptive control scheme must be able to dose
insulin appropriately to the unique identified patient state. As a result, it can be
seen that such an adaptive method will be required to provide tight control for
all patients, rather than fixed clinical protocols.
4.4 Secondary insulin sensitivity markers
4.4.1 Influence of age and weight on insulin sensitivity
The literature is conflicting with regard to the relationship between indicators of
the maturity of the glucose regulatory system and infant age, weight, and whether
a particular infant is small or appropriate weight for gestational age [Van Kempen
et al., 2003; Sunehag et al., 1999; Diderholm et al., 2007]. Model-fitted insulin
sensitivity was compared to gestational age at birth, birth weight and the ratio
of birth weight to gestational age as a measure of size for gestational age, shown
in Figure 4.13. Hourly insulin sensitivity, SI , was also compared to post-birth
age and total age (gestational age + post-birth age) in Figure 4.14 to see if there
was any impact on variability of these factors.
As shown in Figures 4.13 and 4.14, there is no evident relationship between
model-fitted insulin sensitivity and variables related to weight and gestational
age. However, it should be noted that the model already accounts for weight in
endogenous glucose production and central nervous system uptake parameters.
It also accounts for both weight and age in the compartment volume parameters.
Thus, age and weight appear to exert no strong influence on sensitivity to insulin,
perhaps because they are already a part of the model structure.
4.4.2 Influence of indicators of clinical condition
Insulin sensitivity may be related to clinical condition, and could be used as a
marker of the severity of illness, or to provide information on the time course
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(a) Influence of post-birth age on SI . (b) Influence of total age on SI
Figure 4.14: Impact of age on hourly insulin sensitivity. Hourly model-fitted insulin
sensitivity is plotted against patient age.
of conditions such as sepsis [Blakemore et al., 2008]. The model-fitted insulin
sensitivity of the retrospective cohort was thus compared to several commonly
measured clinical variables indicative of patient condition to establish any rela-
tionships. The correlation of model-fitted insulin sensitivity with sodium con-
centration, blood pH, pCO2, urea, lactate and creatinine concentrations, as well
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as lipid administration rate was assessed. In all cases, each clinical variable ex-
plained less than 7% of the variability in insulin sensitivity.
While it is physiologically reasonable that many of the clinical indicators
tested here will have some impact on the body’s processing of insulin and glucose,
confounding physical effects and noise associated with other perturbations or
interventions in patient condition leave no easily identifiable relationship within
the retrospective data.
The effect of insulin syringe changes, red cell transfusions and transfusions
of other blood products on insulin sensitivity was also assessed by comparing the
average model-fitted insulin sensitivity value for two hours before and after the
time of the event. Each of these events may feasibly create a change in apparent
insulin sensitivity through tubing adsorption effects in the case of insulin syringe
changes, and changes in plasma volume in the case of the transfusions. However,
as shown in Figure 4.15, there is also no clear effect of these events on model-fitted
insulin sensitivity.
4.5 Summary
A model of the glucose regulatory system has been adapted from adult critical
care to the neonatal case and validated on retrospective clinical data. Model fits
of insulin sensitivity were generated for 25 patient records and 3,587 hours of ret-
rospective data. Adaptation of several physiological model parameters, including
insulin clearance rate, endogenous production rate and volumes of distribution,
resulted in an average fitting error of 2.10%. The predictive ability of the model
was assessed by assuming insulin sensitivity was constant over the interval. Me-
dian prediction errors at 1, 2 and 4-hour intervals were 5.2%, 9.5% and 14.7%
respectively. The model performance is within variations that would also account
for dynamic patient evolution. The model thus provides a first in-silico result for
modelling the metabolic dynamics of the low-birth weight preterm infant. It also
creates a platform towards better metabolic clinical management of glycaemia in
neonates.
The major assumption used in the predictions made in this study is that the
insulin sensitivity parameter SI is constant over the prediction interval. Hence,
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Figure 4.15: Effect of insulin syringe change and transfusion events on model-fitted
insulin sensitivity.
longer intervals will subsequently show potentially greater variation as patient
condition has a longer time and thus more opportunity to evolve. Thus, the
increasing likelihood of changes over time in insulin sensitivity SI are evident, as
seen previously in the adult population [Hann et al., 2005; Lin et al., 2006, 2008].
Stochastic modelling of insulin sensitivity, as applied in adult critical care patients
[Lin et al., 2006], could provide a more accurate forecast of future SI values and
thus create confidence intervals for predicted blood glucose concentrations that
account for this variation and would thus provide better clinical guidance.
Chapter 5
Insulin sensitivity variation forecasting
Model-based methods allow information about the fundamental metabolic state
of the patient, insulin sensitivity in this case, to be inferred from serial blood
glucose measurements and records of nutrition and insulin administration. Once
the current insulin sensitivity of the infant has been identified, prediction of future
insulin sensitivity ranges or variation is possible. Knowing or estimating these
variations would allow accurate predictions of the range of outcome blood glucose
concentrations for an intended clinical intervention.
Stochastic models provide a means to quantify this probability of a future
insulin sensitivity [Lin et al., 2006, 2008]. Thus, the resulting distribution of
blood glucose concentrations that would result from a given intervention can
be determined. This information can then be used to guide dosing to avoid or
minimise the risk of low blood sugar concentrations, improve overall glycaemic
control, and identify periods of potential high glucose variability that may be
indicative of emerging clinical events, such as infection [Blakemore et al., 2008].
This chapter presents the adaptation of a stochastic model for insulin sensi-
tivity prediction from adult critical care to the unique clinical and physiological
case of the neonate. Several modifications to the initial kernel density estimation
model are used to explore the relationship between the model and the under-
lying data set. In addition, the stochastic modelling approach is extended to
include more than just the prior hour values to determine if improved prediction
can be obtained in this neonatal case. Finally, a time-series model that pro-
vides patient-specific insulin sensitivity forecasts is developed and compared to
the whole-cohort stochastic model.
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5.1 Hourly insulin sensitivity variation in neonates
Figure 5.1 shows the distribution of hourly variation in insulin sensitivity for the
3,567 hours of patient data. Approximately 92% of data values are below 1.5x10-3
L/(mU.min). The fitted insulin sensitivity values presented in Figure 5.1 are un-
smoothed to avoid introducing any artificial temporal effects and to develop the
model to accurately emulate actual clinical usage. It is clear that the variability
of insulin sensitivity over any given fitting time frame is dependent on its present
value, and that the stochastic behaviour or distribution of these variations also
depends on their current state. These distributions are thus a vertical slice at
any x = SI,n value in Figure 5.1 and thus particularly useful where data is dense.
0 0.5 1 1.5 2 2.5
x 10-3
0
0.5
1
1.5
2
2.5
x 10-3
S I,n
S I
,
n+
1
 
Figure 5.1: Variation of fitted insulin sensitivity from hour n to hour n+ 1 for 3,567
hours of fitted data. The distribution of SI,n+1 changes based on the value of SI,n and
cannot be described by a simple statistical distribution.
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5.2 Stochastic model (Lag-1)
5.2.1 Model development
A two-dimensional kernel density estimation method is used to construct the
stochastic model that describes the hourly transition of insulin sensitivity. This
method has the advantage of producing a smooth, continuous function across the
parameter range, and automatically accounts for any possible multi-modality.
The overall result is a bivariate probability density function for the potential
parameter values. The goal of this statistical model is to quantify the range of
insulin sensitivity one hour ahead in time (SI,n+1) based on available data (SI,n,
SI,n−1, SI,n−2, . . . , SI,0) to guide real-time clinical control. Thus, it is important
that the model formulation is computationally feasible for real-time applications
on typical hardware.
The two-dimensional kernel density method is chosen for creating the stochas-
tic model because the distribution of SI,n+1 varies with SI,n, as shown in Fig-
ure 5.1, and cannot be simply described with a standard statistical distribution.
Thus, the variations in SI can be treated as a Markov process. A Markov pro-
cess has the property that the conditional probability density function of future
states of the process, given the current state, depends only upon the current
state. Therefore, using the Markov property of the stochastic behaviour of SI ,
the conditional probability density of SI,n+1 taking on a value y can be calculated
by knowing SI,n = x:
p (SI,n+1 = y |SI,n = x) = p (SI,n+1 = y, SI,n = x)
p (SI,n = x)
(5.1)
Considering the fitted SI in a 2D space, as shown in Figure 5.1, the joint
probability density function across the x-y (SI,n - SI,n+1) plane is defined by the
fitted values shown by the dots whose coordinates are xi and yi, and is defined
using Normal distributions:
p (x, y) =
1
n
n∑
i=1
φ
(
x;xi, σ
2
xi
)
pxi
φ
(
y; yi, σ
2
yi
)
pyi
(5.2)
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where:
pxi =
∫ SI,upper
SI,lower
φ
(
x;xi, σ
2
xi
)
dx (5.3)
pyi =
∫ SI,upper
SI,lower
φ
(
y; yi, σ
2
yi
)
dy (5.4)
Effectively, this joint 2D probability density function is the normalised summation
of all the Normal or Gaussian probability density functions that describe the data
and are centred at individual data points.
In Equations 5.2 - 5.4, the variances σxi and σyi at each data point are
functions of the local data density in a centred and orthonormalised space of x =
SI,n and y = SI,n−1. Putting Equations 5.3 and 5.4 into Equation 5.2 normalises
each φ
(
x;xi, σ
2
xi
)
and φ
(
y; yi, σ
2
yi
)
in the positive domain, effectively putting
boundaries along the x = SI,lower, x = SI,upper, y = SI,lower and y = SI,upper
lines and thus enforcing physiological validity in SI values. For the neonatal
case, the boundary values SI,lower and SI,upper were set to 1x10
-5 L/(mU.min)
and 2.8x10-3 L/(mU.min) respectively to define the computation domain based
on the observed distribution of SI found in fitting the model to the data.
The right hand side denominator of Equation 5.1, p (SI,n = x) can be calcu-
lated by integrating Equation 5.2 with respect to y. Hence, Equation 5.1 can be
rewritten:
p (SI,n+1 = y |SI,n = x) =
∑n
i=1
φ(x;xi,σ2xi)
pxi
φ(y;yi,σ2yi)
pyi∑n
i=1
φ(x;xi,σ2xi)
pxi
=
n∑
i=1
wi(x)
φ
(
y; yi, σ
2
yi
)
pyi
(5.5)
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where:
wi(x) =
φ(x;xi,σ2xi)
pxi∑n
i=1
φ(x;xi,σ2xi)
pxi
(5.6)
Thus, knowing SI,n = x at hour n, the probability of SI,n+1 = y at hour n+1
can be calculated using Equations 5.5 - 5.6 across the x-y plane. Where there is
a higher density of data, more certainty can be drawn on the “true” behavioural
pattern. Note that Equation 5.6 makes use of the local data variances (σ2xi , σ
2
yi
).
Further details of the general modelling approach, theoretical background and
specific computations, including formulation of the local data variance estimator,
are available in [Lin et al., 2006, 2008; Lin, 2007].
5.2.2 Model analysis
Figure 5.2 shows the conditional probability plot for the lag-1 model, where the
forecast probability bounds depend on the current insulin sensitivity value only.
Figure 5.3 shows the 5th, 25th, 50th, 75th and 95th percentile probability bounds,
overlaid on the raw data. The probability bounds of SI,n+1 for a given SI,n = x
are found by integrating the conditional probability function shown in Figure 5.2
along the line x = SI,n, an example of which is shown in Figure 5.3, using
Equation 5.5.
In particular, the 25th to 75th percentile prediction bound is found by deter-
mining the intersection of the 25th percentile and 75th percentile of the resulting
cumulative density function with the line x = SI,n = 1x10
−3. These probability
bounds can then be sequentially substituted for SI into Equation 2.28 to produce
blood glucose concentration forecasts based on the 25th to 75th percentile range
of likely future SI , or any other probability bound. The 5% to 95% probability
interval can be found in a similar manner. Finally, note that the median or 50th
percentile line in Figure 5.3 lies largely along the SI,n+1 = SI,n line indicating no
change hour to hour.
Table 5.1 shows the per-patient in-sample results for the lag-1 model. The
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Figure 5.2: Conditional probability density function for SI,n+1 knowing SI,n. The
structure of the plot is largely unimodal in the region SI,n < 1.5x10-3 and SI,n+1 <
1.5x10-3, corresponding to the region of densest data.
Table 5.1: In-sample results for stochastic model prediction widths. Data are ex-
pressed as cohort medians (n=3,530 predictions).
% SI within prediction interval
[25th - 75th] 62.6%
[5th - 95th] 93.4%
% BG within prediction interval
[25th - 75th] 59.1%
[5th - 95th] 92.2%
% BG prediction interval width
[25th - 75th] 0.78 mmol/L
[5th - 95th] 2.32 mmol/L
Median absolute % BG point prediction error 4.3%
Median absolute BG point prediction error 0.34 mmol/L
overall median per-patient 1-hour point prediction error comparing BG based on
the 50th percentile of predicted SI to the interpolated value from retrospective
data is 4.3%, corresponding to an average BG error of 0.34 mmol/L. The width
of the [25th - 75th] BG probability interval is 0.78 mmol/L. Similarly, the [5th -
95th] BG probability interval width is 2.32 mmol/L. The prediction intervals for
insulin sensitivity and BG concentration are shown graphically for Patient 8 in
Figure 5.4.
Overall, 62.6% of SI,n+1 predictions were within the [25
th - 75th] probability
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Figure 5.3: Hourly insulin sensitivity variation data with probability bounds. The
bounds are computed using an equal-tailed method approximation. An example curve
showing the computation of probability bounds for SI,n = 1x10-3 L/(mU.min) is dis-
played.
intervals, corresponding to 59.1% of BG predictions. A total of 93.4% of SI,n+1
predictions were within the [5th - 95th] probability intervals, corresponding to
92.2% of BG predictions. The proportion of fitted insulin sensitivity that fell
within the [25th - 75th] and [5th - 95th] probability intervals was higher than the
expected 50% and 90%. Thus, the cohort model conservatively captures variation
but the process of fitting the kernel estimator does not capture all of it exactly.
5.2.3 Cross-validation
The lag-1 model was cross-validated by splitting the 25 patient NICU cohort into
5 groups, each containing 5 patients. For each group the model was fitted on
or defined using data from the remaining 20 patients of the cohort representing
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Figure 5.4: Patient 8 with BG forecasts (top panel) and SI parameter forecasts
(bottom panel). The IQR and 5% - 95% prediction bounds for both variables are
displayed as shaded areas, and the model fitted BG and SI are overlaid.
approximately 2,800 hours of data. Out-of-sample insulin sensitivity predictions
were then generated for the 5 patients of the group not used to create the model
and compared to the proportion of fitted insulin sensitivity that fell within the
probability bounds.
Table 5.2 shows the results of this out-of-sample cross-validation of the model.
The results are generally consistent between groups, suggesting the overall model
contains sufficient data to account for the range of dynamics observed in this
cohort. Table 5.2 shows the model consistently over-estimates the probability
bounds, with the proportion of insulin sensitivity within the bounds higher than
expected from the specific bandwidth.
The lag-1 stochastic model presented here has been employed on a cohort of
adult intensive care patients [Lin et al., 2006, 2008]. The results of [Lin et al.,
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2006] also show the model produces conservative probability bounds. However,
their result of 54.0% within the [25th - 75th] percentile bound is closer to the ideal
50%. The results of Tables 5.1 and 5.2 suggest the model prediction coverage is
moderately over-conservative. Therefore, a lag-2 model was developed to inves-
tigate whether these effects could be mitigated by incorporating SI information
from two previous hours, in effect evaluating whether the stochastic model needed
further dynamics not in the lag-1 model.
5.3 Stochastic model (Lag-2)
5.3.1 Model development
The lag-2 model produces probability intervals for SI,n+1 = z at hour n+ 1 given
the insulin sensitivity for the previous two hours: SI,n−1 = x and SI,n = y. The
derivation of the model is similar to that of the lag-1 case, and the conditional
probability estimator is defined:
p (SI,n+1 = z |SI,n−1 = x, SI,n = y) =
∑n
i=1
φ(x;xi,σ2xi)
pxi
φ(y;yi,σ2yi)
pyi
φ(z;zi,σ2zi)
pzi∑n
i=1
φ(x;xi,σ2xi)
pxi
φ(y;yi,σ2yi)
pyi
=
n∑
i=1
wi(x, y)
φ
(
z; zi, σ
2
zi
)
pzi
(5.7)
where:
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wi(x, y) =
φ(x;xi,σ2xi)
pxi
φ(y;yi,σ2yi)
pyi∑n
i=1
φ(x;xi,σ2xi)
pxi
φ(y;yi,σ2yi)
pyi
(5.8)
pzi =
∫ SI,upper
Si,lower
φ
(
z; zi, σ
2
zi
)
(5.9)
where all terms are similar to those used previously and computed with the same
fundamental methods or approach.
5.3.2 Model analysis
Figure 5.5 shows the insulin sensitivity data in the x, y, z coordinate space. The
probability bounds for the lag-2 model are shown in Figure 5.6, together with
slices of probability bound surfaces along several values of SI,n−1. The surface
sliced curves appear smooth around the value of SI,n−1 and less smooth away
from that value. This outcome shape highlights the (expected) result that sudden,
large changes over two hours of patient data are less common, and the less-smooth
regions of the curves are caused by lower data density. Thus, the hour-to-hour
variation observed in the SI data does not show any further temporal dependence
in this analysis.
Table 5.3 compares the coverage proportions for the lag-1 and lag-2 models.
Here, 61.3% of SI fell within the [25
th - 75th] percentile interval for the lag-2
model, similar to the 62.6% result for the lag-1 case. Similarly, 94.6% of SI fell
within the lag-2 [5th - 95th] interval compared to 93.4% for the lag-1 model. These
results further suggest that lag-2 effects do not play a major role in the evolution
of insulin sensitivity in this NICU cohort compared to the simpler lag-1 model
case.
Clinically, the small influence of lag-2 effects is interesting. It says that vari-
ation is largely hour-to-hour in these neonates and effectively random over that
period with little build-up. A second clinical outcome or interpretation is that
major changes in the neonate’s condition are not likely over that long a period
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Figure 5.5: Insulin sensitivity data for lag-2 model. The SI parameter for the up-
coming hour is plotted against SI one and two hours previously.
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Figure 5.6: Lag-2 stochastic model probability bounds. The surfaces on the 3D plot
represent the 5%, 25%, 50%, 75% and 95% bounds for SI,n+1 given SI,n and SI,n−1.
Three slices of the probability bound distribution are presented for SI,n−1 at 0.5x10-3,
1.0x10-3 and 1.5x10-3 L/(mU.min).
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of time (2 hours), and are thus more acute in nature. They thus appear random
over the 1-hour interval used because no finer measurement resolution is available
in this cohort.
5.4 Model bias-variance trade-off
The kernel density estimator method employed in this stochastic model produces
a smooth distribution and, in this case, a conservative model. This conservatism
can provide a layer of safety, as wider probability bounds would be more likely to
capture dynamics and changes not observed in the cohort used to fit the model.
However, wider coverage bands may also impact glycaemic control performance as
wide probability bands used to reduce the risk of hypoglycaemia may needlessly
force a controller to maintain a mildly hyperglycaemic state.
The overall BG width of the [5th - 95th] percentile probability band was
2.32 mmol/L. This 2.32 mmol/L range would severely impact performance for a
controller targeting a typical 4-7 mmol/L target range, as it is almost 50% of a
6 mmol/L target.
Therefore, a trade-off between model bias and variance is required. The cross-
validation showed consistent results. This outcome suggests that the cohort data
set is large enough to satisfy the assumption that the model contains enough data
points to reasonably reflect the vast majority of target patients presented in the
Christchurch Women’s Hospital NICU.
Figure 5.7 shows the proportion of in-sample predictions within the 25% to
75% probability bound grouped by location along the x = SI,n axis. Also plotted
on Figure 5.7 is the number of data points (=number of in-sample predictions)
for each group. The 25th to 75th percentile bounds would be expected to contain
approximately 50% of the data. However, Figure 5.7 shows that the coverage
Table 5.3: Comparison of in-sample insulin sensitivity coverage prediction proportions
for lag-1 and lag-2 stochastic models.
Lag-1 Lag-2
% within 25th - 75th percentile 62.6% 61.3%
% within 5th - 95th percentile 93.4% 94.6%
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often exceeds this expectation. This coverage discrepancy is highest where the
data density is greatest. This apparently contrary result suggests that the local
data density variance estimators (σx, σy) are conservative for this data set and/or
cohort, and may be a source of over-estimation.
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Figure 5.7: Proportion of in-sample predicted insulin sensitivity within the 25%-75%
prediction bounds (bars) and number of predictions (line) grouped by insulin sensitivity
range.
A modification to the model is to multiply the variance estimators by a con-
stant c (ie: cσx, cσy) to explore the model bias-variance trade-off for this data.
The effect of this modification is to tighten the distributions used in Equation 5.2
by reducing the variance. The overall effect on forecast performance for several
values of c is shown in Table 5.4. Reductions of the variance estimators to approx-
imately 10% - 50% (c = 0.1 - 0.5) of their original value yield coverage widths that
contain numbers closer to the approximately expected proportion of in-sample
data values.
Figure 5.8 shows probability plots for c=1.0, c=0.5 and c=0.1. As expected,
the probability distribution becomes less smooth. In particular, it does so for
lower values of c, which is further enhanced for higher values of SI where data
is less dense. Additionally, for lower values of c the [25th - 75th] and [5th - 95th]
percentile probability bounds for SI,n+1 are essentially equal for some regions
of SI,n due to sparse data, which may contribute to the increase in coverage
proportion for c less than 0.1, and show the model possibly over-fitting the data.
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Table 5.4: Comparison of probability bounds for modifications of kernel density esti-
mator (σ′x = cσx and σ′y = cσy).
c
% of SI within
prediction bounds
% of BG within
prediction bounds
0.05 50.8% 90.5% 45.2% 86.2%
0.08 50.8% 90.6% 45.9% 87.1%
0.1 50.7% 90.9% 46.2% 87.5%
0.2 51.7% 90.8% 46.8% 88.3%
0.3 52.2% 90.6% 48.0% 88.8%
0.5 54.7% 90.9% 50.8% 89.5%
1.0 62.6% 93.4% 59.1% 92.2%
2.0 75.4% 96.9% 72.5% 96.4%
Ideal 50% 90% 50% 90%
The value of c=0.5 provides a balance between prediction coverage and over-
modelling the data.
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 Figure 5.8: Probability bound determination using local variance estimator modified
by a constant c. The lower values of c produce a less smooth probability distribution
particularly at higher insulin sensitivity. The individual points represent raw insulin
sensitivity data. The solid lines represent the 5%, 25%, 50%, 75% and 95% probability
bounds.
Despite the over-estimation of the prediction band widths, the 50th percentile
of the fitted probability distribution represents the centre of the data reasonably
well with 49.1% and 50.9% of in-sample predictions above and below the 50th
percentile limit respectively. Thus, the probability bands are well centred on the
data. This result indicates that the median, and likely nearby, variations are
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accurately captured.
Probability bounds for the [50−a, 50+a] percentile limits can be compared
to the ideal prediction coverage, as shown in Figure 5.9. Thus, for example,
for a = 10 the proportion of predictions within the [40th, 60th] percentile limits
of the model distribution can be compared to the ideal value of (2a)% = 20%.
This analysis would thus determine over what centred percentile range the model
prediction is most accurate.
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Figure 5.9: Comparison of integrated area under probability curve with ideal pre-
diction coverage. The dashed line represents the 50th percentile of the distribution,
and the shaded area represents the probability interval of width 2a centred on the 50th
percentile.
Figure 5.10 shows the extent of the model coverage over-estimation across
the range of prediction bounds for c = 0.5 and 1.0. In particular, for c = 1.0,
50% of the data lies between the 31st and 69th percentiles of the model where the
expected coverage is 38%. A total of 90% of the data for c = 1.0 lies between
the 7th and 93rd percentiles where the expected coverage is 86%. It is clear from
Figure 5.10 that these average estimations improve for the c = 0.5 line.
Finally, the variance estimator employed here is aligned with the cardinal
axes. The major and minor axes of the ellipse that forms from the contours
of each individual distribution in Equation 5.5 are aligned with the x and y
directions. A further modification may incorporate a rotation of the distribution
such that the variance in each distribution is described by three parameters (σx,
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Figure 5.10: Comparison of in-sample predicted insulin sensitivity within arbitrary
probability bounds (2a) against ideal proportion of predictions within bounds (y = x
line) for c=1.0 and c=0.5, where the ideal IQR is the 2a = 50% case.
σy, θ) to represent scaling in the x and y directions and rotation respectively
[Kern et al., 2003]. However, the meaning of a rotation is unclear in physiological
or control system terms, and thus not pursued here.
In summary, modifying the local data density variance estimator showed that
less variance (c < 1.0) resulted in distributions that more accurately reflected the
observed data prediction coverage. The ideal value of the adjustment parameter
c was found to be in the range of 0.1 to 0.5. However, Figure 5.8 shows that the
probability bounds of the distribution for small c are not smooth, suggesting that
this particular distribution is over-modelling the data, where a smoother varia-
tion is physiologically more realistic. The method shown in Figure 5.9 provides
a means to produce smooth probability bounds with a customisable trade-off
between glycaemic control performance and hypoglycaemic protection. Overall,
c=0.5 appeared to provide the most suitable trade-off between model bias and
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variance for this cohort, as shown in Table 5.4 and Figure 5.10.
5.5 Measurement density
The cohort data represents 3,567 hours of fitted insulin sensitivity data over 25
patients. Blood glucose measurement density for these patients was typically 2-4
hourly, thus there may be some effect introduced by interpolating between BG
measurements to fit insulin sensitivity. However, a stochastic model produced
by only taking the data closest to each BG measurement still yielded 64.0% of
predicted insulin sensitivity within the 25th to 75th percentiles, over-shooting the
50% expected by a similar value as obtained using the full model. This result
suggests that the blood glucose interpolation is not playing a significant role in
this data set.
Higher blood glucose measurement density may reveal more dynamics that
could be used to refine the blood glucose system model and, subsequently, the
stochastic model. However, such greater measurement density is ethically difficult
in the very low-blood-volume NICU population [Cowett and Farrag, 2004]. Hence,
it is difficult to do more than speculate further on this aspect.
5.6 Probability bound calculation
The non-parametric formulation of the kernel density model automatically ac-
counts for multi-modality. The probability bounds are computed by integrating
the area under the conditional probability curve to create a cumulative density
function which is then used to determine the probability limits. However, an
equal-tailed assumption is used to find the bounds. For a multi-modal distribu-
tion this equal-tailed assumption may lead to regions of lower probability being
included within the percentile bounds.
An alternative method to compute the probability bounds is to use the highest
regions of the conditional probability curve to compute the required area, as
shown in Figure 5.11. A comparison of the bounds computed using the two
methods is shown in Figure 5.12. The probability distribution is largely uni-
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modal in regions of high data density and the bounds computed using the two
methods largely correspond within this region. For higher insulin sensitivity the
two methods diverge slightly. However, there is generally little difference between
the percentile points for either method. These results suggest that the equal-
tailed assumption does not have a large effect on the bounds. This conclusion is
reflected by the proportion of in-sample predictions within the probability bounds
at 62.6% within the [25th - 75th] and 93.4% within the [5th to 95th] percentile
bounds compared to 62.8% within the [25th to 75th] and 93.6% within the [5th
to 95th] percentile bounds for the equal-tailed and highest-probability methods
respectively.
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Figure 5.11: Comparison of probability bound determination using equal-tailed and
highest-probability methods. This forecast ranges are shown as the shaded areas under
the curves. The highest-probability method can produce discontinuous probability
bounds.
The discontinuous probability bounds for regions of higher insulin sensitivity
suggest that intermediate changes in patient metabolic state are less likely during
periods of high insulin sensitivity. They also reveal the clinical possibility for
dramatic change in condition to a lower value at this state. Clinically, such a
sudden or large change could be due to a sudden worsening of condition. Thus,
the multi-modal model may provide some measure of estimating the risk of sudden
significant change (for the worse) at higher insulin sensitivity, which might offer
some significant clinical benefit.
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Figure 5.12: Comparison of probability bounds from equal-tailed and highest-
probability methods. The thin bounds represent the IQR and [5th - 95th] bounds from
the equal-tailed method. The thick lines represent the corresponding bounds from the
highest-probability method.
5.7 Insulin sensitivity in the positive domain
The insulin sensitivity parameter, SI , is constrained to the positive domain for
physiological validity. Normal probability distributions are used in Equation 5.2
to describe the data. There may be some degree of skewness as SI cannot be
negative and the Normal probability function spans the domain of [−∞,∞].
Figure 5.13 shows the joint probability density for six pairs of insulin sensitivity
data extracted from Figure 5.1. The tightness of the peaks is related to the
variance estimator based on local data density, where tighter peaks are generated
in regions of higher concentrations of data and wider peaks are present in regions
of lower data density. In all cases however, the influence of the chosen Normal
distributions is small close to the positive/negative interface shown in Figure 5.13,
demonstrating the use of a Normal probability distribution to have a minor effect
with respect to the requirement of a non-negative SI value.
The quantities pxi and pyi in Equation 5.2 provide a renormalisation to allow
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Figure 5.13: Joint probability density for six pairs of [SI , SI,n+1] data. The shapes
of the peaks are described by Normal probability density functions, and the tightness
of the peaks is related to the local data density variance estimator.
for truncation of the domain of the distributions. The truncation effect is greatest
at the extreme low and high end of the SI domain, as shown in Figure 5.14 where
the percentile bounds are curved in the ranges of SI < 0.2x10
−3 L/[mU.min] and
SI > 2.5x10
−3 L/[mU.min]. The majority of the data lies outside these ranges,
and the probability bounds in this region is not influenced by truncation effects.
Figure 5.14 highlights the 50th and 95th probability bounds, which are used
by model-based controllers for targeted control and hypoglycaemia prevention
respectively, as will be discussed in Chapter 6.
The truncation effect skews insulin sensitivity higher in the low SI range, thus
a controller would subsequently use less insulin for control. The reverse applies
for the high SI range. However, higher insulin sensitivity generally corresponds
with lower overall insulin requirements for glycaemic control. The net result is
that truncation effects in this case create a more conservative control approach
when stochastic forecasts are used to drive model-based control.
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Figure 5.14: Insulin sensitivity percentile probability bounds overlaid on the raw
insulin sensitivity variation data. The 50th and 95th bounds are highlighted.
5.8 Time series modelling for patient-specific forecasting
Overall, the stochastic method provides predictions based on a cohort-wide data
set. The prediction bounds for less dynamic patients would typically be more
conservative than necessary to account for more dynamic patients that make up
the patient population. Thus, the probability bounds are optimised in a cohort
sense, but not necessarily on a per-patient basis. Time-series methods, such as
ARIMA modelling, may provide enhanced prediction performance by customising
the model to the individual patient in real-time. These methods provide the
opportunity to optimise insulin sensitivity forecasting in a per-patient sense for
more optimal control.
This section presents the development of auto-regressive time series models for
insulin sensitivity forecasting. A bootstrap method is used to generate probability
bounds, and the prediction performance of the time-series models are compared
to the stochastic method. The overall approach is thus patient-specific in contrast
to the stochastic cohort-specific model presented in Sections 5.2 - 5.6.
5.8 TIME SERIES MODELLING FOR PATIENT-SPECIFIC FORECASTING 119
5.8.1 Cyclic variation in insulin sensitivity
It is unknown whether neonates exhibit any significant diurnal variations in in-
sulin sensitivity. Circadian rhythmicity has a profound and independent effect
on glucose tolerance in man, as reviewed by [Van Cauter et al., 1997]. In normal,
non-critically ill subjects diurnal patterns in glucose tolerance exist and are bal-
anced by insulin secretion throughout the course of a day. The exact mechanisms
of diurnal glucose tolerance are still under debate, but reduced effective insulin
sensitivity appears to be a major factor [Bolli et al., 1986].
Capturing any diurnal, or similar, rhythms that exist in neonatal insulin
sensitivity would improve model predictions, and hence controller performance.
Rhythms in metabolism may also appear in critical care linked to daily medication
dosing regimens or other routines in clinical practice.
The piecewise constant insulin sensitivity profile obtained from clinical data
(see Section 3.1) can be considered as a discrete time series. A discrete fourier
transform (DFT) was performed on the insulin sensitivity profile generated for
each retrospective patient. Figure 5.15 shows the distribution of the two strongest
frequencies for each patient.
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Figure 5.15: Histogram of the two strongest identified frequencies via DFT for the
retrospective cohort.
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The strongest frequencies for most patients was below 0.4 cycles per day, or
2.5 days per cycle, which is very close to the minimum detectable frequencies for
a number of patients. This result suggests critically ill neonates appear to exhibit
no significant periodicity in effective insulin sensitivity that could be linked to
diurnal cycles. Rather, the data suggests more gradual evolutions in insulin
sensitivity, characterised by non-cyclic trends and higher frequency noise.
5.8.2 Model specification
The structure of the autocorrelation (ACF) and partial-autocorrelation functions
(PACF) allow the order of the time-series model to be inferred from available
data. The relatively strong low frequency periods shown in Figure 5.15 suggest
that the mean value of insulin sensitivity may gradually evolve for a patient, as
suggested in the example profile presented in the top panel of Figure 5.16. Thus,
a first difference was applied to the insulin sensitivity data SI,t to obtain a time
series xt with stable mean:
xt = SI,t − SI,t−1 (5.10)
A sample ACF and PACF are shown in Figure 5.16. From observation of the
ACF and PACF, the structure of the model that appeared most appropriate for
neonatal patients was AR(1) or AR(2). This outcome agrees with the observed
results for the lag-1 and lag-2 stochastic models that showed little performance
improvements with higher lags. Both AR(1) and AR(2) models were assessed in
simulation.
The AR(1) and AR(2) models are of the form:
xt = δ + α1xt−1 + at (5.11)
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Figure 5.16: Example sample autocorrelation functions for Patient 11. The top panel
shows the raw model-fitted insulin sensitivity series. The second panel shows the first
difference of the insulin sensitivity series. The bottom two panels show the sample
autocorrelation function and partial autocorrelation function of the differenced series
respectively.
for AR(1), and for AR(2):
xt = δ + α1xt−1 + α2xt−2 + at (5.12)
where at is a zero-mean, independent random process with common distribution
function Fa, with E[a
2] = σ2a, and δ, α1, α2 are constants. The parameters α1
and α2 may be estimated as αˆ1 and αˆ2 with least squares minimization of the
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Yule-Walker equations [Chatfield, 2004]:
A¯{αˆ}T = b¯ (5.13)
where, for the AR(1) case:
{αˆ} = {αˆ1}, A¯ = (1) , b¯ = r1 (5.14)
and for the AR(2) case:
{αˆ} = {αˆ1, αˆ2}, A¯ =
(
1 r1
r1 1
)
, b¯T =
(
r1 r2
)
(5.15)
The term rk in Equations 5.14-5.15 is the sample autocorrelation, where ck
is the sample autocovariance function at lag k, both of which are defined:
rk =
ck
c0
(5.16)
ck =
1
N
N−k∑
t=1
(xt − x¯) (xt+k − x¯) (5.17)
where x¯ is the sample mean.
The parameter δ of Equations 5.11 and 5.12 may be estimated as δˆ:
δˆ = x¯
(
1−
p∑
i=1
αˆi
)
(5.18)
Further information on the AR methods in this study and their derivation can
be found in [Chatfield, 2000, 2004] and [Bloomfield, 2000] and several other fun-
damental texts on this topic.
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5.8.3 Bootstrap prediction intervals
For prediction bands, the AR bootstrap method of Thombs and Schucany [1990]
is used in this study. This non-parametric resampling method is chosen given that
the parameter SI is forced to account for many complex, non-random effects.
The Thombs and Schucany [1990] method is outlined briefly here for clarity.
Given a data set xt = x1, . . . , xN , the ith residual or error of an AR(p) model
with n data samples is defined:
aˆi = xi − δˆ − αˆ1xi−1 − · · · − αˆpxi−p,
i = t, t− 1, . . . , t− n+ p+ 1 (5.19)
where aˆi replaces the true errors ai of Equation 5.12 in the generation of bootstrap
replicates. The backward representation of the AR series is used to generate
conditional bootstrap replicates that have the same last p values and have the
same correlation structure as the series being predicted:
xt = δ + α1xt+1 + · · ·+ αpxt+p + et (5.20)
where et is a sequence of random variables with a common distribution function
Fe. It can be shown that the true error distributions Fa and Fe of the forward and
backward models are the same when they are normal [Box and Jenkins, 1976].
To obtain a bootstrap replicate, x*, the last p values of the replicate are defined:
x∗t−j+1 = xt−j+1,
j = 1, . . . , p (5.21)
The remainder of x* are generated by the recursive equations:
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x∗j = δˆ + αˆ1y
∗
j+1 + · · ·+ αˆpy∗j+p + e∗j
j = t− p, . . . , t− n+ 1 (5.22)
where eˆ∗j is a random draw from the estimated error distribution function Fˆe.
Hence a typical bootstrap replicate is
(
x∗t−n+1, x
∗
t−n+2, . . . , x
∗
t−p, xt−p+1, . . . , xt
)
.
Figure 5.17 shows six bootstrap replicates generated from an AR(2) process (p =
2), which means that each bootstrap replicate has the same last two values xt−1
and xt.
 
Figure 5.17: Six bootstrap replicates from an AR(2) process (δ = 0, α1 = 1.75, α2 =
-0.76) of length n = 50, conditional on having the last p values x49 and x50. Adapted
from [Thombs and Schucany, 1990].
The bootstrap procedure for a 100β% prediction interval begins by calculating
a bootstrap future value X∗t+k for each of the B replicates. For a single replicate,
X∗t+k is obtained from:
X∗t+k = δˆ
∗ + αˆ1
∗y∗t+k−1 + · · ·+ αˆpy∗t+k−p + aˆ∗t+k (5.23)
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where
(
δˆ∗, αˆ∗
)
are the least squares estimates based on the specific bootstrap
replicate, and aˆ∗t+k is a random draw from Fˆa.
Having obtained the set of B bootstrap future values, the prediction limits
are defined as the quantiles of the bootstrap CDF of X∗t+k. A summary of the
procedure is a follows:
1. Compute residuals from Equation 5.19. Let Fˆa be the empirical CDF of
the residuals.
2. Generate bootstrap replicate using Equations 5.21 and 5.22.
3. Compute AR model paramater estimates δˆ∗ and αˆ∗i , i = 1, . . . , p from the
bootstrap replicate. Compute a bootstrap point prediction as in Equa-
tion 5.23 for lag k, using aˆ∗t+k, a random draw from Fˆa.
4. Repeat Steps 2 and 3 for B bootstrap replicates.
5. Calculate the required prediction band from the quantiles of the bootstrap
CDF.
5.8.4 AR model bootstrap prediction results
Bootstrap windows of 12, 24 and 48 hours for both AR(1) and AR(2) models were
evaluated to determine the performance of the forecasting procedure. Table 5.5
shows the median forecast IQR width over the cohort, together with the 25th and
75th percentiles, for SI and BG. The summary statistics are also reported for the
5% - 95% forecast interval width. All forecasts were for 1-hour prediction inter-
vals. The stochastic model results provided for comparison were generated with
a variance modifier of c = 0.5 (see Section 5.4). Several patients were excluded
from the 24 and 48 hour window analyses due to insufficient retrospective data.
A comparison of insulin sensitivity forecasts for the bootstrap procedure and the
stochastic model is shown in Figure 5.18.
The AR models of both orders gave similar performance across the assessed
range of bootstrap windows. In all cases, the width of the prediction forecast
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Figure 5.18: Comparison of insulin sensitivity forecasts using the bootstrap method
for an AR(2) model with 24-hour bootstrap window (top panel) and stochastic model
(bottom panel). The AR model shows tighter probability band widths compared to
the stochastic model for periods of relatively stable SI .
intervals tightened for longer bootstrap data windows. The 25th and 75th per-
centiles of the IQR and 5% - 95% prediction widths show greater variation for all
forms of the AR model compared to the stochastic model. This result highlights
the AR model bootstrap prediction intervals adapting to less variable periods
by tightening the prediction forecast interval, indicating a more patient-specific
adaptation potentially useful for control.
The proportion of insulin sensitivity and BG values within the forecasted
band was close to the desired 50% and 90% for all AR models, compared to
the relatively conservative result of the stochastic model. Whilst the stochastic
model captures insulin sensitivity variability for an entire cohort of patients,
the AR model will only capture insulin sensitivity variability in a single patient
up to the current time. Thus, there is a possibility that the AR model could
miss a sudden change in insulin sensitivity that is not unlikely in terms of the
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whole cohort, but had not yet been observed in the particular patient. This
possibility suggests that whilst the tighter insulin sensitivity prediction intervals
may encourage more aggressive insulin usage, maintaining global limits on insulin
rates would be prudent to minimise risk due to sudden changes in condition.
Adequate data is required to adequately estimate the error distribution Fˆa.
Thus, an AR method would not be applicable until at least 12-24 hours of data
had been collected for the patient. This aspect is of particular concern for the
neonate as hyperglycaemia often requires treatment within the first day of life.
In contrast, the stochastic method is able to generate forecasts from the 2nd BG
measurement during clinical usage.
Figure 5.18 shows that the prediction bounds tighten during periods of rel-
ative stability in the insulin sensitivity profile for the AR model case, compared
to a relatively constant prediction interval width for the stochastic model case.
Thus, the AR model identifies periods of stable insulin sensitivity as a tighter
prediction interval. However, it is important that this result should not be inter-
preted as a reason for less intensive BG monitoring. Due to the clinical fragility of
this patient group sudden changes in overall patient condition are not uncommon,
such as the onset of a new infection. Such changes have the undesirable effect
of increasing the variability in insulin sensitivity. In particular, the NIRTURE
trial [Beardsall et al., 2008] found most hypoglycaemia was in infants deemed
relatively healthy and concluded that these infants were probably monitored less
intensively, thus missing changes in metabolic condition.
The AR bootstrap procedure can be naturally extended to generate prediction
intervals for longer lags. Equation 5.23 can be applied recursively to generate
prediction intervals for lags greater than 1 hour. A comparison of the insulin
sensitivity prediction performance for an AR(2) model with 24-hour bootstrap
window over lags of 1-4 hours is presented in Table 5.6.
The IQR and 5% - 95% prediction interval widths presented in Table 5.6
increase with longer lags. The prediction performance as assessed by proportion
of values within prediction bounds decreases dramatically over longer time peri-
ods. This is expected as for lags less than the order of the model p, prediction
error variance is due to variability due to the residual term and variability due
to parameter estimation [Thombs and Schucany, 1990]. For longer lags, future
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values will vary with each bootstrap replicate, thus increasing the variance of the
set of future values. Clinically, these changes would also be expected.
The bootstrap method of Thombs and Schucany requires iteration, whereas
the Markov model can be stored as a look-up table, or set of piecewise polynomials
to allow interpolation. Thus, the AR approach is a computationally more expen-
sive routine. For example, a single forecast using the stochastic model requires
< 0.1 seconds of computation time, however it takes approximately 5.4 seconds
to 18.6 seconds for each prediction generated by the AR bootstrap method for
12-hour and 48-hour bootstrap windows respectively. The bootstrapping rou-
tine lends itself well to parallel processing, so execution time may be reduced on
modern multi-core computer processors. This computational speed difference be-
comes a relevant factor for Monte-Carlo analyses, and an increase in simulation
time of up to 18 seconds for the 48-hour window case may cause a noticeable
delay for clinical staff using the system in real-time.
5.9 Summary
A stochastic model to provide insulin sensitivity predictions is developed from
a set of insulin sensitivity data for a neonatal intensive care cohort. The model
provided conservative prediction estimators that provided greater coverage than
expected from the probability bounds. Incorporating lag-2 effects did not improve
the coverage proportion, and greater coverage over-estimation in regions of higher
data density pointed to the variance estimator based on local data density as
a possible source of over-estimation. Modifying the data density estimator by
introducing a constant scaling factor showed appropriate coverage was obtained
at approximately 10-50% of the original value. However, at low values of the
scaling factor the probability bounds were no longer smooth or physiologically
realistic. Smooth probability bounds containing the appropriate proportion of
prediction coverage could be obtained by choosing the probability bounds to
obtain the desired prediction performance.
AR models are able to generate a patient-specific model to allow for tighter
prediction intervals during periods of relative stability in insulin sensitivity. How-
ever, such models require substantial individualised patient data (eg: 12 - 48
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hours) which may not be available at the commencement of real-time glycaemic
control. Thus, the cohort wide model presented here may be employed to pro-
vide prediction bounds until a suitable amount of data is generated to employ a
patient-specific model.
The analyses in this chapter established forecasting performance is influenced
by trade-offs between methods and within methods. The stochastic model uses
a kernel estimator based on the Normal probability distribution. A kernel based
on a different probability distribution may prove more ideal for this data, or
alternatively the ideal kernel for this data may not resemble any commonly used
distribution. Thus, modifying the variance estimator effectively shifts the trade-
off between conservatism and control applicability. A similar trade-off exists
between the stochastic and AR forecast methods. AR models may allow for
tighter control when patients are stable, however stochastic models can provide
a higher level of safety during periods of greater variability. A combination of
forecasting techniques may provide the best of both worlds, and the balance
between these trade-offs can be adjusted based on the qualities of control desired
in a particular clinical application.

Chapter 6
Virtual trials
Several design parameters must be considered in developing a safe, effective and
optimal neonatal glycaemic control algorithm. Virtual trials offer the opportunity
to explore control strategies in simulation before pilot clinical trials. In particu-
lar, the proposed control algorithm needs to reduce elevated blood glucose level
in a controlled, predictable manner accounting for external nutrition. The con-
troller must also account for inter-patient variability and varying physiological
condition. Hence, it must be adaptive and/or able to identify changes in patient
dynamics, particularly with respect to insulin sensitivity. The protocol should
require only infrequent sensor measurements to minimise labour and comply with
existing medical protocols on the treatment of neonatal hyperglycaemia to ensure
the method developed could be readily implemented in a clinical environment.
Finally, the controller must be robust to sensor errors, and other clinical events
that may impact the transition from the simulation environment to clinical prac-
tice.
This chapter will introduce the methodology behind virtual trials and model-
based targeted glycaemic controllers. Several control variables related to con-
troller implementation specifics will be assessed in simulation to determine their
impact on BG control performance. Finally, effects including missed BG mea-
surements, delays in implementing controller recommendations and BG sensor
noise are simulated to test the robustness of the controller.
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6.1 Virtual trial methods
The insulin sensitivity parameter, SI , drives the dynamics of the blood glucose
model and is assumed independent of exogenous insulin and nutrition adminis-
tration [Bergman et al., 1981]. Once a patient-specific profile of time-varying
insulin sensitivity is generated, it can be used to predict blood glucose concentra-
tion based on different insulin and nutrition control schemes by solving the set of
differential equations representing the system over the future time period of in-
terest. Such analyses are effectively in-silico or virtual trials and have been used
extensively in protocol design for adult critical care [Chase et al., 2007; Lonergan
et al., 2006b; Wilinska et al., 2008] and Type I diabetes [Wong et al., 2008].
 
 
 
Patient 
Identification: 
Fit insulin sensitivity. 
Forecast future insulin 
sensitivity. 
Control: 
Iterate possible insulin rates, 
solve model for each iteration, 
find closest match to target BG. 
Adjust insulin rate based on 
stochastic forecast if available. 
Controller 
recommendation 
Measurement: 
• Blood glucose (G(t)) 
Infusion data: 
• Insulin (u(t)) 
• Nutrition (P(t)) 
Figure 6.1: Controller implementation schematic
The clinical implementation procedure for the model-based controller in a
clinical environment is shown in Figure 6.1. A BG measurement and subsequent
controller intervention represents one cycle of the loop in Figure 6.1. Typically,
this process is repeated every 1-2 hours in adult critical care. The virtual trial
procedure replaces the ‘Patient’ in Figure 6.1 with a forward solution of the model
using an insulin sensitivity profile generated from retrospective data, and adds
sensor noise and other variations as required.
The blood glucose history, along with insulin and nutrition history, are used to
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fit the patient’s insulin sensitivity profile in real-time. A forecast for future insulin
sensitivity is then generated using a statistical method or other technique. This
SI profile is then used by the controller to solve Equations 2.28-2.30 (Chapter 2) to
predict blood glucose concentration based on insulin and nutrition rates. Several
combinations of infusion rates can be simulated to select the dosage that will
most likely meet the target BG concentration, as shown in Figure 6.2. Thus,
the controller adapts to the current metabolic state of the neonate in real-time.
The controller employed in this research uses a bisection algorithm, shown in
Figure 6.3 to determine the insulin infusion rate that will bring the BG closest to
a target BG, if the target is physiologically possible with safety. Thus, every BG
measurement is followed by a controller intervention to alter the insulin infusion
rate.
 
tnow – 120mins tnow – 60mins 
NOW 
tnow  tnow + 60mins 
Blood glucose 
Insulin 
sensitivity 
SI fitted over this period 
Insulin rates ‘trialed’ over 
this time period 
Target BG 
(high insulin rate prediction) 
(low insulin rate prediction) 
SI assumed for this 
period 
 
Figure 6.2: Insulin sensitivity period and BG prediction period used by the model-
based controller.
6.1.1 Controller development
Controllers using 1 - 4 hourly BG measurement and intervention intervals were
examined and compared to the retrospective hospital control clinical data and
simulations using a typical insulin sliding scale shown in Table 6.1. All initial
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Upper rate
Mid rate
Lower rate
ODE 
solver
BG
time
BG > target
Set lower rate
= Mid rate
BG
time
BG < target
Set upper rate
= Mid rate
Predicted BG 
at tnow+60
Solve model 
equations
Choose ‘trial’ insulin 
rate = mid rate
Adjust upper/lower 
rates
Perform next iteration
 
Figure 6.3: Iterative bisection method used by the model-based controller to select
an insulin infusion rate.
Table 6.1: Typical insulin sliding scale used in simulation.
Blood glucose Insulin rate
> 20 mmol/L 0.100 U/kg/hr
15 - 20 mmol/L 0.075 U/kg/hr
10 - 15 mmol/L 0.050 U/kg/hr
5 - 10 mmol/L 0.025 U/kg/hr
< 5 mmol/L STOP
simulations were performed with uniformly distributed 7% measurement error,
which is a conservatively large choice [Peet et al., 2002; Chen et al., 2003]. The
insulin sensitivity profiles fitted to the 25-patient retrospective cohort provided
the virtual patients for simulation. The blood glucose target is 6.0 mmol/L or
a 15% reduction per hour from the current BG concentration, whichever is the
greater value. The controllers developed modulated only the insulin infusion
rate and used the retrospective parenteral dextrose and enteral nutrition infusion
profiles. Controllers that modulate both insulin and nutrition are investigated in
Section 6.4.
Crucially, blood volumes in neonates are small [Cassady, 1966; Leipala et al.,
2003], which restricts the frequency of BG sampling. This restriction provides an
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additional challenge for model-based control in the neonatal setting compared to
the adult case. Thus, it is important to optimise the number of BG measurements
required for control. Clinically, volume restrictions mean most neonates will not
be sampled more than 2-hourly (12 per day) as a maximum rate overall.
The metabolic status of a critically ill neonatal patient can change rapidly.
This change is reflected by sudden rises and drops in insulin sensitivity. Addi-
tionally, sudden changes in apparent insulin sensitivity may be caused by sensor
noise and/or measurement error [Chase et al., 2008b]. Thus, for example, a bal-
ance is required between the speed at which a controller reacts to correct blood
glucose rises due to sudden changes in metabolic state, and the risk of running
higher insulin infusion rates when a sudden apparent rise in blood glucose resolves
quickly, or was due to measurement error.
To explore the balance between speed of control response and robustness
against either real sudden metabolic changes or large sensor errors (false changes),
two sets of controller schemes were evaluated. Scheme ‘A’ controllers set a rela-
tively high upper limit of 0.5 U/kg/hr for the maximum controller insulin infusion
rate, and limited the maximum increase in insulin infusion rate permitted from
one intervention to the next. Scheme ‘B’ controllers used a lower maximum in-
sulin infusion rate of 0.1-0.5 U/kg/hr based on reported trials of insulin infusion
in neonates [Collins et al., 1991; Kanarek et al., 1991; Meetze et al., 1998], but
no limit on the ability to increase the insulin infusion rate (up to the maximum
allowable rate). Note that both schemes have no limit on decreasing the infusion
rate to allow the protocol to ‘back-off’ quickly.
Performance was measured as more BG measurements within a clinically
recommended target 4 - 7 mmol/L band, while minimizing or eliminating mea-
surements lower than 2.6 mmol/L. The LBG-P (Low BG to Performance) ratio
provides a measure of the increased risk of low BG measurements under tight
glycaemic control compared to the increase in measurements within the target
BG band. The LBG-P ratio is defined as:
% measurements < 2.6 mmol/L
% measurements within 4-7 mmol/L band
∗ 100 (6.1)
Both insulin rate control schemes were tested with 1, 2, 3 and 4 hour BG
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measurement intervals to assess the robustness of each scheme to increasing mea-
surement interval length. The best performing controller was subjected to further
analysis, including simulated BG sensor error and clinical delays.
6.2 Controller analysis
6.2.1 Controller limits
A comparison of controller rules on insulin infusion for several combinations of
maximum insulin infusion rate and maximum increase in insulin infusion rate
per intervention is presented in Table 6.2. Interestingly, despite the targeted
BG controller using model-based BG forecasts to implement insulin dosage, the
implementation of limits on maximum insulin rate and rate of change of insulin
infusions produced noticeable variations in controller quality, as evidenced by the
spread of times in relevant glycaemic bands and the LBG-P ratio. This result
highlights the dynamic, evolving nature of the neonatal patient and emphasises
the importance of relatively frequent BG measurement and control cycles.
Scheme ‘A’ with a 0.01 U/kg/hr limit on insulin infusion rate increases had a
median BG greater than 6.0 mmol/L for all measurement interval cases, as well as
a relatively low proportion of measurements within the 4 - 7 mmol/L range. Thus,
this scheme does not react to changes in metabolic state fast enough for optimal
control. The results for Scheme ‘A’ simulations with allowable insulin infusion
rate increases of 0.03 and 0.05 U/kg/hr per intervention show a similar level of
performance. The 0.05 U/kg/hr increase limit achieved a higher percentage of
measurements within the target BG band. However, the 0.03 U/kg/hr increase
limit achieved a lower LBG-P ratio for 2-4 hourly measurement intervals.
Scheme ‘B’ with the lower upper insulin rate of 0.1 U/kg/hr yielded a lower
percentage of measurements within the 4 - 7 mmol/L range across all measure-
ment frequencies compared to the higher-performing Scheme ‘A’ results, suggest-
ing that 0.1U/kg/hr is too low for a maximum insulin infusion rate for most pa-
tients. The results for Scheme ‘B’ simulations with 0.3 U/kg/hr and 0.5 U/kg/hr
upper insulin rate limits showed little difference in measurements within the 4 -
7 mmol/L band despite the availability of higher insulin infusion rates. However,
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these two control schemes recorded the highest percentage of measurements less
than 2.6 mmol/L, and the high LBG-P ratio reflects that the increased risk of
low BG measurements was greater than the possible increase in measurements in
the target BG band compared to the other insulin schemes.
Thus, Scheme ‘A’ with a 0.03 U/kg/hr allowable insulin infusion increase rate
and Scheme ‘B’ with an upper limit of 0.15 U/kg/hr of insulin represent the best
performing versions of each control scheme. The Scheme ‘B’ simulation achieved a
higher proportion of measurements within the target band across all measurement
frequencies. However, the Scheme ‘B’ simulation showed a higher proportion of
measurements below 2.6 mmol/L for longer measurements intervals than the
Scheme ‘A’ counterpart, a result emphasised by the higher LBG-P ratio. Thus,
Scheme ‘A’ with a maximum increase in insulin rate of 0.03 U/kg/hr, highlighted
in Table 6.2, provides an effective compromise between controller performance
and robustness to increased times between measurements, and was chosen as the
controller for the remaining simulations in this study.
6.2.2 Comparison with retrospective and sliding-scale con-
trol
The impact of constant measurement frequency with different measurement pe-
riods was investigated for the model-based controller and the sliding scale of
Table 6.1. The results were also compared to hospital control in the retrospective
clinical data. Clinical implementation requires efficient use of clinical staff time
and hospital resources. Measurement frequency is often a balance between nurs-
ing burden and accuracy of control [Chase et al., 2008a; Mackenzie et al., 2005].
An additional aspect to more frequent blood glucose measurement specific to the
neonatal case is that the doors to the incubator are open more often, which may
negatively affect the infant’s hydration status [Hartnoll, 2003].
Table 6.3 compares blood glucose performance metrics, along with insulin
intake, between the actual retrospective NICU control, and simulated sliding scale
and targeted control. The median BG for all model-based control cases presented
in Table 6.3 is at, or close, to the target BG. The percentage of measurements
within the 4 - 7 mmol/L and 4 - 8 mmol/L ranges are [65% - 82%] and [76% -
6.2 CONTROLLER ANALYSIS 141
T
ab
le
6.
3:
C
om
pa
ri
so
n
of
gl
yc
ae
m
ic
co
nt
ro
l
pe
rf
or
m
an
ce
be
tw
ee
n
re
tr
os
pe
ct
iv
e
co
nt
ro
l,
ty
pi
ca
l
sl
id
in
g
sc
al
e
co
nt
ro
l
an
d
ta
rg
et
ed
m
od
el
-
ba
se
d
co
nt
ro
l
w
it
h
in
cr
ea
si
ng
B
G
m
ea
su
re
m
en
t
in
te
rv
al
.
C
on
tr
ol
sc
h
em
e
M
ea
su
re
m
en
t
fr
eq
u
en
cy
T
ot
al
m
ea
su
re
m
en
ts
M
ed
ia
n
B
G
(m
m
ol
/L
)
B
G
IQ
R
(m
m
ol
/L
)
%
of
m
ea
su
re
m
en
ts
w
it
h
in
ra
n
ge
A
v
g.
in
su
li
n
(U
/k
g/
h
r)
4-
7
m
m
ol
/L
4-
8
m
m
ol
/L
<
2.
6
m
m
ol
/L
M
o
d
el
-b
as
ed
co
n
tr
ol
le
r
1-
h
ou
rl
y
35
55
6.
1
[5
.6
-6
.6
]
82
%
90
%
0.
23
%
0.
05
4
2-
h
ou
rl
y
17
71
6.
0
[5
.4
-6
.8
]
76
%
86
%
0.
45
%
0.
05
6
3-
h
ou
rl
y
11
75
6.
0
[5
.3
-7
.0
]
69
%
81
%
0.
60
%
0.
05
7
4-
h
ou
rl
y
87
9
6.
1
[5
.2
-7
.2
]
65
%
76
%
0.
91
%
0.
05
5
R
et
ro
sp
ec
ti
ve
10
91
8.
0
[6
.3
-9
.9
]
31
%
46
%
0.
73
%
0.
03
4
S
li
d
in
g
sc
al
e
1-
h
ou
rl
y
35
55
8.
6
[6
.8
-1
0.
4]
26
%
40
%
0.
20
%
0.
02
9
2-
h
ou
rl
y
17
71
8.
6
[6
.9
-1
0.
5]
25
%
39
%
0.
34
%
0.
02
9
3-
h
ou
rl
y
11
75
8.
5
[6
.8
-1
0.
6]
25
%
41
%
0.
34
%
0.
03
0
4-
h
ou
rl
y
87
9
8.
5
[6
.9
-1
0.
8]
24
%
41
%
0.
57
%
0.
03
0
142 CHAPTER 6 VIRTUAL TRIALS
90%] which is [103% - 161%] and [61% - 91%] higher than retrospective hospital
control respectively. The sliding scale results showed higher median BG than
either model-based control or retrospective results.
The length of time between blood glucose measurements reduces the quality of
model-based control, dropping from 82% to 65% of BG measurements within the
4 - 7 mmol/L band for 1-hour to 4-hour measurement intervals. The proportion
of simulated measurements below 2.6 mmol/L is less than retrospective control
for 1 - 3 hourly measurements, but slightly greater for 4-hourly measurements.
The width of the IQR for retrospective control was 3.6 mmol/L and for sliding
scale control was 3.6 - 3.9 mmol/L, in contrast to a much tighter 1.0 - 2.2 mmol/L
for 1 and 4-hour simulations.
The results for the sliding scale protocol showed very little variation over the
1 to 4 hourly measurement intervals simulated. This result may be due to the
very discrete nature of the sliding scale used, and perhaps highlights that more
frequent measurement must be combined with a more refined protocol in order
to safely achieve glycaemic reductions and control with this type of approach.
Table 6.3 shows that time in a relevant glycaemic band is a clearer indication
of control performance when comparing control protocols than a median value.
The median blood glucose did not change significantly within protocols. How-
ever, time in band decreased dramatically in the presence of longer measurement
intervals out to 4 hours for the model-based controller, indicating increased gly-
caemic variability and thus potentially worse outcomes [Egi et al., 2006; Krinsley,
2008]. The BG IQR width also showed the changes in BG variability. However,
time in band provides an easy-to-visualise method of comparison.
Cumulative distribution functions provide not only the means to compare
protocols, but also obtain time in any glycaemic band preferred. Figure 6.4
shows the empirical cumulative distribution functions (CDF) for BG measure-
ment between simulated trials and retrospective control. The results for 1 - 4
hour measurement frequencies all intersect the 50th percentile area at approxi-
mately the target value of 6.0 mmol/L. The major difference in control quality
between the simulations lies within the slope of the lines, where more frequent
BG measurement and controller intervention results in a steeper slope, and thus
a tighter BG distribution.
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Figure 6.4: Empirical cumulative distribution functions of BG measurements for ret-
rospective hospital control versus simulated model-based control trials of 1, 2, 3 and
4-hour measurement and intervention frequency.
Finally, it is equally interesting to note that higher (or lower) insulin usage is
also not associated with an increase (or decrease) in hypoglycaemia. In this case,
the model-based controller used more insulin, but had the least hypoglycaemia.
Hence, it is not the amount of insulin used, but how it is used, that results in
variability and hypoglycaemic risks.
Insulin usage between the measurement frequencies was similar for model-
based control, and 65% - 74% higher than hospital control. It is interesting to
note in Table 6.3 that higher average insulin rates did not necessarily correspond
with greater proportion of measurements within target BG ranges. The highest
proportion of measurements within the target band was for the 1-hour control,
yet this measurement frequency used the least insulin of all simulated trials.
All model-based controller results are significantly different from the retro-
spective BG measurement distribution. It is important to note the curves pre-
sented in Figure 6.4 are not symmetrical - the slope at lower BG ranges is steeper.
Thus, BG results when not within the target range are skewed towards the upper
BG range, as mild hyperglycaemia is considered safer than an increased risk of
hypoglycaemia.
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Figure 6.5 shows the median CDF and 5% - 95% range of CDFs of the per-
patient control results for the model-based controller with 2-hourly measurement
frequency and those for the retrospective data. The inter-patient variation in BG
control with the model-based controller is much tighter compared to retrospective
control. Thus, the model-based controller better modulates insulin to account for
each individual patient’s glycaemic response.
 
Figure 6.5: Median and 5%-95% interval of per-patient BG CDFs.
Figure 6.6 compares the proportion of BG measurements within the target
4 - 7 mmol/L band for retrospective and simulated model-based control. Only
one patient retrospectively had greater than 50% of BG measurements within
the target band under hospital control. All patients had greater than 50% of BG
measurements within the target band in simulation. The 45◦ line in Figure 6.6
represents the line of no-change in performance. All results are above this line in-
dicating that the model-based controller achieved more BG measurements within
the target band than retrospective control for a range of preterm neonates. The
distance from the line is a measure of the increase in BG measurements within
the target band per-patient.
Figures 6.7a, 6.7b and 6.8 compare retrospective control and simulated model-
based control for three typical patients. The bottom panel of Figures 6.7a, 6.7b
and 6.8 show the model’s ability to track the insulin sensitivity profile in real-
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Figure 6.6: Comparison of percentage of BG measurements within the 4 - 7 mmol/L
BG range for retrospective and 2-hour simulated control. Each circle represents one of
the 25 patient profiles.
time based on data available at the bedside. This tracking is achieved through the
integral-based fitting method and through the independence of insulin sensitivity
as a model parameter.
6.2.3 BG-based measurement scheme
A BG measurement timing scheme based on current BG concentration was tested.
In particular, a high BG concentration carries little risk of hypoglycaemia and
may thus require less frequent BG sampling compared to periods at lower concen-
trations. Thus, a BG-concentration derived measurement scheme was simulated
where measurements were taken every 3 hours if BG > 8 mmol/L and any de-
crease in BG since the last measurement was less than 2 mmol/L/hr. A measure-
ment period of 3 hours was also used if the last 4 hours have been within the 4-8
mmol/L band, as a response to relative glycaemic stability. Measurements were
otherwise taken 2-hourly if BG was within the 4-8 mmol/L range, and hourly if
BG was less than 4 mmol/L.
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Figure 6.8: Comparison of blood glucose, insulin, nutrition and SI profiles for Patient
21 under retrospective control (dashed) and simulated model-based control (solid).
Table 6.4 shows BG control performance metrics for the BG concentration-
based variable measurement frequency scheme. A total of 1,446 simulated mea-
surements were used across the cohort, representing an average measurement
frequency of 2.4 hours. The summary BG control metrics for the BG-based mea-
surement scheme in Table 6.4 were computed using the model-fitted BG concen-
tration at 2.4 hour intervals to remove bias introduced by different measurement
frequencies at different BG concentrations. The BG-based measurement scheme
resulted in lower time in target BG band, higher median BG and wider BG inter-
quartile range when compared to 2- and 3-hour constant measurement frequency
schemes. Interestingly, this result is not necessarily expected. The primary ba-
sic course is a delay in response to changes in patient condition after periods of
relative glycaemic stability, slowing the response to hyperglycaemia as shown by
the higher BG upper quartile result for the BG-based scheme.
Figure 6.9 shows a simulated trial using the BG-based measurement and inter-
vention scheme. This timing scheme demonstrates the effects of non-symmetrical
control rules. The controller has limitations on increases in insulin infusion rates,
whereas there is no limit on decreases in insulin infusion rates. Thus, as fewer BG
measurements are taken at higher BG concentrations under this timing scheme,
there are fewer iterations of the control cycle and thus a slower increase of insulin
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Table 6.4: BG controller performance for BG-based measurement interval scheme.
Measurement scheme
BG-based 2-hour 3-hour
Num. measurements 1,446 1,771 1,175
% measurements within 4 - 7 mmo/L 63.6% 76% 69%
% measurements < 2.6 mmol/L 0.45% 0.45% 0.60%
BG median [mmol/L] 6.2 6.0 6.0
BG IQR [mmol/L] [5.3 - 7.5] [5.4 - 6.8] [5.3 - 7.0]
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Figure 6.9: Patient 11 simulated control using a BG-based measurement and inter-
vention timing scheme. The dashed line in the top panel represents the retrospective
blood glucose concentration under hospital control.
infusion rate in response to higher BG levels. As more measurement/control
cycles are performed at lower BG concentrations, there is a higher chance the
insulin infusion may be stopped.
Several examples of this effect are shown for Patient 11 in Figure 6.9 at
4,000, 5,500 and 6,500 minutes. The insulin infusion is stopped during periods
of frequent BG measurement. Subsequent BG measurements do not cause a
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Table 6.5: Glucose control performance and frequency of measurement for insulin
volume-based BG measurement scheme.
Insulin
volume
Num.
measure-
ments
BG (mmol/L) % of measurements within range
Median IQR
4-7
mmol/L
< 4
mmol/L
< 2.6
mmol/L
0.4 mL 2,239 6.1 [5.6 - 6.8] 76.6 2.0 0.2
0.5 mL 1,845 6.1 [5.5 - 7.0] 73.0 2.4 0.3
0.6 mL 1,612 6.1 [5.5 - 7.1] 70.6 3.6 0.4
0.7 mL 1,429 6.2 [5.4 - 7.1] 68.5 4.2 0.3
change in the insulin infusion rate - these measurements act as ‘confirmation’
measurements rather than ‘control’ measurements. Thus, the BG-based scheme
makes less efficient use of BG measurements for control purposes compared to
constant measurement schemes due to anti-symmetry in the control rules, and
highlights the use of virtual trials as an iterative design tool to develop optimised
protocols.
6.2.4 Infusion-volume based measurement scheme
A novel BG measurement and controller intervention timing scheme based on the
rate of insulin infusion was investigated. Standard insulin delivery pumps used
in neonatal intensive care can be programmed to deliver a set amount of insulin
at a specified rate, and then cease infusions. This feature can provide a safeguard
against over-infusion of insulin, and provides a natural reminder for the nursing
staff to take another BG measurement. Simulations were performed with BG
measurements spaced by the amount of time taken for a set volume of insulin to
be infused into the patient. Thus, higher rates of insulin infusion will incur more
frequent BG measurements. Insulin concentrations of 0.25 U/kg/mL, as used in
the Neonatal Department of Christchurch Women’s Hospital, were assumed in
the simulations. Measurement timings based on insulin volumes for 0.4 - 0.7 mL
were investigated, as shown in Table 6.5 and Figure 6.10.
The insulin volume cutoffs presented in Table 6.5 equate to measurement
frequencies of 1.6 - 2.6 hours. While median BG was relatively constant between
simulations, glycaemic control performance steadily decreased with higher vol-
umes of infused insulin between BG measurements, as expected given the results
of Table 6.3. However, the distribution of BG shown in Figure 6.10 displays little
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Figure 6.10: Empirical CDFs of model-based controller results for insulin-volume
based BG measurement scheme.
overall difference in BG control.
6.2.5 Comparison of measurement schemes
BG and control intervention timing schemes have been investigated in simula-
tion for three cases: constant frequency, BG-concentration based and insulin
volume based measurement schemes. Figure 6.11 compares the glycaemic control
performance, as measured as percentage of BG measurements within the 4 - 7
mmol/L band compared to the total number of BG measurements. The effective-
ness of glucose control with respect to frequency of blood glucose measurement
is compared, which has implications for both nursing burden and blood volume
requirements.
The line of best fit through the constant measurement frequency results pro-
vide a cut-off for comparing performance. Results above the line indicate higher
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Figure 6.11: Comparison of BG control performance with different measurement
and control timing schemes. The dashed line represents a line of best fit through the
constant measurement frequency results.
control performance per BG measurement, and below the line indicate less control
performance per BG measurement. Constant measurement frequency showed the
best performance results, with the insulin-volume measurement scheme achieving
a similar level of performance. The BG-based measurement scheme resulted in
a similar level of performance for an equivalent number of BG measurements,
and retrospective control had the lowest overall percentage of BG measurements
within the target band. Thus, these measurement frequency schemes and proto-
cols do not make a more optimal use of the measurements available compared to
the clinically easier regular measurement frequency.
6.2.6 Stochastic model
Stochastic modelling of the insulin sensitivity parameter can provide bands of
forecasted BG probability for a given intervention. These bands can delimit
the 5%-95% confidence interval for future BG concentration based on current
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insulin sensitivity for a particular patient and observed changes in insulin sen-
sitivity within the retrospective patient cohort used to generate the stochastic
model. The forecast bands can be used to provide further protection against
hypoglycaemia by providing a statistical measure of confidence against low BG
concentrations.
The stochastic model developed in Chapter 5 was incorporated into the con-
troller to provide safety against hypoglycaemia. The median forecasted insulin
sensitivity was used by the controller to select an insulin infusion rate that will
produce a forecasted BG concentration closest to target. The 95th percentile of
forecasted insulin sensitivity corresponds to the lower 5% limit of forecasted BG
concentration for a given insulin intervention. This outlying value was used to
adjust the the insulin infusion rate so that the lower 5% bound of forecasted BG
was always greater than 4 mmol/L. This adjustment resets the target to provide
a guaranteed maximum risk of 5% for a BG measurement less than 4 mmol/L.
Table 6.6: BG controller performance incorporating cohort-wide stochastic model.
No stochastic
forecasts
Stochastic
model
% measurements within 4 - 7 mmo/L 76% 76%
% measurements < 4 mmol/L 3.4% 3.2%
% measurements < 2.6 mmol/L 0.45% 0.34%
BG median 6.0 6.0
BG IQR [5.4 - 6.8] [5.4 - 6.8]
LBG-P ratio 0.59 0.44
Table 6.6 shows the effect of the stochastic model with 7% simulated BG
sensor error on BG performance results for the 2-hourly controller. The lower 5%
limit of the forecast bound was set to 4 mmol/L. The stochastic model resulted
in a reduction in BG measurements less than 4 mmol/L and 2.6 mmol/L, and a
reduction in the LBG-P ratio, thus lessening the risk and extent of hypoglycaemia.
Interestingly, incorporating the stochastic model resulted in a relatively small
control improvement as shown in Table 6.6. While it appears the stochastic model
was not able to prevent a period of hypoglycaemia, it did significantly limit
the length of time spent at hypoglycaemic BG concentrations. The stochastic
modelling approach employed here was originally developed for adult critical
care, which used a lower target BG concentration of 5 mmol/L [Lin et al., 2006,
2008], compared to the 6 mmol/L used in this study. Thus, the higher target
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for this initial neonatal controller will also avoid some hypoglycaemia, and it is
expected the incorporation of the stochastic model would have a greater effect
on control performance for lower target BG concentrations.
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Figure 6.12: Comparison of glycaemic control performance for model-based controller
with and without stochastic model insulin sensitivity forecasts, highlighting the effect
of skewed probability bounds at low insulin sensitivity.
Figure 6.12 shows simulations of model-based control for Patient 11 with and
without stochastic insulin sensitivity forecasts. A main feature of this patient’s
insulin sensitivity record is a period of very low insulin sensitivity between 3,000
and 4,000 minutes. As discussed in Section 5.7, the physiological requirement
that SI must be positive creates truncation effects at the extreme low region of
the insulin sensitivity domain. Figure 6.12 shows the stochastic model forecasted
insulin sensitivity is consistently higher than the patient SI profile during this
period. The controller selects lower insulin infusion rates as a conservative re-
sponse during this period of resistance to insulin, and consequently the simulated
BG concentration is higher compared to a controller that did not use stochastic
forecasting.
Whilst the stochastic model in this study is derived from a patient cohort that
would represent a typical case-mix of patients in a typical NICU, one cannot be
certain that all types of patients are covered in the initial 25 patient episode
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data set. Thus, the combination of stochastic model and limits on the controller
provide a very safety-conscious control system that is aware of possible limitations
in both information about clinical condition and model fit/prediction ability.
However, the model validation on retrospective data and the evidenced robustness
of the controller to errors and delays suggests that these errors will have a rather
small impact on overall controller performance.
6.2.7 Clinical BG targets
The ideal range for blood glucose concentration in neonatal intensive care is
under debate. Unlike adults, a major proportion of energy for brain metabolism
is provided by fuels other than glucose (eg: ketones) [Avery et al., 1994]. Thus,
the neonatal brain may be more resistant to hypoglycaemia compared to the
adult. However, persistent low blood glucose concentration (< 2.6 mmol/L)
can reduce cerebral development and lead to long term neurological deficiencies
[Lucas et al., 1988]. Likewise, the upper limit for clinically desirable blood glucose
concentration is also subject to debate [Cowett and Farrag, 2004]. For this study,
the range of 4 - 7 mmol/L, as used in several adult studies, was targeted. However,
to date, no outcome based study has provided a specific insight or result in this
regard. Thus, glucose management goals vary widely between intensive care units
[Alsweiler et al., 2007], targets for glucose control have varied between insulin
therapy studies [Beardsall et al., 2008; Vlasselaers et al., 2009], and it is likely
that the desired target for glucose control may change in the future.
The model-based controller was tested on the retrospective cohort with tar-
gets of 4 mmol/L, 5 mmol/L, 7 mmol/L and 8 mmol/L, which represent a range
of target glucose concentrations likely to be encountered in neonatal critical care.
All simulations used a constant 2 hour period between BG measurements and
a 7% BG sensor error. The stochastic model was employed to limit the risk
of undesired low BG concentrations. For the 4 mmol/L and 5 mmol/L targets
the lower bound for the stochastic model forecast was set to 3 mmol/L and 3.5
mmol/L respectively. A comparison of overall control performance for different
BG targets is presented in Table 6.7, and the cumulative distribution functions
for BG concentration are presented in Figure 6.13.
The controller achieved a median BG close to target for the 6, 7 and 8 mmol/L
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Table 6.7: Glucose control performance for different BG targets for the model-based
controller.
Target BG
BG (mmol/L) % of measurements within range
Median IQR
4-7
mmol/L
< 4
mmol/L
< 2.6
mmol/L
4 mmol/L 5.3 [4.8 - 6.3] 78.7 6.7 0.6
5 mmol/L 5.4 [4.8 - 6.3] 77.9 6.9 0.6
6 mmol/L 6.0 [5.4 - 6.8] 75.6 3.2 0.3
7 mmol/L 7.0 [6.2 - 7.8] 48.4 1.5 0.3
8 mmol/L 7.9 [7.0 - 8.7] 23.7 1.5 0.3
targets. The stochastic model prevented lower BG targets from being achieved
despite reducing the prescribed lower bound for forecasted BG concentration.
This result is largely due to the use of higher simulated insulin infusions to achieve
the lower targets, which thus also widens the forecast band for a specific value of
insulin sensitivity, and effectively cancels the effect of the reduced lower forecast
bound. This result is highlighted in Figure 6.13, where the 4 mmol/L and 5
mmol/L results largely correspond. Relaxing the stochastic safety constraints
may have allowed a slightly lower median in the 4 mmol/L and 5 mmol/L target
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Figure 6.13: Empirical CDFs of model-based controller results incorporating BG
targets of 4 - 8 mmol/L. The results for 4 mmol/L and 5 mmol/L are essentially
overlaid.
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cases, but a corresponding rise in hypoglycaemia events.
Figure 6.13 shows the different distributions of simulated BG measurements
have largely the same shape, but are shifted for the different targets. They are
particularly different when compared to the retrospective control results pre-
sented in Figure 6.4. More specifically, the model-based controllers are steeper
and thus tighter in performance.
Model-based control can be set to target a specific glucose concentration rel-
atively easily. This ease and directness in setting a target is in contrast with fixed
sliding scale or similar control approaches that must be completely re-calibrated.
This target setting feature may be useful in research settings outside of routine
critical care to elucidate the specific effects of glucose control to a range of targets
on patient outcome.
Thus, the control targets are customisable to within a reasonable range. Very
low targets run higher risks of hypoglycaemic measurements, and very high tar-
gets cannot be achieved without increasing dextrose infusions. Clinicians may
also select a BG target on a per-patient basis, or change the level of glucose
control in the future based on emerging research in this field.
6.3 Clinical implementation testing
Clinical implementation of any control system requires a transfer of technology
from the precise, exact simulation environment to the busy clinical setting where,
despite best training practices, the potential for errors and mistakes remain.
The BG measurement input may contain errors due to sensor noise. Human
errors can include missed BG measurements and delays in implementing controller
recommendations. These effects were introduced into the simulation environment
to stress-test the controller against a range of possible clinical complications.
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Table 6.8: Comparison of glycaemic control performance with increasing simulated
BG sensor error for 2-hourly measurement interval.
Sensor
error
BG (mmol/L) % of measurements within range
Median IQR
4-7
mmol/L
< 4
mmol/L
< 2.6
mmol/L
2% 6.0 [5.4 - 6.7] 78% 3.2% 0.40%
5% 6.0 [5.4 - 6.7] 77% 3.3% 0.34%
7% 6.0 [5.4 - 6.8] 76% 3.4% 0.45%
10% 6.1 [5.3 - 6.8] 75% 3.1% 0.40%
15% 6.1 [5.3 - 7.0] 69% 4.8% 0.51%
20% 6.1 [5.2 - 7.3] 65% 5.3% 0.40%
6.3.1 BG sensor error
Glycaemic control performance was tested with simulated uniformly distributed
BG measurement errors of 2%, 5%, 7%, 10%, 15% and 20%, representing the
range (and beyond) seen in clinical practice depending on the BG measurement
device/analyser used [Peet et al., 2002; Chen et al., 2003]. Table 6.8 shows most
accurate control was achieved, as expected, with the minimum amount of mea-
surement noise with 78% versus 65% time in the 4-7 mmol/L band for ±2% versus
±20% measurement error, for a 2-hourly BG measurement interval. Decreases in
time in glycaemic control bands showed a similar pattern for other measurement
frequencies simulated. Figure 6.14 shows the percentage of measurements within
the 4 - 7 mmol/L band and less than 4 mmol/L for 1-4 hour measurement fre-
quencies. Absolute time in band decreased 7% - 17% for an 18% absolute increase
in simulated sensor error, and a corresponding absolute increase of 1.0% - 2.6%
for measurements less than 4 mmol/L. The effect of sensor error on overall BG
control is shown in Figure 6.15. Increased measurement error results in a less
steep CDF. However, even with 20% simulated sensor error Figure 6.15 shows
significantly increased tightness of BG control compared to retrospective clinical
results.
As much as possible, accurate, safe glycaemic control requires a complete
and accurate knowledge of the model inputs. The integral-based fitting method
provides robustness by effectively acting as a low-pass filter to reduce the effect
of noise in blood glucose concentration sensing, as shown by the relative robust
results of Table 6.8. As well as blood glucose concentration, the history of insulin
and nutrition administration needs to be accurate to effectively determine patient-
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Figure 6.14: Effect of simulated BG sensor error on BG control.
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Figure 6.15: Empirical CDFs of model-based controller results incorporating sensor
error compared to retrospective hospital control. The main group of CDFs represent
2% - 20% sensor error for the model-based controller as summarised in Table 6.8.
specific and/or time-varying parameters. Thus, efficient data flow is an important
design concern to minimise time consuming and error-prone bedside data entry.
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Table 6.9: Glucose control performance for delays between BG measurement and
insulin infusion rate change.
Delay
BG (mmol/L) % of measurements within range
Median IQR
4-7
mmol/L
< 4
mmol/L
< 2.6
mmol/L
None 6.0 [5.4 - 6.8] 75.6 3.2 0.3
10 min 6.1 [5.5 - 6.9] 74.0 2.9 0.4
20 min 6.1 [5.5 - 6.9] 73.7 2.7 0.3
30 min 6.2 [5.5 - 7.0] 73.0 2.4 0.3
40 min 6.2 [5.5 - 7.1] 71.0 2.7 0.5
6.3.2 Clinical intervention delays
A common source of delay is a lag between the time of BG measurement and
the time the insulin infusion rate is changed to the amount recommended by the
controller. As insulin may cause irreparable damage in extreme circumstances,
special precautionary procedures are taken by clinical staff when handling insulin
infusions. Typically, any change in rate must be approved and signed by an
attending clinician, and the change in rate on the pump must be sighted by at
least two members of clinical staff. However, due to the spontaneous nature
of emergency child-birth, doctors are often away from the unit assisting with a
delivery. Additionally, nursing staff may be unavailable due to clinical instability
with either the patient receiving insulin or another patient within the unit that
requires immediate attention. Thus, substantial delays can exist between the
time of BG measurement and eventual adjustment of insulin infusion rate.
The effect of these delays are modelled by incorporating a lag between the
time of the BG measurement and the time of insulin infusion change. Delays of
an added 10, 20, 30, and 40 minutes were assessed. The results in Table 6.9 show
that the controller is robust to these delays, with the small change in performance
tending towards higher BG concentrations.
The results of Figure 6.16 confirm the model-based controller is robust to de-
lays in insulin infusion rate changes, tending towards a marginally higher propor-
tion of hyperglycaemic measurements with longer delays. The stochastic model
is a source of protection against significant increases in low BG measurements.
Thus, the lower limits of the curves of Figure 6.16 are essentially identical.
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Figure 6.16: Empirical CDFs of model-based controller results incorporating delays
between BG measurement and change of insulin infusion rate of 10 to 40 minutes.
The controller attempts to lower BG concentration though steady reductions
in BG level per hour, rather than trying to reach the target range as quickly
as possible, and the limits on the controller assessed in Section 6.2.1 results in
generally gradual changes in insulin infusion rate. Thus, it is likely some measure
of the robustness of the controller can be attributed to reduced accumulated
errors as the change in insulin infusion rate between successive interventions is
generally small.
6.3.3 Missed BG measurements
A missed BG measurement may occur for a number of reasons, many of which
are related to clinical workload. A missed BG measurement means both a missed
data point and a missed iteration of the control cycle of Figure 6.1. Control
simulations were performed with a missed BG measurement chance of 1/3, 1/4,
1/5 and 1/6, from a base measurement frequency of 2 hourly. These proportions
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Table 6.10: Glucose control performance and frequency of measurement versus chance
of a missed BG measurement.
Chance
Num.
measure-
ments
BG (mmol/L) % of measurements within range
Median IQR
4-7
mmol/L
< 4
mmol/L
< 2.6
mmol/L
1/3 1371 6.3 [5.5 - 7.5] 62.1 4.8 0.7
1/4 1453 6.2 [5.5 - 7.4] 66.1 3.7 0.8
1/5 1551 6.2 [5.5 - 7.2] 69.2 3.9 0.6
1/6 1564 6.2 [5.5 - 7.3] 67.4 3.6 0.6
None 1771 6.0 [5.4 - 6.8] 75.6 3.2 0.3
of missed BG measurements (17% to 33% of measurements) are likely to be much
higher than typical clinical practice, and thus represent a worst-case scenario test.
The resulting BG control performance is presented in Table 6.10, with simulated
BG CDFs presented in Figure 6.17.
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Figure 6.17: Empirical CDFs of model-based controller results for simulated missed
BG measurements.
The missed BG measurements extended the average measurement frequency
from the base value of 2 hours to 2.3 - 2.6 hours. A general decrease in BG
control quality is evident with increasing frequency of missed BG measurements.
However, the quality of BG control is relatively consistent across the proportions
of missed BG measurements, which may be attributed to the limits placed on the
stochastic forecasting method and BG controller to target more gradual changes
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in BG concentration.
6.4 Dextrose modulation
The targeted controller can be used to optimise several glycaemic control inputs
simultaneously within clinical limits. In the glycaemic control case, both insulin
and nutrition inputs may be modulated to adapt control to the infant’s changing
metabolic condition, as captured by the fitted insulin sensitivity parameter. For
example, a constant dextrose infusion rate may be selected, and may be modified
during periods of low insulin sensitivity where benefit-to-risk ratio for insulin
infusions is lower.
To provide an example for comparison, simulations were performed over the
virtual patient cohort with a controller that targeted a 10 mg/kg/min parenteral
dextrose infusion rate for all patients. The dextrose rate was lowered in steps
of 20% only if the maximum allowable insulin rate would result in a predicted
BG concentration higher than target. The dextrose rate was raised in steps of
20% if the forecasted BG concentration was below target with zero insulin input.
The stochastic model was employed to minimise the risk of hypoglycaemia and
constant 2-hourly BG and measurement intervals were used. Enteral feeds, a
minor source of nutrition, were not altered from retrospective data. The target
BG concentration was 6 mmol/L.
The simulation results are presented in Table 6.11 and Figure 6.18. Dextrose
rate data is presented as an average per-hour on a whole-cohort basis (n=3,492
data points).
The BG control performance again showed lower, tighter control compared
to retrospective clinical data, while the distribution of dextrose infusions was si-
multaneously increased. Thus, both lower, tighter glycaemia and higher rates
of dextrose administration may be achieved with a patient-specific adaptive con-
troller. While the median and IQR of dextrose infusions were close to target,
patients spent approximately 30% of the time with a dextrose infusion rate less
than the target of 10 mg/kg/min. These lowered rates coincide with periods of
relatively low insulin sensitivity. Thus, the controller uses reduced dextrose rates
as a tool to control glycaemia during periods when insulin infusions alone would
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Table 6.11: Glucose control performance and parenteral dextrose infusions for model-
based controller modulating both insulin and dextrose compared to retrospective hos-
pital control.
Dextrose
modulation
Retrospective
Median BG (mmol/L) 6.1 8.0
BG IQR (mmol/L) [5.4 - 6.8] [6.3 - 9.9]
Median dextrose (mg/kg/min) 10.0 8.2
Dextrose IQR (mg/kg/min) [8.7 - 10.0] [5.6 - 9.5]
% measurements within 4 - 7 mmol/L 75.4 30.9
% measurements < 4 mmol/L 3.3 4.9
% measurements < 2.6 mmol/L 0.5 0.7
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Figure 6.18: Empirical CDFs of BG concentration and parenteral dextrose infusion
rate for controller modulating both insulin and dextrose, compared to retrospective
data.
provide limited efficacy. An example is presented in Figure 6.19, where the insulin
sensitivity is relatively low between 90 and 130 hours. The controller lowers the
dextrose infusion rate to approximately 5 mg/kg/min to maintain glucose control
instead of increasing an already high insulin infusion rate. Hence, where the risk
of adding more insulin is high, safety from hypoglycaemia limits what can be
achieved. Reducing dextrose infusions thus provides a safe avenue of control for
these periods of a patient’s stay.
Higher dextrose infusions generally require higher overall insulin infusions,
increasing both sides of the glucose-insulin balance. This may magnify the pa-
tient glycaemic response to changes in patient condition, which may result in
more dramatic changes in glycaemia for changes in insulin sensitivity. Addition-
ally, whilst it may be possible to feed significantly higher dextrose by using high
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Figure 6.19: Controller simulation for Patient 15 incorporating modulation to the
parenteral dextrose infusion rate. Dashed lines represent retrospective data, and solid
lines represent simulation results. The top panel shows blood glucose concentration.
The second and third panels display the rate of insulin and parenteral dextrose infusion
respectively. The bottom panel shows model-fitted insulin sensitivity.
insulin rates, over-aggressive feeding may lead to non-productive somatic growth,
and could have negative implications for metabolism in later life such as insulin
resistance, obesity and diabetes [Hay, 2006].
A paper-based protocol that uses both insulin and nutrition inputs for control
has also been used on 394 adult intensive care patients in large-scale clinical im-
plementation [Chase et al., 2008b]. SPRINT uses 1-2 hourly measurements, and
modulates both insulin and nutrition to achieve tight glycaemic control. SPRINT
targets a 4.0 - 6.1 mmol/L BG band, and achieved 79% of measurements within
the 4 - 7 mmol/L band, which is similar to the 82% and 76% of simulated mea-
surements in this study within same band using 1-hour and 2-hour measurement
frequencies. The addition of nutrition modulation provides another pathway for
BG reduction that can be effective during periods of very low insulin sensitiv-
ity, particularly as adults appear to exhibit greater insulin effect saturation than
preterm neonates [Rizza et al., 1981]. In contrast, extremely preterm infants
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lack substantial endogenous stores of energy, and thus must be fed constantly to
maintain basal energy expenditure and provide excess for growth [Hume et al.,
2005]. Given the relatively new practice of tight glycaemic control using insulin
in neonates, any similar system for neonates would likely be initially an ‘insulin-
only’ controller or one that sought to maximise nutritional inputs.
Further improvements to the model could incorporate daily nutritional and
fluid volume goals that can be set by clinicians with model-based targeted control
taking care of glycaemia - thus relieving clinical staff from estimation and ad-
hoc decision making. The ideal content and composition of nutritional regimes
for preterm infants is still under debate [Hay et al., 1999]. The appropriate
proportions of dextrose, protein and lipids given in the NICU may be different to
what an infant receives in-utero. While the relevant major organs express many
of the biological mechanisms responsible for glucose regulation from a relatively
early age, the foetus depends upon the mother to control energy supply. Thus, the
controller is essentially attempting to replicate some of the mother’s functions,
as well as account for the synchronised processes that regulate foetal growth that
are perturbed by premature birth and life outside the womb. This outcome may
also highlight the model-based controller as an investigative tool to help clinicians
test different nutrition intakes and their effect on indicators of infant health.
6.5 Impact of controller technologies
The simulation studies in this chapter aimed to explore the impact of controller
design and clinical variables on control quality. The results were used to create
an optimum controller suitable for long-term clinical glycaemic control, which
was piloted in clinical trials as described in Chapter 7.
A detailed example demonstrating the control impact of the technologies
developed in this research is presented in this section for a typical real-life con-
trol scenario. Figure 6.20 shows one of the pilot clinical trials that used the
model-based controller. This clinical study will be presented in full in Chapter 7.
The model-based controller utilised in the clinical trial used 2-hourly BG mea-
surements and employed stochastic model forecasts to aid intervention selection.
Overlaid on the clinical BG results are re-simulations using the sliding scale con-
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Figure 6.20: Patient F clinical trial with re-simulated controllers. The top panel shows
the BG concentration as measured during the clinical trial, as well as the simulated
response for sliding scale and unoptimised model-based controllers. The shaded area
indicates the stochastic model forecast bounds generated during the clinical trial. The
second panels shows the insulin infusion rate during the clinical trial and for the two
simulated controllers. The bottom panel shows the identified insulin sensitivity profile.
troller of Table 6.1 and an unoptimised model-based controller with no stochastic
model and 4-hour BG measurement intervals.
The identified insulin sensitivity profile for this clinical trial patient is shown
in the bottom panel. This patient began the trial with low insulin sensitivity,
which underwent a rapid increase at 10 hours into the trial. Thus, this patient
profile provides a benchmark to compare how different controllers react to this
example of intra-patient variability.
The model-based controllers both achieved tight BG control compared to
the sliding scale controller, which fails to adapt to changing patient condition.
Due to a longer BG measurement interval, and no stochastic forecasting, the
unoptimised model-based controller misses the rapid rise in insulin sensitivity.
Thus, this controller causes a period of mild hypoglycaemia in this case. The
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clinical model-based controller, optimised through simulations on virtual patients
and using interventions guided by stochastic forecasts, responds adequately to rise
in insulin sensitivity to maintain a safe level of control.
Thus, this result demonstrates the complementary nature of the technologies
developed in this and previous chapters. The parameter identification methods al-
lows the identification of insulin sensitivity in clinical real-time. This information
is used by model-based controllers to provide adaptive, targeted BG control. The
controllers are optimised based on virtual simulation results that highlight the
importance of frequent BG measurements on control quality, explore the effects
of speed of controller response, and assess robustness to clinical implementation
variables. The stochastic model provides forecasts of future insulin sensitivity to
adjust interventions for a guaranteed level of safety from hypoglycaemia. Finally,
the virtual trial framework creates an environment where different protocols can
be compared in simulation to aid clinical decision-making. Thus, the suite of tech-
nologies combine to create a system that can respond adequately to the dynamic
critically ill neonate.
6.6 Summary
An adaptive, model-based predictive controller designed to incorporate the unique
metabolic state of the neonate was presented. The controller was developed in
simulation on a 25 patient cohort and results were compared to retrospective
hospital control. Time in the target 4 - 7 mmol/L band was increased by up
to 161%. The effects of measurement frequency schemes were evaluated, and a
stochastic model provided further protection against the risk of hypoglycaemia.
Bringing a control system from the perfectly-compliant environment of com-
puterised simulation to implementation in a busy, spontaneous critical care en-
vironment requires assessing the robustness of the control scheme to real-life
situations. In this chapter missed measurements, errors in the measurement de-
vices and delays in implementing the controller actions were tested. In all cases,
the controller proved robust, and thus suitable for initial pilot trials and further
longer-term nurse-driven usage.
The studies presented here highlight the flexibility of the virtual patient simu-
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lation environment. Controllers can be developed to handle the evolving critically
ill patient, as well as the evolving field of glycaemic control in critical care.
Chapter 7
Clinical trials
All reported insulin infusion trials in neonates have used either protocols that
fixed insulin dosing to weight or other factors [Beardsall et al., 2007b], or clini-
cian judgment to determine insulin infusion rates. Additionally, it is well known
that neonatal response to insulin and glucose infusions exhibits significant inter-
patient variations [Cowett and Farrag, 2004], which would render such fixed pro-
tocols ineffective because they do not adapt well to different patients or to the
dynamic changes within a patient’s stay as their condition evolves. Model-based
blood glucose control can provide more optimised care by adapting in real-time to
identified parameters representing the current metabolic state of the infant, and
use this information to drive insulin dosing. Succinctly, clinically derived fixed
or largely fixed protocols cannot offer the patient-specific adaptation necessary
to manage the clinically observed inter- and intra- patient variations.
This chapter presents the pilot trials of the first model-based blood glucose
control system in preterm neonates. The main goals of the pilot trials were to
assess the efficacy and safety of model-based control of blood glucose using insulin
infusions in neonates. The ability to accurately forecast blood glucose concentra-
tions in real-time to reduce hyperglycaemia in a controlled manner was assessed.
The stochastic model is also used to provide a guaranteed pre-specified maxi-
mum risk of hypoglycaemia. Overall, these model-based trials assess the ability
to successfully translate this model-based control method from a simulation en-
vironment into typical clinical practice.
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7.1 Study design
7.1.1 Study population
Very low birth weight infants who met eligibility criteria were recruited between
August 2008 - February 2009 from the Christchurch Women’s Hospital Neonatal
Intensive Care Unit. Inclusion criteria included birth weight < 1,500 grams,
blood glucose > 10 mmol/L, a clinical decision to commence insulin infusions,
and an in-situ arterial line. Infants that were severely moribund or not expected
to survive for more than 72 hours were excluded. Written parental consent was
obtained for each study participant. The study was approved by the Upper South
A Regional Ethics Committee, New Zealand.
7.1.2 Clinical protocol
The timing of intervention actions is shown in Figure 7.1. Blood glucose measure-
ments were taken every 1 to 3 hours for up to 24 hours, and the insulin infusion
rate was adjusted as determined by the model-based controller after each BG
measurement. The study dictated a maximum of 12 BG measurements over the
24 hour period to converse blood volume. Measurements were generally spaced
2-hourly. However, this measurement interval was adjusted as determined by the
attending clinician based on factors relating to clinical condition. Occasionally,
extra blood gases, which include BG measurement, were taken for some patients.
This extra data was used during the trial to update the insulin infusion rate,
and did not contribute to the 12 measurements/day limit. All blood was drawn
from an in-situ arterial line, to minimise patient discomfort, and analyzed with
a Bayer 850 blood gas analyzer (Bayer AG, Leverkusen, Germany).
The blood glucose profile together with the insulin and nutrition administra-
tion profiles were used by the computer algorithm to determine insulin infusion
rates to reach the target blood glucose range of 4 to 7 mmol/L. Insulin sensi-
tivity was identified from the measured clinical data in real-time to identify the
current metabolic state of the infant. The controller used the fitted insulin sensi-
tivity value to iterate through several possible insulin infusion rates and forecast
a BG concentration 2 to 3 hours ahead, depending on the anticipated time of
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Figure 7.1: Study protocol BG measurement and intervention timing. Each star
represents a BG measurement and update of the insulin infusion rate.
the next BG measurement. The insulin infusion rate forecasted to achieve a BG
concentration closest to target was selected. The control software accounted for
any delays between BG measurement and change in insulin infusion rate. The
stochastic model was used to provide confidence bounds on the forecasted BG
concentration. For safety, the selected insulin infusion rate was adjusted to en-
sure that the lower 5% probability bound of forecasted BG was greater than 4
mmol/L providing a guaranteed risk against hypoglycaemia.
The risk of hypoglycaemia is often cited as a barrier to large-scale adoption of
glycaemic control via insulin infusions. Most neonatal hypoglycaemia appears to
be asymptomatic [Lucas et al., 1988]. Many external signs of low BG (tremors,
etc.) are not specific to this condition in neonates. As a result, hypoglycaemic
symptoms could only be clearly attributed to low BG in 5 out of 660 clinical
cases [Lucas et al., 1988].
Studies in the neonatal rat brain suggest repeated, prolonged exposure to hy-
poglycaemia resulted in negative neurodevelopment outcomes [Zhou et al., 2008].
Vlasselaers and colleagues [2009] and Beardsall and colleagues [2008] found sig-
nificantly increased hypoglycaemia in their insulin therapy cohorts compared to
controls. As discussed at the beginning of this chapter, such outcomes are, at
least, partly due to the protocols control performance and inability to adapt to
changes in patient condition or inter-patient variability.
In contrast, SPRINT (developed from a model-based controller) had a hypo-
glycaemic occurrence similar to retrospective hospital glucose control protocols
in adult critical care [Chase et al., 2008b]. Hence, the lower BG forecast limit of 4
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mmol/L selected for this study was a relatively conservative choice, reflecting the
nature of these pilot trials as the first model-based BG control study performed
in preterm neonates.
Infants were mostly fed via parenteral solutions with 10%-12.5% dextrose
content. Several infants also received expressed breast milk (EBM), and some
infants received morphine and dobutamine infusions prepared using 5% glucose
solution. All sources of glucose infusion were reported and considered by the
model-based controller algorithm when recommending insulin infusion rates.
Insulin was given via intravenous cannula using Alaris CC pumps (Alaris, San
Diego, California, USA) as a continuous infusion. The concentration of insulin
was [5*weight (kg)] U made up to 20 mL with 0.9% saline solution to achieve a
concentration of 0.25 U/kg/mL. Insulin tubing was flushed with this solution to
ensure plastic receptor binding occurs to minimise adsorption to tubing [Hewson
et al., 2000]. New insulin infusion rates were determined after every measurement.
For additional safety, a neonatal clinician approved every change in insulin infu-
sion rate before adjusting the pump. All patients enrolled into this study were
already receiving insulin infusions. Hence, this study only attempted to opti-
mise the insulin infusion rate to more accurately achieve target blood glucose
levels. This study is thus a clinical pilot to test the efficacy and safety of this
model-based controller.
7.2 Results
7.2.1 Clinical summary
Table 7.1 presents the clinical details of the study population. Six infants were
included in the trial with birth weight ranging from 540g to 995g and gestational
age at birth of 24.4 to 27.3 weeks. Infants were enrolled at 1 to 9 days of age
and had received insulin for 0 to 91.6 hours before the study period began. The
intervals between commencement of insulin and the start of the trial were due to
obtaining parental consent and ensuring an arterial line was available.
Figure 7.2 presents the blood glucose measurements during the study for
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Table 7.1: Clinical details of study population
Patient
Gestational
age at birth
[weeks]
Age at start
of trial [days]
Birth
weight [g]
Insulin usage
before trial
[hours]
A 24.4 7 685 15.3
B 27.3 9 770 15.0
C 25.4 1 720 3.2
D 25.4 7 785 91.6
E 25.9 4 540 2.2
F 27.0 2 900 0.0
G 25.0 6 995 11.5
each of the seven study patients. In each case, the model-based controller reduced
blood glucose from hyperglycaemic concentrations towards the target 4-7 mmol/L
band, and maintained BG control within the band. The evolution of model-fitted
insulin sensitivity is presented for each patient in Figure 7.3. The overall range
and variation of insulin sensitivity shown in Figure 7.3 was highly patient-specific.
However, Figure 7.2 shows a generally uniform glycaemic response, suggesting
the model-based controller is capturing and accounting for these patient-specific
dynamics.
Table 7.2 summarises the clinical inputs for blood glucose control during
the trials. Infants were fed a median of 4.1 to 9.6 mg/kg/min dextrose via the
parenteral route, and up to 11 mL of EBM. Median insulin usage was 0.040
U/kg/hr to 0.191 U/kg/hr. The median BG measurement frequency was 1.7 to
2.5 hours. Finally, the model-fitted insulin sensitivity value showed large inter-
patient variation, with medians spanning [0.14 - 1.25]x10-3 L/(mU.min).
In particular, several studies have shown that there is no simple relationship
between insulin and glucose infusions and level of glycaemia. Great inter-patient
heterogeneity is a hallmark of neonatal glucose metabolism making safe, ade-
quate control difficult [Cowett and Farrag, 2004; Collins et al., 1991]. Table 7.2
shows that within this relatively small study population a 2.3x spread of median
dextrose infusion rates were used, and an 8.9x spread of insulin sensitivity was
computed. In response, the controller used a 7.6x spread of median insulin infu-
sion rates. Thus, fixed insulin protocols may not accurately account for this level
of inter-patient variability. In contrast, an adaptive protocol, as presented here,
can provide greater benefit.
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Figure 7.2: BG concentration during computerised insulin dosing. Each line rep-
resents blood glucose concentration for one patient while insulin infusion rates were
chosen by the computerised controller. The shaded region represents the 4-7 mmol/L
target band.
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Figure 7.3: Model-fitted insulin sensitivity during trials. Each line represents the
evolution of one patient’s sensitivity to exogenous insulin fitted as an hourly step-wise
function.
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The following sections presents the clinical control data for the seven study
patients. The BG concentrations presented in each section are compared to the
model-predicted values as plotted in Figures 7.4 to 7.9. The shaded areas of each
trial plot represent the 5% - 95% BG forecast bound generated by the stochastic
model. The insulin and nutrition infusion data during the trial are also shown,
where bars represent EBM feedings for those infants receiving EBM. Hourly step-
wise model-fitted insulin sensitivity is shown on the bottom panel of each plot.
7.2.2 Patient A
Patient A experienced a four-fold increase in insulin infusion over the 12 hour
trial period. However, there was relatively very little change or variation in the
glycaemic response. This result may have reflected high insulin resistance due to
clinical condition, or could be caused by a technical fault such as an unnoticed
blocked line.
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Figure 7.4: BG control during clinical trial for Patient A. The BG measurements are
shown in the top panel together with the 5%-95% BG prediction forecast (shaded).
The second panel shows insulin infusions (solid line), dextrose infusions (dashed line)
and EBM (bars). The third panel shows model-fitted insulin sensitivity.
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Patient A was unique as the only infant from an Asian background, whilst the
remaining study patients were all Caucasian. Insulin sensitivity differs amongst
ethnic groups in adults, where [Chiu et al., 2000] reported Asian-Americans had
an ethnic propensity to insulin resistance not related to obesity. It is unknown
whether such ethnic differences in insulin sensitivity are also present in preterm
neonates.
7.2.3 Patient B
Patient B was on insulin overnight before the study commenced. The controller
maintained BG within the target band throughout the majority of the trial. This
patient had several extra blood gases taken due to changes in mechanical ventila-
tion settings and strategy, and these measurements were thus also used to adjust
the insulin infusion rate that generally steadily increased over the trial. This pa-
tient had comparatively high insulin sensitivity, and thus most BG measurements
were towards the lower end of the BG forecast range.
7.2.4 Patient C
Patient C received 34%-60% of the total dextrose infused from glucose admin-
istered with morphine and dobutamine solutions due to critical illness. The
controller achieved a steady decrease in BG from 14.4 mmol/L over 10 hours to
the target band. At approximately 27 hours the patient self-extubated and was
in a stressed condition, resulting in a sharp rise in BG at the end of the trial.
Arterial access was lost soon after this time and the study was therefore stopped
after only 20 hours of control.
7.2.5 Patient D
Patient D was the twin of Patient C, and, in contrast to Patient C, had received
insulin for several days before the trial commenced. Hence, the starting BG
concentration was lower than for most other patients. The controller modulated
insulin infusions to maintain glycaemia within the target 4-7 mmol/L band. This
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patient was metabolically relatively stable over the trial period, as evidenced by
the relatively high and stable model-fitted insulin sensitivity, and similarly stable
insulin and nutrition interventions.
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Figure 7.6: BG control during clinical trial for Patient D. The BG measurements are
shown in the top panel together with the 5%-95% BG prediction forecast (shaded).
The second panel shows insulin infusions (solid line), dextrose infusions (dashed line)
and EBM (bars). The third panel shows model-fitted insulin sensitivity.
7.2.6 Patient E
Patient E was the smallest trial subject, with birth weight of 540g. The first 12
hours of the trial showed a controlled decrease of BG from 12.6 mmol/L to 6.5
mmol/L. The lower bound of the forecast band reached the 4 mmol/L limit for
much of the trial. This limit indicates how the combination of low birth weight,
relatively low insulin sensitivity, and relatively high insulin infusion rate created
a risk of low BG. This risk was minimised by adjusting the 50th percentile target,
as required. Thus, for several measurements towards the end of the trial the
controller targeted a BG concentration slightly over 7 mmol/L to keep the lower
bound of the forecast range at 4 mmol/L.
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Figure 7.7: BG control during clinical trial for Patient E. The BG measurements are
shown in the top panel together with the 5%-95% BG prediction forecast (shaded).
The second panel shows insulin infusions (solid line), dextrose infusions (dashed line)
and EBM (bars). The third panel shows model-fitted insulin sensitivity.
7.2.7 Patient F
Patient F showed a period of relatively rapid change in insulin sensitivity during
the study. Between hours 10 and 13 insulin sensitivity rose 165%. This rise was
at the extreme end of observed changes in insulin sensitivity, evidenced by the
BG measurement at 14 hours below the 5% BG forecast limit. Between 18 - 20
hours insulin sensitivity decreased relatively rapidly, showing a BG measurement
above the 95% BG forecast limit. Post-trial analysis of the clinical data showed
no new medications administered over this period or any diagnosed change in
condition that could be directly linked to the change in insulin sensitivity.
7.2.8 Patient G
A major feature of the BG control for Patient G was the high rates of insulin
infusion employed during the study. The controller reduced the BG concentration
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Figure 7.8: BG control during clinical trial for Patient F. The BG measurements are
shown in the top panel together with the 5%-95% BG prediction forecast (shaded).
The second panel shows insulin infusions (solid line), dextrose infusions (dashed line)
and EBM (bars). The third panel shows model-fitted insulin sensitivity.
to < 8 mmol/L over the first seven trial hours. Due to high insulin infusion rates,
the stochastic model forecasts drove the controller BG targets. The controller
aimed to hold the BG concentration over 7 mmol/L for most of the trial, as
dictated by the requirement to maintain the 5% BG forecast bound at no less
than 4 mmol/L.
At approximately 32 hours the patient’s insulin sensitivity rapidly increased,
causing a 1.6 mmol/L drop in BG from the previous measurement. The decrease
in BG was adequately contained, avoiding hypoglycaemia. There appeared to be
no appreciable change in clinical condition during this time. Thus, the stochastic
model directed a period of higher BG, based on the risk of high insulin infusion
rates and insulin sensitivity variability observed in retrospective data, to provide
an extra buffer that helped avoid hypoglycaemia when a rapid change occurred
in insulin sensitivity.
This patient provides a salient example of routine BG measurement and
stochastic forecasting providing a layer of safety. Longer BG measurement inter-
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Figure 7.9: BG control during clinical trial for Patient G. The BG measurements are
shown in the top panel together with the 5%-95% BG prediction forecast (shaded).
The second panel shows insulin infusions (solid line), dextrose infusions (dashed line)
and EBM (bars). The third panel shows model-fitted insulin sensitivity.
vals may have likely missed the relatively rapid rise in insulin sensitivity between
hours 31-33 of the study. A more aggressive use of insulin may have lead to a
hypoglycaemic event in this case.
The patient did not exhibit significant changes in any other routinely mea-
sured clinical variable during this time. Thus, it is possible that there was a
change in some aspect of glucose metabolism that is not typically measured
during neonatal intensive care. This example demonstrates robustness in the
controller to account for clinically un-measurable and un-modelled effects.
7.3 Model prediction accuracy
Table 7.3 shows the mean model BG prediction accuracy expressed as a percent-
age and an absolute concentration. The BG prediction accuracy assessment was
generated post-trial by synchronising the forecasted BG concentration with the
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Table 7.3: BG prediction accuracy and stochastic model prediction coverage.
Patient
Median BG prediction error
(absolute)
BG within forecast
range
[%] [mmol/L] IQR 5% - 95%
A 19.2% 1.47 33% 83%
B 8.6% 0.52 31% 85%
C 7.6% 0.77 80% 90%
D 8.4% 0.53 33% 100%
E 6.4% 0.48 100% 100%
F 8.5% 0.72 50% 83%
G 5.9% 0.44 92% 100%
Cohort 7.6% 0.54 62% 92%
actual time of measurement to account for deviations in measurement frequency
experienced in clinical practice. The overall cohort BG prediction error was 7.6%
(0.54 mmol/L) over an average measurement interval of 2.1 hours.
The efficacy of the stochastic model was assessed by comparing the percent-
age of forecasted BG concentrations within the IQR and 5%-95% of prediction
bounds. Specifically, 62% of BG predictions were within the forecast IQR and
92% of BG predictions were within the 5%-95% forecast range. These values are
slightly higher than those in Chapter 5 for c = 0.5 (Table 5.4) for these short-
term trials. The distributions of BG prediction errors are shown in Figure 7.10,
where 69% and 84% of BG measurements were within ±10% and ±20% of the
forecasted concentration, respectively.
The stochastic model employed in this study is built from a whole-cohort
perspective using retrospective data from 25 patients as detailed in Chapter 5.
Figure 7.3 shows the degree of variability in insulin sensitivity is patient-specific.
The amount of patient variability may be linked to other clinical and diagnostic
variables. Thus, with further clinical use and data the model may be improved
to more clearly identify patients at different stages of development or with differ-
ent clinical issues. Individualised stochastic models may provide tighter forecast
bands by identifying the levels of glycaemic stability per-patient, as discussed in
Chapter 5. However, these models require significant data for calibration and
were not applicable for these 24-hour pilot trials.
Thus, the glycaemic control problem becomes one of identifying the current
(evolving) patient state and managing patient variability in clinical real-time.
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Model-based control provides real-time identification of insulin sensitivity, and
its evolution with time. However, identification of insulin sensitivity relies on
the availability of blood glucose measurements. Thus, two- to three- hourly
BG measurements were used in these pilot trials, based on simulation results as
presented in Chapter 6 as a compromise between accurate metabolic identification
and nursing/patient burden - a factor magnified in preterm neonates with limited
blood volumes.
Frequent glucose sampling has been shown to be an important precursor for
tight glycaemic control in simulation studies [Lonergan et al., 2006b; Chase et al.,
2007]. Some insulin infusion studies in preterm neonates used longer measure-
ment and intervention intervals of up to 6 hours [Beardsall et al., 2008]. These
latter studies failed to achieve tight control or safety from hypoglycaemia, and
long measurement intervals likely contributed negatively to the level of glycaemic
control achieved, as patient condition can evolve significantly over that timeframe
as seen in this clinical study.
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 Figure 7.10: Blood glucose prediction errors during trials (expressed as absolute
concentration in left panel, and percentage of measured BG concentration in right
panel).
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7.4 Comparison with retrospective cohort
The control of blood glucose concentrations during clinical trials was compared to
simulated 24-hour control trials on the retrospective cohort. The 24-hour control
simulation period was selected using the same inclusion criteria as for the clinical
trial patients. Simulations were performed on 24 patients from the retrospective
cohort, with a total of 312 BG measurements/interventions. Patient 13 was
excluded from this analysis as the large spike in glucose for this patient due to a
glucose-insulin bolus (see Figure 4.7), a clinically unusual event that would not
be expected to occur during the trials.
Figure 7.11a compares CDFs of clinical trial BG measurements and model-
fitted SI to the retrospective cohort simulated 24-hour trials. The BG distribu-
tions are close to significantly different (p = 0.054, Mann-Whitney test). The in-
sulin sensitivity distributions are significantly different (p < 0.01, Mann-Whitney
test), where the greatest discrepancy is due to a high proportion of very low in-
sulin sensitivities in the clinical cohort. Figure 7.11b shows the overall range of
insulin sensitivity values were similar between cohorts, and highlights the group
of ‘difficult’ or more insulin-resistant patients encountered in the clinical trials.
The BG and SI distribution analysis was repeated using a subset of patients
from the retrospective cohort selected to provide the best possible overall match
for gestational age and weight. The details of the matched cohorts are presented
in Table 7.4, and the BG and SI CDFs are presented in Figure 7.12a. The
histograms of insulin sensitivity distribution for the two cohorts are presented
in Figure 7.12b. The BG distributions in this case are not significantly different
(p = 0.22, Mann-Whitney test). However, the significant difference in insulin
sensitivity remains.
The differences in insulin sensitivity separation effect may be due to small
patient numbers, particularly in the clinical trial cohort. There may have also
been some bias in the selection of study patients, as the study was a proof-of-
concept pilot trial with no randomization. Thus, the presence of the trial may
have influenced clinical decisions to commence treatment with insulin. There
may also have been selection bias in choosing the periods of trial simulation from
the retrospective cohort.
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Table 7.4: Trial patients and matched simulation cohort
Patient match Trial Matched Retro.
Trial Retro. Gest. Age Weight Gest. Age Weight
A 14 24.4 wks 685g 24.9 wks 735g
B 8 27.3 wks 770g 26.6 wks 825g
C 4 25.4 wks 720g 23.7 wks 625g
D 7 25.4 wks 785g 26.3 wks 810g
E 2 25.9 wks 540g 24.4 wks 650g
F 15 27.0 wks 900g 26.9 wks 880g
G 6 25.0 wks 995g 25.0 wks 900g
No significant changes in clinical practice had occurred with respect to any
likely metabolic input over the period spanning the retrospective cohort data up
to the clinical pilot trials. Thus, given the matched cohort results of Figures 7.12a
and 7.12b, the only likely clinical difference between retrospective clinical control
cohort and the pilot trials cohort was that higher rates of insulin infusion may
have been used in the latter. An underestimation of the saturation of the insulin-
mediated glucose uptake pathway, represented by αG in the glucose compartment
equation, may manifest itself as an artificially low insulin sensitivity value during
periods of greater insulin infusions.
The parameter αG was set to zero in this study to reflect the reported lack of
saturation of the insulin-mediated glucose uptake pathway, within the physiolog-
ical range of insulin concentrations [Farrag et al., 1996]. Insulin sensitivity was
then re-identified for both the retrospective and clinical trial data for two further
cases of αG values:
• αG = 165 : This reflects the value used in adult models [Hann et al., 2005].
• αG = 120 : Given the typical concentrations of insulin in neonates, this value
would be likely to cause a significant effect during typical neonatal control
situations (if the saturation effect does exist).
Simulation comparisons were performed for both the entire retrospective cohort
(n=24) and the matched cohort of Table 7.4. Figure 7.13 presents a comparison
of BG and SI distribution for each value of αG assessed.
There is little difference in the distribution of both BG and SI for αG = 0
and αG =
1
65
, largely due to the lower insulin concentrations in neonates that
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Figure 7.13: Comparison of BG distribution and insulin sensitivity distribution for
clinical pilot trials and 24-hour simulations. Plots in the top row show αG = 0, the
middle row αG = 165 , and the bottom row αG =
1
20 .
prevents most saturation effects for a half-maximum effect concentration of 65
mU/L. The BG distributions are closer for αG =
1
20
. However, the insulin sen-
sitivity distributions are now separated further. Any increase in differences in
model-identified parameters between cohorts is unlikely, given the similar clin-
ical condition of the retrospective and clinical cohorts. Thus, any error in the
190 CHAPTER 7 CLINICAL TRIALS
estimation of insulin-mediated glucose uptake saturation, an important parame-
ter in adult glucose control, does not appear to explain the difference in insulin
sensitivity observed between cohorts in this study.
As a result of this last analysis, these differences may be due to clinical se-
lection bias, small cohort numbers or another un-measured clinical difference.
However, despite the differences in insulin sensitivity between the clinical cohort
and retrospective counterparts the model-based controller achieved a similar level
of glycaemic control performance between groups, highlighting the adaptive abil-
ity of the system.
7.5 Clinical trial control compared to overall hospital
control
The BG control during the pilot clinical trial study period was compared to the
entire record of BG control for each of the study patients. Figure 7.14 high-
lights the periods of insulin usage and model-based control. The concentration
of dextrose solution used to deliver glucose the patient is also shown.
The model-based controller generally assisted in consistently lowering BG to
the target band, or maintaining control within the band. There was no clear re-
lationship between the concentration of dextrose solution and level of glycaemic
control either within the study or under hospital control. Blood glucose control
was generally more variable outside the model-based control period. In particular
patients B, E, F and G showed significant rebound hyperglycaemia once insulin
infusions were stopped. These results highlight the significant glycaemic variabil-
ity of critically ill neonates and the necessity for adequate criteria for stopping
insulin infusions once a patient is adequately self-regulating. Large scale imple-
mentation of the SPRINT protocol [Chase et al., 2008b] used explicitly defined
stopping criteria based on a combination of glycaemic stability, low insulin infu-
sion rate and high glucose intake rate. Large-scale implementation of model-based
glycaemic control in a neonatal ward would require similar stopping rules.
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Figure 7.14: Blood glucose control for entire period of insulin usage. Model-based
control period and insulin usage are highlighted (continued).
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7.6 Model-based control effects
The model-based control method provides some insulin dosing recommendations
that differ from conventional insulin protocols. Figure 7.15 highlights two specific
interventions during clinical trials for Patients C and F where the controller
increased the insulin infusion rate. What is unique versus any typical clinical
practice is that it did so despite a decrease in the BG concentration over the
previous two measurements, as well as relatively constant nutrition inputs and
model-fitted insulin sensitivity over the period.
These controller effects result from the form of the glucose compartment
equation, summarised as:
G˙ = −pGG− SIG Q
1 + αGQ
+ glucose input (7.1)
By way of example, two similar simplified cases are considered:
• a) A reduction in blood glucose concentration from 9 mmol/L to 8 mmol/L
over one hour.
• b) A reduction in blood glucose concentration from 7.5 mmol/L to 6.5
mmol/L over one hour.
In both cases, the left hand side of Equation 7.1, G˙, is equal to -1 mmol/L/hr, and
the same glucose input and SI parameter values are assumed for this analysis.
The pGG term is smaller in magnitude for case (b) compared to case (a) due to
the lower BG concentration. Thus, to balance the left-hand side of Equation 7.1
the term SIG
Q
1+αGQ
must be larger in magnitude for case (b). As the parameter
SI is constant in this example, and G is lower in case (b), the value of Q must
be larger in case (b), relative to case (a). The magnitude of Q, representing the
insulin delay compartment, is directly related to the rate of insulin infusion.
Hence, due to the structure of Equation 7.1, a model-based controller would
select an increase in the insulin infusion rate for the example presented in (b),
despite the lower BG concentration, to maintain a desired constant rate of change
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Increased insulin rate despite 
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Figure 7.15: Clinical model-based control trial results, highlighting controller inter-
ventions that increased insulin infusion rate, despite lower BG concentration. The top
panel plots BG concentration (with stochastic model forecasts shaded). The second
panel plots the insulin infusion rate. The third panel displays nutrition via TPN and
EBM, and the bottom panel shows model-fitted insulin sensitivity.
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of glucose concentration. This effect is essentially the reverse of a sliding scale
approach, and can occur if the desired rate of change of glucose concentration was
negative, implying the current BG concentration is above target. In these two
simplified cases, the BG was above the target of 6 mmol/L. Hence, one can see
an increase in insulin near to the target that one might see well above the target.
The model view of this scenario can be pictured in terms glucose transport via
facilitated diffusion, as shown in Figure 7.16.
This example highlights how control interventions depend upon the model
structure used to approximate the physiological system. The model structure
in this case influences control to use a more aggressive insulin dosing response,
where a sliding scale approach would have been more conservative. As discussed
in Chapter 2, models for control applications must balance physiological validity
and real-time identifiability using available clinical data. Thus, under-modelled
physiologies may introduce a source of error and impact control performance.
Hence, insulin limits are used in the model-based controllers in this research, as
developed in Chapter 6, as a response to the balance between dynamics captured
well by the model and the effects of a model structure designed for clinical con-
trol applicability over total physiological completeness. In the controllers of this
thesis, it should be noted that such effects are also mitigated by the stochastic
model limits and the use of percentage reductions of BG rather than defined fixed
rates of change (e.g. 15% reduction rather than -1 mmol/L per hour).
7.7 Summary
Pilot clinical trials of an adaptive, model-based predictive controller designed to
incorporate the unique metabolic state of the neonate showed promise in effec-
tively controlling glycaemia. The controller was used to achieve glycaemic control
in seven preterm, low-birth weight neonatal patients during 12-24 hour pilot tri-
als. Significant inter-patient variation in insulin sensitivity was observed in the
study cohort, and the controller adequately captured this dynamic variation to
regulate blood glucose levels whilst avoiding hypoglycaemia. Comparison to ret-
rospective patient data revealed the model-based controller presented a consistent
level of glycaemic control performance for significantly insulin-resistant patients.
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Figure 7.16: Model-based structure effect on controller interventions, based on insulin-
mediated glucose transport as a facilitated diffusion process. The 9 mmol/L to 8
mmol/L case is presented in the left panel, and the 7.5 mmol/L to 6.5 mmol/L case is
presented in the right panel.
Chapter 8
Conclusions
The work in this thesis presents the development of a complete system for model-
based targeted glycaemic control in preterm neonates from initial models through
to proof-of-concept clinical pilot trials. A valid, control-applicable physiologi-
cal system model was developed that incorporated the unique physiology of the
neonate. Prediction and control were aided by a stochastic model of insulin
sensitivity variation and time-series forecasting methods. A clinical simulation
framework built around trials on ‘virtual patients’ provided an environment to
optimise protocol development before clinical implementation. Pilot clinical tri-
als validated the model and control system in a clinical setting and provided tight
control of glucose levels on a heterogenous neonatal cohort.
Hyperglycaemia is a common occurrence amongst the youngest and sickest
neonates that receive intensive care. A growing body of evidence links the de-
gree of hyperglycaemia to increased morbidity and mortality, and reflects similar
findings in the adult critical care case. Recent studies in adults have shown that
a 17% - 45% reduction in mortality can be gained if tight glucose regulation
is achieved to average levels from 6.0 mmol/L - 7.75 mmol/L [Van den Berghe
et al., 2001, 2003; Krinsley, 2003b, 2004; Chase et al., 2008b]. However, such a
level of tight control has not yet been achieved for the preterm neonate. The
immaturity of the glucose regulatory system in the preterm infant as a cause of
hyperglycaemia adds an extra dimension to the stress-induced hyperglycaemia
case common to adult critical care. The goals for tight control in neonates em-
phasise nutrition and growth outcomes in addition to the protective effects of
insulin and normoglycaemia.
Significant physiological differences mean there is no simple translation of
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adult therapies to the unique neonatal case. Model-based methods can identify
patient-specific parameters in real-time and adapt control, and provide a pathway
for clinically realistic glycaemic control systems that handle the great heterogene-
ity that is the hallmark of neonatal glucose metabolism. Glucose-insulin system
dynamics are described by models designed for applications from interpreting de-
tailed tracer studies and quantifying human physiology to control system models
that capture patient dynamics and variability based on the limited data available
in critical care. Whilst the glucose-insulin system dynamics in neonates have not
to date been extensively modelled, the rich history of model-based methods in
adults helps guide the adaptation of the model to the neonatal case.
A widely validated model of the glucose regulatory system was adapted from
adult critical care to the neonatal case. Model fits of insulin sensitivity were
generated for 25 patient records and 3,587 hours of retrospective data. Adapta-
tion of several physiological model parameters, including insulin clearance rate,
endogenous production rate and volumes of distribution, resulted in an average
fitting error of 2.10%. The predictive ability of the model was assessed by assum-
ing insulin sensitivity was constant over the interval. Prediction error at 1, 2 and
4-hour intervals were 5.2%, 9.5% and 14.7% respectively. The model performance
was within variations that would also account for dynamic patient evolution. The
model thus provided a first in-silico result for modelling the metabolic dynamics
of the low-birth weight preterm infant. It also created a platform towards better
metabolic clinical management of glycaemia in neonates. The model developed
provided an overall measure of a critically ill patient’s sensitivity to exogenous
insulin and nutrition inputs and allowed comparison of adult and neonatal insulin
sensitivity dynamics.
A stochastic model to provide insulin sensitivity predictions was developed
from a set of insulin sensitivity data for a neonatal intensive care cohort. The
model provided conservative prediction estimators that resulted in greater cov-
erage than expected from the probability bounds. Incorporating lag-2 effects did
not improve the coverage proportion, and greater coverage over-estimation in re-
gions of higher data density pointed to the variance estimator based on local data
density as a possible source of over-estimation. Modifying the data density esti-
mator by introducing a constant scaling factor showed appropriate coverage was
obtained at approximately 10-50% of the original value. However, the probability
bounds were no longer smooth or physiologically realistic. Smooth probability
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bounds containing the appropriate proportion of prediction coverage could be
obtained by choosing the probability bounds to obtain the desired prediction
performance.
AR models were able to generate a patient-specific model to allow for tighter
prediction intervals during periods of relative stability in insulin sensitivity. How-
ever such models require substantial individualised patient data (eg: 12 - 48
hours) which may not be available at the commencement of real-time glycaemic
control. Hence, time-series models provide the opportunity for tighter control
during periods of patient stability, whereas cohort-wide stochastic models provide
extra protection during periods of highly dynamic changes in insulin sensitivity.
An adaptive, model-based predictive controller was designed to leverage meta-
bolic state and forecast information for optimal control. The controller was de-
veloped in simulation on a 25 patient cohort and results were compared to retro-
spective hospital control. Time in the target 4 - 7 mmol/L band was increased
by up to 161%, and a range of measurement frequency schemes were evaluated
to choose the best compromise between control quality and conservation of the
neonate’s limited blood supply.
Designing for the transition of a control system from the perfectly-compliant
environment of computerised simulation to implementation in a busy, sponta-
neous critical care ward required assessing the robustness of the control scheme
to real-life situations. Missed measurements, errors in the measurement devices
and delays in implementing the controller actions were tested. In all cases, the
controller proved robust, and thus suitable for initial pilot trials and further
longer-term nurse-driven usage.
Pilot clinical trials showed promise in effectively controlling glycaemia, val-
idating the overall targeted model-based control method in neonates. The con-
troller achieved glycaemic control in seven preterm, low-birth weight neonatal
patients during 12-24 hour trials. Significant inter-patient variation in insulin
sensitivity was observed in the study cohort, and the controller adequately cap-
tured this dynamic variation to regulate blood glucose levels whilst avoiding hy-
poglycaemia. Comparison to retrospective patient data revealed the model-based
controller presented a consistent level of glycaemic control performance for sig-
nificantly insulin-resistant patients.

Chapter 9
Future Work
The models and control methods presented in this thesis provide a framework for
glucose control in neonatal critical care. These developments open the doors for
wider use of tight glucose control as a treatment in neonatal care, as well as in
older pediatric cases, plus related further research opportunities.
9.1 Further clinical validation
The pilot trials presented in this thesis provided an initial validation of the model-
based control techniques in this unique patient group. Longer trials and the
incorporation of the model-based system as a standard treatment modality for
hyperglycaemia in a neonatal intensive care ward would provide validation of
long-term control performance. Additionally, longer trials would allow the use
of time-series based insulin sensitivity forecasting, as presented in Chapter 5,
providing a vehicle for clinical validation of the prediction method. Nutrition
modulation may be included to pilot tight glycaemic control with goal nutrition
rates in neonatal care.
Long-term follow-up of hyperglycaemic infants with subsequently controlled
glucose levels would allow the benefits of tight glycaemic control to be evaluated.
Outcome variables such as mortality and in-hospital infections can be evaluated
over the course of weeks to months. Overall physical, mental and metabolic
development may be assessed over the course of years. Theories of ‘metabolic
programming’ suggest that early post-natal nutrition patterns may have a signif-
icant impact on later insulin resistance, obesity and risk of diabetes [Hay, 2006].
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Finally, the model-based system can target a range of physiologically sound
levels of glycaemia, as well as account for any nutrition and/or insulin infusion
rate desired by the clinical. Thus, model-based control may prove useful as a
tool in research to compare effects of a range of glucose levels, glucose infusion
rates or levels of insulin infusion. Research variables may include concentrations
of insulin-like growth factors, rates of proteolysis or other markers of metabolic
state across a range of clinical conditions. Such information is not generally
available in detail in the neonatal literature.
9.2 Investigation of stochastic behaviours
The stochastic models presented in this thesis are created using general neonatal
intensive care data for 25 episodes of insulin usage over 21 patients. Further
data over a range of infants of gestational age, birth weight and level of critical
illness may isolate some particular characteristics of a specific patient group in
the resulting stochastic model. Otherwise, it can help by confirming that insulin
sensitivity variation, as modelled, is generic across critically ill neonates.
Observations of stochastic behaviour between patient characteristics can fur-
ther help the development of different protocols for different patient groups. The
overall result would be more tailored control. In addition, identifying such dif-
ferences may bring to light a deeper understanding of the ontogeny of neonatal
glucose metabolism. This point is particularly relevant given the number of hor-
monal control mechanisms that are still poorly understood in the preterm infant,
and the difficulty in performing many intensive pharmacokinetic and pharmaco-
dynamic studies.
9.3 Insulin sensitivity as a marker of illness
Timely diagnosis and treatment of sepsis in critical illness requires significant
clinical effort, experience and resources. Insulin sensitivity is known to decrease
with worsening condition and could thus be used to aid diagnosis. Initial studies
in adults have shown insulin sensitivity provides a negative predictive diagnostic
for sepsis [Blakemore et al., 2008]. Premature newborns are at much higher risk
9.4 CLINICAL IMPLEMENTATION 203
of sepsis than children and adults because of their immature immune system. Ac-
curate and timely diagnosis of early onset neonatal sepsis remains challenging to
the clinician and the laboratory. Thus, real-time, model-fitted insulin sensitivity
may provide a novel marker of sepsis in this cohort.
9.4 Clinical implementation
Long-term implementation of model-based glycaemic control in neonatal inten-
sive care would require developing robust, verified software. Critical care nursing
is a highly technical profession, and staff are typically proficient with comput-
erised technology. Any system needs to operate using terminology and workflow
patterns familiar to clinical staff to reduce training time and ease implementation.
A computerised protocol, provided through an easily used graphical user in-
terface, is a standard implementation modality for model-based control. The
software may be stored on dedicated bedside computers, or accessed through
intranet- or web-based means. An further embodiment of the software would
include its incorporation into standard hospital and laboratory information sys-
tems, or implemented on programmable infusion pumps.
The metabolic information provided by model-based control relies on accurate
knowledge of inputs into the system. New generations of pumps are able to
transmit infusion details to hospital information systems, which can be queried
by glucose control software. This approach would ensure accurate information
is used for control recommendations, reducing double-entry by nurses of infusion
information into both the hospital record information system and glucose control
software, and move one step along the path to more automated control.
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